epoetin alfa profile

Epoetin Alfa: A recombinant glycosylated form of erythropoietin which stimulates the differentiation and proliferation of erythroid precursors. It is used for the treatment of ANEMIA associated with CHRONIC RENAL FAILURE in dialysis and predialysis patients. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	92043599
MeSH ID	M0028770

Synonym
113427-24-0
epoetin alfa
rhepo
(4r,5s,6s,7r,9r,10r,11e,13e,16r)-10-[(2r,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-6-[(2s,3r,4r,5s,6r)-5-[(2r,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-7-(2-hydroxyethyl)-5-methox

Excerpt	Reference	Relevance
"Darbepoetin alfa (DA) is a long-acting ESA used to treat anemia in premature neonates and in children with chronic kidney disease or on cancer chemotherapy."	( Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease. Rv, S; S, R, 2023)	1.95
"Darbepoetin alfa is a new erythropoietic protein with greater biologic activity and a longer dosing interval than those of r-HuEPO."	( Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Hudson, JQ; Sameri, RM, 2002)	1.35
"Darbepoetin alfa is a new erythropoietic agent with a 3-fold longer half-life and increased in vivo potency relative to r-HuEPO."	( Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Scott, SD, 2002)	1.04
"Darbepoetin alfa is an erythropoiesis-stimulating glycoprotein with up to 3 times longer half-life than recombinant human erythropoietin (rHuEPO) in humans. "	( [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa]. Cacho, M; De Gracia, MC; García Hernández, MA; Molina, M; Navarro, MJ; Pérez Silva, F, 2004)	1.16
"Epoetin alfa is an established treatment of anemia in patients with cancer who are receiving chemotherapy with or without radiation therapy. "	( Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy. Shasha, D; Williams, D, 2006)	2.23
"Epoetin alfa appears to be a safe alternative to PAD in patients who are at risk for transfusion in the perioperative period following total knee arthroplasty."	( Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. Deutsch, A; Marcus, RE; Spaulding, J, 2006)	1.42
"Darbepoetin alfa also is an effective treatment for anemia in patients with cancer not receiving chemotherapy, at extended dosing intervals of at least 3 weeks."	( Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. Natale, JJ; Stevenson, JG, 2007)	1.38

Excerpt	Reference	Relevance
"Darbepoetin alfa has a longer half-life than epoetin alfa, enabling less frequent administration."	( Novel approaches to anemia associated with cancer and chemotherapy. Kolesar, JM, 2002)	0.8
"Epoetin alfa has been the standard of therapy for patients with renal disease and cancer-related anemia for more than a decade."	( Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Boggie, D; DeLattre, M; Morreale, A; Plowman, B; Schaefer, M, 2004)	1.32
"Epoetin alfa has been well tolerated so far in the study."	( A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study. Cassandro, R; Dicuonzo, G; Esposito, V; Groeger, AM; La Cesa, A; Malafarina, V; Montesarchio, V; Navajas, F; Santini, D; Tonini, G; Vincenzi, B; Virzi, V, )	1.18
"Epoetin alfa has been used to treat the anemia that develops in the HDCT setting."	( Epoetin alfa and high-dose chemotherapy. Henry, DH, 1998)	2.46
"Epoetin alfa has been widely used to treat the anemia that develops in the HDCT setting."	( [The use of erythropoietin alpha in programs of high-dose chemotherapy]. Aglietta, M; Danova, M; Ferrari, S; Henry, D; Perillo, A; Pierelli, L; Scambia, G, 2000)	1.03
"Epoetin alfa has been shown to accelerate erythropoiesis and reduce allogeneic blood transfusion in major elective, noncardiac, nonvascular surgery and in certain anemic patients with chronic renal failure, nonmyeloid malignancies and human immunodeficiency virus infection."	( Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. Bieber, E, 2001)	1.29
"Epoetin alfa has been shown to safely increase preoperative hemoglobin (Hb) levels in anemic patients undergoing elective noncardiac, nonvascular surgery and is more effective than preoperative autologous blood donation in reducing the need for perioperative blood transfusions in orthopedic surgery patients."	( Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery. Stovall, TG, 2001)	1.34
"Epoetin alfa has been shown to increase haemoglobin concentration, decrease transfusion requirements and increase quality of life."	( Managing cancer-related anaemia with epoetin alfa. Itri, LM, 2002)	1.31
"Epoetin alfa has been in use for over a decade to increase hemoglobin in patients with cancer who develop chemotherapy-associated anemia. "	( The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Itri, LM, 2002)	2.15

Excerpt	Reference	Relevance
"Epoetin alfa patients had lower transfusion requirements (28.2% versus 33.3%), improvement or preservation versus deterioration of quality of life, and a higher proportion of responders (patients achieving a > or = 2 g/dL increase in hemoglobin levels unrelated to transfusion) (68.0% versus 22.9% for placebo)."	( Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Bajetta, E; da Costa, RM; Guastalla, JP; Janmohamed, R; Matulonis, U; Reinhardt, U; Vercammen, E, )	1.23

Excerpt	Reference	Relevance
"The Epoetin alfa-treated group showed a statistically significant improvement in the Kidney Disease Questionnaire symptom of fatigue in comparison with placebo."	( Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Agodoa, I; Churchill, DN; Gandra, SR; Gantotti, S; Gitlin, M; Keown, PA; Lei, L; Mayne, TJ; Poulin-Costello, M, 2010)	1.13
"Epoetin alfa treatment is optional for patients with cancer-related anemia and hemoglobin levels>10 g/dL and <12 g/dL, depending on clinical circumstances."	( Epoetin alfa therapy for patients with hematologic malignancies and mild anemia. Straus, DJ, 2003)	2.48
"Epoetin alfa treatment was well tolerated."	( Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy. de Wasch, G; Freund, M; Littlewood, TJ; Nortier, J; Pawlicki, M; Rapoport, B; Schuette, W; Vercammen, E; Wils, J, 2003)	2.48
"Epoetin alfa treatment in patients with a variety of malignancies has been shown to decrease transfusion requirements and improve hemoglobin levels and quality-of-life efficacy parameters."	( Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Bajetta, E; da Costa, RM; Guastalla, JP; Janmohamed, R; Matulonis, U; Reinhardt, U; Vercammen, E, )	1.23
"Epoetin alfa treatment was well tolerated."	( Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Bajetta, E; da Costa, RM; Guastalla, JP; Janmohamed, R; Matulonis, U; Reinhardt, U; Vercammen, E, )	1.23
"Epoetin alfa treatment was started on average at an Hb level of 10.6g/dl for NSCLC and 10.4g/dl for SCLC, respectively."	( Anaemia management with epoetin alfa in lung cancer patients in The Netherlands. Biesma, B; Brok, RG; Melissant, CF; van de Werf, PR, 2007)	1.37
"The Epoetin alfa treatment would continue for a total of 16 weeks."	( Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy. Sriuranpong, V; Suwanrusme, H; Voravud, N, 2007)	1.08
"Epoetin alfa treatment was also associated with significantly higher reticulocyte counts and serum erythropoietin levels in the preoperative period compared with placebo."	( Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery. Althaus, U; Galliker, B; Haeberli, A; Nydegger, UE; Rosenmund, A; Spirig, P; Walpoth, B, 1996)	1.47
"Epoetin alfa treatment plus either oral or IV iron supplementation significantly increased total RBC production, Hb, Hct, and reticulocytes over the values seen with the respective placebo treatments (p = 0.0001). "	( Role of oral versus IV iron supplementation in the erythropoietic response to rHuEPO: a randomized, placebo-controlled trial. Gassmann-Mayer, C; Hayes-Licitra, SA; Megens, JG; Musto, P; Nogarin, L; Olijhoek, G; Vercammen, E, 2001)	1.75
"Treatment with epoetin alfa resulted in significant increases in hemoglobin (P<0.0001)."	( Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Chakraborty, B; Helmke, S; Mancini, D; Maurer, MS; Teruya, S, 2013)	0.95
"Treatment with epoetin alfa also improved health-related quality of life in anemic cancer patients undergoing chemotherapy, and several controlled studies have documented increases in quality-of-life scores correlated with increases in hemoglobin."	( Chemotherapy-induced cognitive dysfunction: a clearer picture. O'Shaughnessy, JA, 2003)	0.66
"Treatment with epoetin alfa for this mixed anemia significantly improved hemoglobin levels and quality of life, and enabled adequate dosages of ribavirin to be maintained."	( Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. Chawla, S; Rivkin, AM, 2005)	2.11
"Treatment with epoetin alfa has repeatedly been shown to improve the quality of life (QoL) of cancer patients with anaemia. "	( Meta-analysis of the effects of epoetin alfa treatment on quality of life in anaemic cancer patients. , 2005)	0.96
"Treatment with epoetin alfa, an erythropoiesis-stimulating agent, as a means of reducing transfusion requirements has been studied in the critically ill and in patients receiving long-term mechanical ventilation."	( Anemia in the long-term ventilator-dependent patient with respiratory failure. Silver, MR, 2005)	0.67
"Treatment with epoetin alfa as a single weekly dose significantly increased Hb levels in patients with cancer who were undergoing radiotherapy. "	( Once-weekly dose of epoetinum alfa in cancer patients with anemia receiving radiotherapy. Carrizosa, CL; de Dios Sáez Garrido, J; Delgado Pérez, JM; Ocaña, CV; Ots, PM; Pérez, AR, 2005)	0.68
"Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events."	( Efficacy and safety of epoetin alfa in critically ill patients. An, R; Bowers, PJ; Burton, P; Corwin, HL; Corwin, MJ; Fabian, TC; Gettinger, A; Heard, S; Klausner, MA; May, A; Pearl, RG, 2007)	0.99
"Treatment with epoetin alfa led to an increase (albeit nonsignificant) in the number of AB units predonated compared with i.v."	( Epoetin alfa plus autologous blood donation in patients with a low hematocrit scheduled to undergo orthopedic surgery. Tryba, M, 1996)	2.08
"Treatment with epoetin alfa has also been shown to increase Hb and HCT levels and improve QOL in anemic cancer patients undergoing chemotherapy."	( Epoetin alfa use in gynecology. Past, present and future. Bachmann, GA, 2001)	2.09
"Treatment with epoetin alfa was well tolerated."	( Epoetin alfa in patients not on chemotherapy - Canadian data. Burdette-Radoux, S; Couture, F; Dolan, S; Kovacs, M; Lau, CY; McKenzie, M; Quirt, I; Robeson, C; Tang, SC, 2002)	2.1

Excerpt	Reference	Relevance
" We prospectively examined adverse events and vital signs after administering 100 mg of IV iron sucrose in each of 10 consecutive dialysis treatment sessions and compared results with those recorded in each of three consecutive dialysis sessions without iron treatment."	( Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Adhikarla, R; Cavallo, G; Charytan, C; Gagnon, S; Levin, N; Spinowitz, BS; Van Wyck, DB, 2000)	0.31
" We assessed safety by recording blood pressure and adverse events after iron sucrose injection and comparing results with those for the same patients during an observation control period."	( Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Al-Saloum, M; Charytan, C; Gagnon, S; Hafeez, T; Levin, N; Van Wyck, DB, 2001)	0.31
" Early placebo-controlled, randomized studies, as well as recent large, community-based trials in thousands of patients, have consistently shown recombinant human erythropoietin (rHuEPO, epoetin alfa) to be effective and safe in the treatment of chemotherapy-associated anemia."	( The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Itri, LM, 2002)	0.9
" This article provides an overview of the recent history and growing understanding of ESA-associated PRCA together with current approaches to the management of this rare side effect of an otherwise valuable therapy."	( Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)? Macdougall, IC, 2005)	0.33
" Adverse events were comparable between treatment groups."	( Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. Feusner, J; Hinds, PS; Hockenberry, M; Hord, JD; Rackoff, WR; Razzouk, BI; Williams, D, 2006)	0.55
"Clinical data have repeatedly shown that the erythropoiesis stimulating agents (ESAs) Epoetin alfa and darbepoetin alfa are safe and efficacious to treat anemia in patients on dialysis when used in accordance with the product label The safety profile of ESAs has recently been updated based on reports from clinical investigations that studied off-label uses of ESAs at doses designed to raise the Hb to above 13."	( Safety of erythropoiesis stimulating agents in patients on dialysis: current issues for nephrology nurses. Carter, B; Keen, M, )	0.35
" Erythropoietin seems to act as an anti-oxidant, diminishing the toxic oxidative effects of VCM on renal tissues."	( Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Aslan, C; Cetin, H; Ciris, M; Oktem, F; Olgar, S; Ozguner, F; Uz, E, 2007)	0.34
"Studies showing an adverse effect of ESA therapy on patient survival generally exhibit considerable methodological deficiencies."	( Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Dunst, J; Nowrousian, MR; Vaupel, P, 2008)	0.35
"When used as indicated, ESAs are valuable and safe drugs for the treatment of anemia and do not negatively affect patient survival."	( Erythropoiesis-stimulating agents: favorable safety profile when used as indicated. Dunst, J; Nowrousian, MR; Vaupel, P, 2008)	0.35
" Primary (safety) endpoints were the occurrence of anti-erythropoietin antibodies and the evaluation of adverse events (AEs)."	( Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Baldamus, C; Bronn, A; Koytchev, R; Krivoshiev, S; Siebert-Weigel, M; Wolf-Pflugmann, M, 2008)	0.35
" Deep vein thrombosis was diagnosed by Doppler result or adverse event report."	( An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Enny, C; Jones, SC; Langholff, W; Leitz, G; Stowell, CP, 2009)	0.59
"1%) in the standard of care group had a diagnosis of deep vein thrombosis either by Doppler or by adverse event report with normal Doppler."	( An open-label, randomized, parallel-group study of perioperative epoetin alfa versus standard of care for blood conservation in major elective spinal surgery: safety analysis. Enny, C; Jones, SC; Langholff, W; Leitz, G; Stowell, CP, 2009)	0.59
" Aside from these two events, reported adverse events were as expected for patients with Stage III - V CKD and similar in both treatment groups."	( Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Eckardt, KU; Haag-Weber, M; Hörl, WH; Roger, SD; Roth, K; Vetter, A, 2012)	0.38
" This article reviews the published data on the effectiveness of intravenous ascorbic acid in increasing the hemoglobin levels of patients with hyporesponse to epoetin alfa, as well as adverse effects of the administration of intravenous ascorbic acid specifically in relation to hyperoxalemia."	( Is intravenous ascorbic acid an effective and safe option for increasing hemoglobin levels in patients with a hyporesponse to epoetin alfa? Kear, TM, )	0.53
"Using the EMA dossiers and journal publications, this article reviews clinical safety data for these products, with emphasis on serious/severe adverse events and a special consideration of immunogenicity, venous thromboembolism, and mortality."	( Clinical safety of biosimilar recombinant human erythropoietins. Abraham, I; MacDonald, K, 2012)	0.38
" Adverse findings for both ior(®) EPOCIM and Eprex(®) were similar and were a consequence of thrombotic events (ulcerative skin lesions, swollen hock joints/lameness, stomach ulcers) and decreased body weight gains, all known adverse reactions to this class of drug in rats."	( Safety and biosimilarity of ior(®) EPOCIM compared with Eprex(®) based on toxicologic, pharmacodynamic, and pharmacokinetic studies in the Sprague-Dawley rat. Bolger, GT; Ledon, N; Pucaj, K; Riddle, K; Taylor, SR, 2014)	0.4
" The primary efficacy variable for both studies was change in blood hemoglobin (Hb) level from baseline to each post-baseline visit, and safety outcomes included adverse events (AEs)."	( Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies. Akizawa, T; Bernhardt, T; Berns, JS; Iekushi, K; Krueger, T; Macdougall, IC; Staedtler, G; Taguchi, M, 2019)	0.51
" Cumulative probabilities of recording an adverse event, either in terms of lack of effectiveness or safety issue, were the same for two switching categories CONCLUSIONS: In this large-scale Italian observational multi-database study, switching versus non-switching as well as switching from biosimilar/originator ESA α to any other epoetin in CKD patients is not associated with any effectiveness and safety outcomes."	( Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study. Addis, A; Belleudi, V; Cananzi, P; Davoli, M; Gini, R; Ientile, V; Ingrasciotta, Y; Pastorello, M; Scondotto, S; Tari, M; Traversa, G; Trifirò, G; Trotta, F, 2019)	0.51
" In addition, the safety analysis, consisting of adverse events and adverse drug reactions, showed comparable results between the two groups."	( Efficacy and Safety of CKD-11101 (Proposed Biosimilar of Darbepoetin-Alfa) Compared with Darbepoetin-Alfa in Patients on Hemodialysis: A Randomized, Double-Blinded, Parallel-Group Phase III Study. An, WS; Cho, WY; Chung, W; Do, JY; Jeon, JS; Jin, K; Joo, KW; Kang, DH; Kang, GW; Kim, DJ; Kim, JK; Kim, SW; Kim, Y; Kim, YL; Lee, CH; Lee, JP; Lee, JS; Lee, KW; Lee, KY; Oh, DJ; Park, SK; Shin, SK; Son, SH, 2020)	0.56
"The aim was to explore the adverse event (AE) reporting patterns and detect disproportionate reporting signals for cancer supportive care biosimilars in the US compared to their originator biologics."	( Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Almahasis, S; Qian, J; Tanni, KA; Truong, CB, 2021)	0.62
"The US Food and Drug Administration Adverse Event Reporting System database (January 1, 2004-March 31, 2020) was used to identify AE reports for filgrastim, pegfilgrastim, and epoetin alpha by type of product (originator biologics vs."	( Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Almahasis, S; Qian, J; Tanni, KA; Truong, CB, 2021)	0.62
" Prespecified adverse events of interest following administration, including blood transfusions requirement, blood pressure and hemoglobin excursions, the relationship between C - Reactive Protein (CRP) and hemoglobin, were assessed."	( Comparative Efficacy and Safety Study of Darbepoetin Alfa El-Ashmawy, NE; Ibrahim, AO; Khedr, EG; Kotb, NS; Salem, F, 2022)	0.98
" There were no significant differences in the incidence of adverse events between the EPIAO® and EPREX® groups."	( Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. Alexandrov, IV; Davydkin, IL; Isachkina, AN; Khadikova, NG; Kvitkova, LV; Li, M; Li, X; Miao, B; Mironova, TP; Omelchenko, AM; Perlin, DV; Selyutin, AA; Shilo, VY; Shutov, EV; Solovyova, OM; Tutin, AP; Vareesangthip, K; Vetchinnikova, ON; Zuev, AV, 2022)	0.72
" Overall, 527 adverse events of special interest (AESI) including PRCA occurred in 418 (6."	( Three-year safety observation of subcutaneous administration of epoetin-zeta in patients with chronic renal anemia: Results from PASCO II study. Fowler, H; Gomez Perez, S; Guilatco, R; Iwanowitsch, A; Kohnle, M; Patsialas, S; Salts, S; Xia, FR, 2023)	0.91
" The most frequently reported grade 3 or 4 treatment-emergent adverse events with luspatercept (≥3% patients) were hypertension, anaemia, dyspnoea, neutropenia, thrombocytopenia, pneumonia, COVID-19, myelodysplastic syndromes, and syncope; and with epoetin alfa were anaemia, pneumonia, neutropenia, hypertension, iron overload, COVID-19 pneumonia, and myelodysplastic syndromes."	( Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. Cluzeau, T; Degulys, A; Della Porta, MG; Dimicoli-Salazar, S; Fenaux, P; Garcia-Manero, G; Giuseppi, AC; Hayati, S; Jonasova, A; Keeperman, KL; Komrokji, RS; Kreitz, S; Li, J; Lin, CC; Paolini, S; Platzbecker, U; Pozharskaya, V; Prebet, T; Rose, S; Santini, V; Shetty, JK; Shortt, J; Tiong, IS; Valcarcel, D; Vodala, S; Zeidan, AM; Zhang, J, 2023)	1.35
"HIF-PHIs may be a convenient and safe alternative to ESAs in patients with NDD-CKD and anemia."	( An updated meta-analysis on the efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor treatment of anemia in nondialysis-dependent chronic kidney disease. Jia, L; Li, P; Zhang, HL; Zhao, H, 2023)	0.91

Excerpt	Reference	Relevance
" The half-life in the beta-phase was prolonged at lower doses of antiserum."	( Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. Kamiyama, H; Kato, M; Kato, Y; Kumaki, K; Miura, K; Okazaki, A; Sugiyama, Y, 1997)	0.3
" Standard pharmacokinetic methods were employed for analysis of the serum concentration time data."	( Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Johnson, CA; Kosorok, MR; Taylor, CA; Zimmerman, SW, 1999)	0.58
"The pharmacodynamic responses were equivalent between groups despite expected differences in total erythropoietin exposure."	( Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Cheung, W; Gunawardena, K; Minton, N, 2001)	0.58
"The aim of this multicenter, randomized, open-label study was to compare the pharmacokinetic and pharmacodynamic profiles of darbepoetin alfa, a new erythropoiesis-stimulating protein, and recombinant human erythropoietin (epoetin) after repeated intravenous dosing in patients with chronic kidney disease receiving hemodialysis."	( Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M; Heatherington, AC; Kaupke, C; Kleinman, K; Maroni, BJ; Messer-Mann, L; Olson, K; Walczyk, M, 2002)	0.78
" Pharmacokinetic profiles were measured during weeks 1 and 12 and at hemoglobin steady state (defined as a hemoglobin concentration within the target range for 4 consecutive weeks after week 12 with no change in study drug dose) or between weeks 36 and 40, whichever occurred first."	( Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M; Heatherington, AC; Kaupke, C; Kleinman, K; Maroni, BJ; Messer-Mann, L; Olson, K; Walczyk, M, 2002)	0.57
"At each of the 3 time points evaluated, the terminal half-life of darbepoetin alfa was 2 to 3 times longer and the clearance approximately 4 times slower than those of epoetin."	( Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M; Heatherington, AC; Kaupke, C; Kleinman, K; Maroni, BJ; Messer-Mann, L; Olson, K; Walczyk, M, 2002)	0.81
"The pharmacokinetic and pharmacodynamic profiles and safety data for darbepoetin alfa demonstrate that it can be administered less frequently than epoetin in patients with chronic kidney disease receiving hemodialysis, thus simplifying anemia management."	( Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M; Heatherington, AC; Kaupke, C; Kleinman, K; Maroni, BJ; Messer-Mann, L; Olson, K; Walczyk, M, 2002)	0.81
"A pharmacokinetic and pharmacodynamic (PK/PD) model for recombinant human erythropoietin (Epoetin alfa) in healthy subjects was developed to describe the time profiles of changes in serum Epoetin alfa and the pharmacological responses of percent reticulocytes, total red blood cell counts, and hemoglobin after single and multiple subcutaneous administration of Epoetin alfa."	( Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Cheung, WK; Jusko, WJ; Krzyzanski, W; Minton, N; Wacholtz, MC, 2005)	0.55
" No significant correlations were observed between pharmacokinetic parameters and pharmacodynamic effects."	( Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Burghen, E; Freeman, BB; Hinds, P; Iacono, LC; Razzouk, BI; Stewart, CF, 2006)	0.58
" Interesting but insignificant trends were noted in pharmacodynamic effects."	( Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Burghen, E; Freeman, BB; Hinds, P; Iacono, LC; Razzouk, BI; Stewart, CF, 2006)	0.58
"To describe the erythropoietin pharmacokinetic profile after once-weekly epoetin alfa treatment in critically ill patients."	( Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. Beaver, JS; Creteur, J; Diltoer, M; Hubloue, I; Piagnerelli, M; Roman, A; Spapen, HD; Stevens, E; Vercammen, E; Vincent, JL, 2006)	0.8
" We compared the two epoetins in two 12-week efficacy studies (S1, S2) with twice-weekly dosing, and a single-dose crossover pharmacokinetic (PK) study in severely anemic hemodialysis patients."	( Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Milutinović, S; Plavljanić, E; Trkulja, V, 2006)	0.33
" This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis."	( Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Beaver, JS; Massarella, J; McGowan, T; Vaccaro, NM; Wolfson, M, 2008)	0.78
"Extended dosing interval regimens of epoetin alfa yielded modest pharmacokinetic differences but a similar pharmacodynamic response, suggesting that less frequent, higher dosages of epoetin alfa may be as effective as the current three-times-weekly regimen in anemic patients who have chronic kidney disease and are not on dialysis."	( Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Beaver, JS; Massarella, J; McGowan, T; Vaccaro, NM; Wolfson, M, 2008)	0.86
"The pharmacokinetic properties of a new recombinant erythropoietin preparation (epoetin zeta, CAS 604802-70-2) compared to a reference product (epoetin alfa, CAS 113427-24-0) were analyzed after a single intravenous bolus injection of 10,000 IU in a two-period crossover design in 24 healthy volunteers."	( Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st Communication: A monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arsova, S; Bronn, A; Dimitrova, V; Kirkov, V; Koytchev, R; Kromminga, A; Richter, W; Siebert-Weigel, M; Wolf-Pflugmann, M, 2008)	0.76
"The subcutaneous bioavailability of a new recombinant erythropoietin preparation (epoetin zeta, CAS 604802-70-2) and the pharmacokinetic properties of this drug compared to a reference product (epoetin alfa, CAS 113427-24-0) were analyzed after a single intravenous bolus injection or subcutaneous injection of 10,000 IU in a three-period crossover design in 48 healthy volunteers."	( Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers. Arsova, S; Bronn, A; Dimitrova, V; Kirkov, V; Koytchev, R; Kromminga, A; Richter, W; Siebert-Weigel, M; Wolf-Pflugmann, M, 2008)	0.75
"To describe the pharmacokinetic profiles of six different dosing regimens for epoetin alfa, and whether more rapid and robust reticulocytosis can be elicited with more frequent administration of epoetin alfa in anemic critically ill patients."	( Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Arroliga, AC; Beaver, JS; Guntupalli, KK; Kelly, K; Langholff, W; Marino, K, 2009)	0.84
" The pharmacokinetics of epoetin alfa did not predict pharmacodynamic response in anemic critically ill patients."	( Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Arroliga, AC; Beaver, JS; Guntupalli, KK; Kelly, K; Langholff, W; Marino, K, 2009)	0.92
"The aim of this study was to compare the pharmacokinetic and pharmacodynamic characteristics of a new recombinant human erythropoietin (test) formulation with an existing branded (reference) formulation after a single subcutaneous administration."	( Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers. Jang, IJ; Kim, BH; Kim, KP; Kim, TE; Shin, SG; Yu, KS, 2010)	0.36
" Serial blood samples were taken up to 120 hours after drug administration for the pharmacokinetic assessments and up to 240 hours for reticulocyte counts as the pharmacodynamic end point."	( Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers. Jang, IJ; Kim, BH; Kim, KP; Kim, TE; Shin, SG; Yu, KS, 2010)	0.36
"In this small, selected group of healthy male volunteers, there were no significant differences in pharmacokinetic parameters or effects on reticulocytes between a test formulation and a reference formulation of recombinant human erythropoietin."	( Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers. Jang, IJ; Kim, BH; Kim, KP; Kim, TE; Shin, SG; Yu, KS, 2010)	0.36
" A dense-sampling 48-hour pharmacokinetic profile was recorded at steady state after 11 doses of 100 IU epoetin alfa per kg of bodyweight."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Lissy, M; Ode, M; Roth, K, 2011)	0.8
" Moreover, an equivalent pharmacodynamic response was achieved with all compared epoetin alfa products, as confirmed by the hemoglobin AUEC ratio's 90% CI falling within the predefined acceptance margins of 96."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Lissy, M; Ode, M; Roth, K, 2011)	0.81
"The aim of this study was to develop an integrated pharmacokinetic and pharmacodynamic (PK/PD) model and assess the comparability between epoetin alfa HEXAL/Binocrit (HX575) and a comparator epoetin alfa by a model-based approach."	( Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. Balser, S; Berghout, A; Fink, M; Krzyzanski, W; Lowe, PJ; Yan, X, 2012)	0.79
"Our objective was to show, using two examples, that a pharmacokinetic (PK) similarity analysis can be performed using nonlinear mixed-effects models (NLMEM)."	( Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling. Balser, S; Dubois, A; Gsteiger, S; Mentré, F; Pigeolet, E; Pillai, G; Steimer, JL, 2012)	0.38
" The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software (Thermo Scientific, ver."	( The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients. Djukanović, L; Ležaić, V; Marić, I; Miljković, B; Pejovic, V; Petković, N; Simić-Ogrizović, S; Vučićević, K, 2013)	0.39
"020) and elimination half-life (50."	( The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients. Djukanović, L; Ležaić, V; Marić, I; Miljković, B; Pejovic, V; Petković, N; Simić-Ogrizović, S; Vučićević, K, 2013)	0.39
"Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients."	( The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients. Djukanović, L; Ležaić, V; Marić, I; Miljković, B; Pejovic, V; Petković, N; Simić-Ogrizović, S; Vučićević, K, 2013)	0.39
"This study examined the safety, pharmacodynamic (PD), and pharmacokinetic (PK) biosimilarity of the human recombinant erythropoietin (EPO) products ior(®) EPOCIM and Eprex(®) following a 28-day repeated intravenous dose administration in male and female Sprague-Dawley rats with a 14-day recovery period."	( Safety and biosimilarity of ior(®) EPOCIM compared with Eprex(®) based on toxicologic, pharmacodynamic, and pharmacokinetic studies in the Sprague-Dawley rat. Bolger, GT; Ledon, N; Pucaj, K; Riddle, K; Taylor, SR, 2014)	0.4
"A population pharmacokinetic pharmacodynamic (PK/PD) model describing the effect of epoetin alfa on hemoglobin (Hb) response in hemodialysis patients was developed."	( Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model. Doshi, S; Mould, DR; Perez Ruixo, JJ; Wu, L, 2015)	0.9
" This study was planned to demonstrate the pharmacokinetic and pharmacodynamic comparability of PDA10 to an existing epoetin alfa (Eprex) after a single intravenous administration to healthy adult male volunteers."	( Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study. Cho, DY; Oh, M; Yoon, J, 2015)	0.63
" Plasma erythropoietin concentrations were measured using an enzyme-linked immunosorbent assay and the pharmacokinetic parameters of the two treatments were compared."	( Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study. Cho, DY; Oh, M; Yoon, J, 2015)	0.42
"PDA10 and Eprex met the regulatory criteria for bioequivalence with respect to their pharmacokinetic profiles and pharmacodynamic actions."	( Pharmacokinetic and Pharmacodynamic Comparison of Two Recombinant Human Erythropoietin Formulations, PDA10 and Eprex, in Healthy Korean Male Volunteers: A Randomized, Double-Blinded, Single-Dose, Two-Period Crossover Study. Cho, DY; Oh, M; Yoon, J, 2015)	0.42
" The primary PD end point was the geometric mean ratio (GMR) of the 2 treatments for area under the effect curve for Hb from day 1 through 48 hours after the final dose of study drug administration on day 26, and the primary PK end point was the GMR of the 2 treatments for AUC0-48 and Cmax for epoetin after the final dose of study drug on day 26."	( Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects. Kumbhat, S; Martin, N; Ramaiya, A; Reid, S; Stalker, D; Zhang, J, 2016)	0.43
"The purpose of this study was to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) equivalence of single 100 U/kg subcutaneous doses of Epoetin Hospira and Epogen in healthy male subjects as part of an overall program to demonstrate biosimilarity of Epoetin Hospira to the reference product Epogen."	( Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects. Martin, NE; Ramaiya, A; Reid, S; Stalker, D; Wisemandle, WA, 2016)	0.43
" The primary PK end points were the geometric mean ratios (GMRs) of the 2 treatments for AUC0-t and Cmax based on the BAEC, and the primary PD end points were the GMRs of the 2 treatments for AUC0-t and Cmax for reticulocyte percentage."	( Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects. Martin, NE; Ramaiya, A; Reid, S; Stalker, D; Wisemandle, WA, 2016)	0.43
" The primary objective was to compare the pharmacokinetic profile of different formulations of epoetin alfa after a single subcutaneous administration to healthy volunteers of 40 000 IU of Eprex/Erypo® and Hemax® PFS."	( Pharmacokinetic and pharmacodynamic study of three products of epoetin alfa as single subcutaneous dose in healthy volunteers. Beider, L; di Girolamo, G; Diez, RA; Fornari, MC; González Bagnes, MF; González, CD; González, E; Keller, GA, 2023)	1.37

Excerpt	Reference	Relevance
" Therefore, we conducted a 6-month, prospective, randomized trial comparing low-dose rHuEPO alone and in combination with androgens for the treatment of the anemia of end-stage renal failure."	( A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Buhsmer, JP; Burke, JF; Dunn, SR; Gaughan, WJ; Liss, KA; Mangold, AM; Michael, B, 1997)	0.3
"In the current meta-analysis of published literature, erythroid response (ER) rates with EPO as a single agent versus its combination with granulocyte-colony-stimulating factor (G-CSF) or granulocyte-macrophage-colony-stimulating factor (GM-CSF) were compared."	( An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Duh, MS; Lefebvre, P; Moyo, V; Mundle, S; Rastogi, R; Vekeman, F, 2009)	0.35
"001) or in combination with G-CSF/GM-CSF (50."	( An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Duh, MS; Lefebvre, P; Moyo, V; Mundle, S; Rastogi, R; Vekeman, F, 2009)	0.35
"In the current meta-analysis, higher doses of EPO demonstrated better ER rates compared with EPO at standard doses alone or in combination with G-CSF/GM-CSF."	( An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Duh, MS; Lefebvre, P; Moyo, V; Mundle, S; Rastogi, R; Vekeman, F, 2009)	0.35

Excerpt	Reference	Relevance
" However, bioavailability is improved by instilling the dose into a dry peritoneum."	( Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Johnson, CA; Kosorok, MR; Taylor, CA; Zimmerman, SW, 1999)	0.58
" In hemodialysis patients, subcutaneous epoetin omega apparently provides greater bioavailability and anti-anemic effect per administered dose (IU) than epoetin alpha."	( Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. Milutinović, S; Plavljanić, E; Trkulja, V, 2006)	0.33
"The subcutaneous bioavailability of a new recombinant erythropoietin preparation (epoetin zeta, CAS 604802-70-2) and the pharmacokinetic properties of this drug compared to a reference product (epoetin alfa, CAS 113427-24-0) were analyzed after a single intravenous bolus injection or subcutaneous injection of 10,000 IU in a three-period crossover design in 48 healthy volunteers."	( Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers. Arsova, S; Bronn, A; Dimitrova, V; Kirkov, V; Koytchev, R; Kromminga, A; Richter, W; Siebert-Weigel, M; Wolf-Pflugmann, M, 2008)	0.75
"The results show, for the first time in a prospective randomized clinical study, equivalent bioavailability at steady state and similar potency of the US-marketed Epogen® and the European-marketed Binocrit®."	( Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study. Lissy, M; Ode, M; Roth, K, 2011)	0.58

Excerpt	Relevance	Reference
") treatment with epoetin alfa 300 IU/kg twice weekly for 3 weeks was the optimum dosage for facilitation of AB donation and minimization of the decrease in Hct prior to elective orthopedic surgery."	( Epoetin alfa for autologous blood donation in patients with rheumatoid arthritis and concomitant anemia. Mercuriali, F, 1996)	2.08
" However, the optimum dose and dosage regimen remains to be defined."	( Autologous blood donation plus epoetin alfa in nonanemic orthopedic surgery patients. Baudoux, E, 1996)	0.58
"The optimum dosage of subcutaneous (s."	( Use of epoetin alfa in autologous blood donation programs for patients scheduled for elective cardiac surgery. Althaus, U; Galliker, B; Haeberli, A; Nydegger, UE; Rosenmund, A; Spirig, P; Walpoth, B, 1996)	0.75
" A randomized, multicenter trial was conducted comparing the safety and efficacy of a weekly Epoetin alfa dosing regimen in patients with hemoglobin levels > or = 10 to < or = 13 g/dL scheduled to undergo major elective orthopedic arthroplasty, with a daily regimen previously shown to be effective."	( A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Di Cesare, P; Frei, D; Friedman, RJ; Goldberg, MA; Guilfoyle, M; Jove, M; McCutchen, JW; Poss, R; Young, D, 1996)	0.75
" Optimal dosing regimens and surgical patients most likely to benefit fro Epoetin alfa therapy must be established."	( Improving the efficacy of preoperative autologous blood donation in patients with low hematocrit: a randomized, double-blind, controlled trial of recombinant human erythropoietin. Abels, RI; Bolgiano, DC; Goodnough, LT; Hellman, RM; Johnston, MF; Price, TH; Sacher, RA; Vogler, WR, 1996)	0.52
" On the basis of these results, perioperative Epoetin alfa therapy in conjunction with iron supplementation may have a place as an adjunct to elective orthopedic surgery, particularly if dosing regimens less frequent than once daily can be established."	( Use of recombinant human erythropoietin in the perioperative period of orthopedic surgery. Faris, P, 1996)	0.55
" We evaluated several dosing regimens and schedules for perioperative epoetin alfa administration."	( Perioperative epoetin alfa increases red blood cell mass and reduces exposure to transfusions: results of randomized clinical trials. Goldberg, MA, 1997)	0.89
" Reductions in epoetin alpha dosage were made during the study if Hb level increased to >15 g dl(-1)."	( Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer. Bell, DR; De Campos, ES; Ewers, SB; Morant, R; Rosso, R; Schatzmann, E; Steward, WP; Stocker, H; Sundal, E; Thatcher, N; Vansteenkiste, JF; Varghese, G, 1999)	0.3
" The current study was designed to determine whether absorption after administration into a dry peritoneum is improved by extending the dry dosing period from 4 to 8 hours."	( Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique. Johnson, CA; Kosorok, MR; Taylor, CA; Zimmerman, SW, 1999)	0.58
" Only patients with a serum ferritin level greater than 1,000 microg/L were excluded; patients with a serum ferritin level below 150 microg/L were given a more aggressive IV dosing regimen to get into range for the standard protocol."	( Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Chandler, G; Elston, O; Harchowal, J; Macdougall, IC, 1999)	0.3
" dosing is undesirable."	( Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients. Bhattacharya, A; Burkart, J; Johnson, CA; Kosorok, MR; Taylor, CA; Wakeen, M; Zimmerman, SW, )	0.39
"To determine the impact of two different recombinant human erythropoietin (epoetin alfa) dosing strategies on the number of red blood cell (RBC) transfusions, and explore relationships between specific patient and drug regimen variables with epoetin alfa therapy outcomes."	( Factors associated with successful epoetin alfa therapy in premature infants. Reiter, PD; Rosenberg, AA; Valuck, RJ, 2000)	0.81
"Infants who received epoetin alfa therapy three times weekly for more than one week were categorized into two epoetin alfa dosing strategy groups: group A (300-749 units/kg/wk) and group B (750-1200 units/kg/wk)."	( Factors associated with successful epoetin alfa therapy in premature infants. Reiter, PD; Rosenberg, AA; Valuck, RJ, 2000)	0.9
" No significant impact on outcome was attributed to overall dosing strategy (group A vs."	( Factors associated with successful epoetin alfa therapy in premature infants. Reiter, PD; Rosenberg, AA; Valuck, RJ, 2000)	0.58
"Epoetin alfa dosing strategy, as defined in our study, did not significantly affect the number of transfusions."	( Factors associated with successful epoetin alfa therapy in premature infants. Reiter, PD; Rosenberg, AA; Valuck, RJ, 2000)	2.03
" Three open-label community-based studies of epoetin alfa in cancer-related anemia (two using three-times-weekly dosing and one using once-weekly dosing) in more than 7,000 patients have been performed."	( Management of cancer-related anemia: epoetin alfa and quality of life. Soignet, S, 2000)	0.84
"To determine whether the response to recombinant erythropoietin is dose dependent in men undergoing radical prostatectomy and to elucidate the relative cost-effectiveness of two dosing regimens."	( Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Lepor, H; Nieder, AM; Rosenblum, N, 2001)	0.31
" The 300 IU/kg dosing regimen was significantly more cost effective than the 600 IU/kg dosing regimen."	( Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. Lepor, H; Nieder, AM; Rosenblum, N, 2001)	0.31
" Based on the results of this study, the clinical benefits and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are similar to those observed in the historical experience with the three-times-weekly dosage schedule."	( Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Cleeland, CS; Einhorn, LH; Gabrilove, JL; Livingston, RB; Sarokhan, B; Winer, E, 2001)	0.78
" Recent data indicate that several factors, including time on dialysis, Epoetin alfa dosing practices, peritoneal dialysis modality, younger age, African American race, and some comorbidities, may increase the risk for lower hemoglobin levels."	( Hyporesponse to Epoetin alfa: patients at risk. Case study of the anemic patient. Deziel, SM, 2002)	0.89
" The efficacy and safety of epoetin alfa did not vary according to dosing frequency (1 vs."	( Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Blasi, MV; Demetri, GD; Gabrilove, JL; Glaspy, J; Hill, RJ, 2002)	0.99
" A large community-based trial has demonstrated that the more convenient once-weekly dosing schedule resulted in good efficacy and safety profiles."	( The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Itri, LM, 2002)	0.7
" The purpose of this randomized, double-blind, noninferiority study is to determine whether darbepoetin alfa is as effective as epoetin for the treatment of anemia in hemodialysis patients when administered at a reduced dosing frequency."	( Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Beatey, R; Lindberg, JS; Maroni, BJ; McDermott-Vitak, A; Nissenson, AR; Picarello, N; Soroka, SD; Swan, SK; Wang, C, 2002)	0.81
"These results show that darbepoetin alfa maintains hemoglobin concentrations as effectively and safely as epoetin in patients with CKD, but with a reduced dosing frequency."	( Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Beatey, R; Lindberg, JS; Maroni, BJ; McDermott-Vitak, A; Nissenson, AR; Picarello, N; Soroka, SD; Swan, SK; Wang, C, 2002)	0.88
" Dosage should be initiated at 10 000 IU three times/week or 40 000 IU once/week and be titrated to maintain hemoglobin at 12 g/dl."	( Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Blade, J; Dammacco, F; Degos, L; Itri, L; Kyle, R; Liso, V; Littlewood, TJ; Ludwig, H; Mandelli, F; Meloni, G; Molica, S; Osterborg, A; Pangalis, GA; Rai, K; San Miguel, J; Schmitt, B; Voliotis, D, 2002)	0.31
" Nursing knowledge and management of Epoetin alfa dosing and administration techniques, peritonitis and other infections, and iron supplementation may help improve anemia-related outcomes in peritoneal dialysis patients."	( Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient. MacCracken, MA, 2001)	0.58
"The data from this study suggest that this dosing regimen of epoetin alfa is effective and safe in pediatric cancer patients with chemotherapy-related anemia."	( Is epoetin alfa a treatment option for chemotherapy-related anemia in children? Akyüz, C; Büyükpamukçu, M; Kutluk, T; Varan, A, 2002)	1.18
" Darbepoetin alfa is a new erythropoietic protein with greater biologic activity and a longer dosing interval than those of r-HuEPO."	( Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease. Hudson, JQ; Sameri, RM, 2002)	1.39
" Recombinant HuEPO produces a hemoglobin response in 50-60% of patients with cancer; however, to obtain this response rate, frequent dosing is required."	( Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Valley, AW, 2002)	0.55
" These properties allow patients to be treated with longer dosing intervals than with r-HuEPO."	( Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Scott, SD, 2002)	0.56
" Less strong evidence supports an alternative weekly (40 000 U/wk) dosing regimen, based on common clinical practice."	( Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Bennett, CL; Browman, GP; Cella, D; Djulbegovic, B; Goode, MJ; Gordon, MS; Jakubowski, AA; Lee, SJ; Lichtin, AE; Miller, CB; Rarick, MU; Regan, DH; Rizzo, JD; Seidenfeld, J; Woolf, SH, 2002)	0.31
" They should be aware of clinical trials that have suggested advantages of improved dosing schedules and new applications for epoetin alfa."	( Epoetin alfa: current and future indications and nursing implications. Buchsel, PC; Murphy, BJ; Newton, SA, )	1.78
" Dosing was discontinued for 3 patients prior to receiving all 24 doses because of gastric residuals (n = 1; 5 mL/kg), stage I NEC (n = 1; 10 mL/kg), or symptomatic patent ductus arteriosus (n = 1; 20 mL/kg)."	( Tolerance of simulated amniotic fluid in premature neonates. Ashmeade, TL; Auerbach, DA; Beltz, SE; Calhoun, DA; Christensen, RD; Hudak, ML; Maheshwari, A; Sullivan, SE, 2002)	0.31
"The aim of this multicenter, randomized, open-label study was to compare the pharmacokinetic and pharmacodynamic profiles of darbepoetin alfa, a new erythropoiesis-stimulating protein, and recombinant human erythropoietin (epoetin) after repeated intravenous dosing in patients with chronic kidney disease receiving hemodialysis."	( Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Allon, M; Heatherington, AC; Kaupke, C; Kleinman, K; Maroni, BJ; Messer-Mann, L; Olson, K; Walczyk, M, 2002)	0.78
" Further research is ongoing with less frequent dosing regimens."	( Epoetin alfa as a supportive measure in hematologic malignancies. Straus, DJ, 2002)	1.76
"Fixed dosing is potentially more convenient than weight-based dosing for both patients and physicians."	( Comparing the efficacy and safety of fixed versus weight-based dosing of epoetin alpha in anemic cancer patients receiving platinum-based chemotherapy. Gasparini, G; Granetto, C; Lampignano, M; Mantovani, G; Martoni, A; Mattioli, R; Pezzella, G; Porrozzi, S; Ricci, S; Tacconi, F; Testore, F, )	0.13
" Further evaluation of alternative epoetin alfa dosing schedules and use of epoetin alfa in treating anemia in patients with specific hematologic malignancies is ongoing."	( Epoetin alfa therapy for patients with hematologic malignancies and mild anemia. Straus, DJ, 2003)	2.04
"QW dosing of epoetin alfa is as effective as TIW dosing in increasing Hb levels, which was associated with improved QOL in anemic HIV-positive patients."	( Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients. Bowers, P; Goon, B; Grossman, HA; Leitz, G, 2003)	1.07
"0001), and the mean changes in RBV dosage were -34 mg/day for epoetin alfa versus -146 mg/day (p=0."	( Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R, 2003)	0.94
" These data were used to determine the initial dose and dosing schedule, dose changes, and changes in hemoglobin concentrations after 4, 8, and 12 weeks of treatment, adjusted for red blood cell (RBC) transfusions, and the incidence of RBC transfusions over time."	( A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Adamson, R; Rossi, G; Schwartzberg, L; Shiffman, R; Stolshek, B; Tomita, D, 2003)	0.53
"2%]) received an initial dosage of 200 microg q2wk."	( A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Adamson, R; Rossi, G; Schwartzberg, L; Shiffman, R; Stolshek, B; Tomita, D, 2003)	0.53
" Clinical considerations, dosing equivalency, direct and indirect costs, payer mix, and reimbursement level are issues that should be considered by a multidisciplinary team."	( Considerations in darbepoetin alfa cost and reimbursement: a model for pharmacy managers. Anderson, ER; Gibson, G, 2003)	0.63
" Results from this pilot study suggest that higher initial once-weekly dosing of epoetin alfa followed by less frequent maintenance dosing appears to be feasible for treating anemia in cancer patients undergoing chemotherapy."	( Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Kuzur, M; Liggett, W; Miranda, F; Patton, J; Porter, L; Varsos, H, 2004)	1.99
" Ongoing research is now evaluating ways to improve the response rate to epoetin alfa, the potential benefits of alternative dosing regimens and early treatment intervention, and nonanemia-related indications (e."	( The evolving role of epoetin alfa in cancer therapy. Henry, DH, 2004)	0.87
" Additional studies regarding patients most likely to benefit from EPO therapy, the most effective dosing regimen, and use of adjunctive therapies are needed."	( Use of epoetin alfa in critically ill patients. Camamo, JM; Erstad, BL; Pajoumand, M, 2004)	0.78
" The longer dosing intervals offered by these new preparations may decrease healthcare expenses and enhance patient adherence."	( Managing hematologic toxicities: novel therapies. Nirenberg, A, 2003)	0.32
"Although direct comparative trials have not been performed with these agents, information published in the last several years regarding their clinical efficacy, safety, and dosing is sufficient, in most cases, to compare costs."	( Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Boggie, D; DeLattre, M; Morreale, A; Plowman, B; Schaefer, M, 2004)	0.6
" Recent clinical trials in the nephrology and oncology therapeutic areas are summarized, highlighting study designs, dosing regimens, patient entry criteria, study endpoints, and published results."	( Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Boggie, D; DeLattre, M; Morreale, A; Plowman, B; Schaefer, M, 2004)	0.6
"Therapeutic substitution with darbepoetin alfa was started according to the US Oncology Pharmacy and Therapeutics Committee's recommended dosing guidelines: anemic patients with cancer received a starting dosage of darbepoetin alfa 200 microg every 2 weeks regardless of whether or not they had previously received epoetin alfa."	( Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Alley, JL; Giffin, SA; Scheifele, AC; Smith, SL; Thames, WA; Yao, B, 2004)	0.82
" No variation in transfusion rates was observed across weight categories in patients who received a fixed dosage of darbepoetin alfa."	( Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Alley, JL; Giffin, SA; Scheifele, AC; Smith, SL; Thames, WA; Yao, B, 2004)	0.75
"A darbepoetin alfa starting dosage of 200 microg subcutaneously every 2 weeks administered according to US Oncology-recommended dosing guidelines is effective in treating chemotherapy-induced anemia in both epoetin alfa-naive patients and those switched from epoetin alfa."	( Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naïve patients and patients switched from epoetin alfa. Alley, JL; Giffin, SA; Scheifele, AC; Smith, SL; Thames, WA; Yao, B, 2004)	1.02
" However, recent studies suggest that epoetin alfa can increase hemoglobin levels and facilitate maintenance of RBV dosage in patients with chronic hepatitis C who became anemic during standard combination therapy."	( Role of epoetin alfa in maintaining ribavirin dose. Afdhal, NH, 2004)	1.03
" Anaemia in patients treated with interferon plus RBV combination therapy can be managed effectively and safely with once weekly epoetin alfa without sacrificing optimal dosing of RBV."	( Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Bräu, N, 2004)	1.97
" We conclude that there is no basis for inferring the survival benefits (or detriments) of increasing a patient's hematocrit by adjusting the dosing of epoetin."	( Improved survival with higher hematocrits: where is the evidence? Cotter, DJ; Stefanik, K; Thamer, M; Zhang, Y, )	0.13
" The secondary aim was to assess whether the frequency of dosing (once, twice or thrice weekly) influenced the Hb concentration response."	( Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Becker, GJ; Kent, AB; Leikis, MJ; McMahon, LP, 2004)	0.57
" Similar significant changes in the Hb concentration were seen at different dosing frequencies."	( Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. Becker, GJ; Kent, AB; Leikis, MJ; McMahon, LP, 2004)	0.57
" The current study was conducted to evaluate the clinical safety and efficacy of a less frequent dosing regimen (once weekly) in this population."	( Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Fink, JC; Garcia-Mayol, L; Provenzano, R; Suchinda, P; Von Hartitzsch, B; Woollen, SB; Zabaneh, R, 2004)	0.7
" Other, smaller studies using different dosing regimens in critically ill patients have also demonstrated that epoetin alfa can decrease the need for transfusion."	( Is there a place for epoetin alfa in managing anemia during critical illness? Givens, M; Lapointe, M, 2004)	0.85
" Because of the scarce amount of evidence and the diversity of dosing regimens used used, no strict recommendations can be drawn from this review."	( Is there a place for epoetin alfa in managing anemia during critical illness? Givens, M; Lapointe, M, 2004)	0.64
"Results of this study suggest that epoetin alfa at a dose of 40,000 IU administered five times over 2 weeks may confer even higher response rates than those seen with standard dosing regimens."	( Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy. Accettura, C; Beccaglia, P; Bertelletti, D; Cortesi, E; D'Auria, G; De Marinis, F; De Pasquale Ceratti, A; Mancuso, A; Pizzardi, N, 2004)	0.85
" to the subcutaneous route required an increase in dosage and in substantial additional cost."	( Epoetin in haemodialysis patients: impact of change from subcutaneous to intravenous routes of administration. Decaudin, B; Gautier, S; Lemaitre, V; Urbina, MA, 2004)	0.32
" The indicated dose of epoetin alfa is 150-300 IU/kg three times per week, but it is commonly dosed at 40,000-60,000 IU once weekly based on trial data and extensive clinical use."	( Treatment of cancer-related anemia with epoetin alfa: a review. Bajetta, E; Bidoli, P; Buzzoni, R; De Candis, D; De Dosso, S; Del Vecchio, M; Ferrari, L; Ferrario, E, 2004)	0.9
" Although peak serum concentrations of all compounds were inversely proportional to body weight, the percentage of change during dialysis was not related to dosage or body weight."	( Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. Chester, K; McMahon, LP; Walker, RG, 2004)	0.56
" No difference in conversion dosage could be determined between patients who were epoetin sensitive (<200 units/kg per week) or resistant (>200 units/kg per week, P = NS)."	( What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Cooper, B; Roger, SD, 2004)	0.57
"The original dosage reduction after the switch from epoetin alfa to weekly intravenous darbepoetin alfa may offset the increased relative cost of the latter."	( What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials? Cooper, B; Roger, SD, 2004)	0.82
" In recent years, concerns have been raised over the inconvenience and costs associated with the conventional three-times weekly (tiw) epoetin dosing regimen."	( Optimising anaemia management with epoetin beta. Morère, JF; Reed, N, 2004)	0.32
" A Cox proportional hazard regression analysis, adjusted for baseline variables, and a 5-knot cubic regression spline were used to model the dose-response relationship between epoetin and all-cause mortality."	( Epoetin requirements predict mortality in hemodialysis patients. Cotter, DJ; Kaufman, J; Stefanik, K; Thamer, M; Zhang, Y, 2004)	0.32
" In contrast to conventional wisdom, this study suggests that epoetin dosing requirements could provide important prognostic information beyond that predicted by hematocrit alone."	( Epoetin requirements predict mortality in hemodialysis patients. Cotter, DJ; Kaufman, J; Stefanik, K; Thamer, M; Zhang, Y, 2004)	0.32
" In the near future we expect that a wider range of epoetins, drug patent expiry, a more appropriate patient selection criteria and an improved dosage schedule may help increase the efficiency of cancer-related anaemia management."	( Clinical and economic impact of epoetins in cancer care. Barosi, G; Marchetti, M, 2004)	0.32
"For individuals with chemotherapy-related anemia, the clinical effectiveness of epoetin alfa (EPO) dosed once weekly ([QW], 40,000 units per dose) has been demonstrated to be indistinguishable from that observed with thrice-weekly dosing ([TIW], 10,000 units per dose)."	( Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. Crémieux, PY; Fastenau, JM; Fendrick, AM; Kosicki, G; Piech, CT, )	0.6
"To conduct a cost-minimization analysis comparing QW and TIW EPO dosing from a societal perspective."	( Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. Crémieux, PY; Fastenau, JM; Fendrick, AM; Kosicki, G; Piech, CT, )	0.37
" In the absence of cost differences between regimens, the noneconomic advantages of less-frequent dosing intervals should make weekly dosing increasingly attractive to patients, clinicians, and payers."	( Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia. Crémieux, PY; Fastenau, JM; Fendrick, AM; Kosicki, G; Piech, CT, )	0.37
"This study evaluated the impact of a new epoetin alfa dosing regimen on quality of life (QOL), transfusion requirements, and hemoglobin (Hb) levels in 133 patients with low-risk myelodysplastic syndrome (MDS) and Hb < or =10 g/dl."	( Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Azzarà, A; Balleari, E; Capochiani, E; Clavio, M; Cortelezzi, A; D'Arena, G; De Biasi, E; Ferrari, D; Francesconi, M; Grossi, A; Latagliata, R; Mitra, ME; Monarca, B; Musto, P; Niscola, P; Pagnini, D; Pecorari, P; Perego, D; Petti, MC; Pisani, F; Reyes, MT; Scaramella, G; Spadano, A; Spiriti, MA; Volpe, E, 2005)	0.87
" Dose adjustments effectively treat these hematologic side effects, but the resulting suboptimal dosing and potential impact on virologic response are major concerns."	( The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. Collantes, RS; Younossi, ZM, 2005)	0.33
" The aim of this study was to determine whether successful management of anemia could be maintained by changing the dosing schedule of epoetin alfa from 2 or 3 times per week to once-weekly administration via not only the subcutaneous (s."	( Efficacy of once-weekly epoetin alfa. Barre, P; Barth, C; Reichel, H; Suranyi, MG, 2004)	0.83
" There was a 46% drop in exposure of EPO from the first to the subsequent dosing events."	( Population pharmacokinetics of erythropoietin in critically ill subjects. Chakraborty, A; Cheung, W; Guilfoyle, M; Morgan, N; Natarajan, J; Vercammen, E, 2005)	0.33
" The most common initial dosage of darbepoetin alfa was 200 microg every two weeks (61% of darbepoetin alfa recipients), and the most common initial dosage of epoetin alfa was 40,000 units weekly (72%)."	( Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Boccia, RV; Davidson, SL; Green, L; Herrington, JD; Smith, RE; Tomita, DK, 2005)	0.93
"The most common initial dosage of darbepoetin alfa for CIA was 200 microg every two weeks, and the most common initial dosage of epoetin alfa was 40,000 units weekly."	( Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Boccia, RV; Davidson, SL; Green, L; Herrington, JD; Smith, RE; Tomita, DK, 2005)	0.93
" Postprotocol data showed statistically significant improvements in epoetin alfa dosing and monitoring and in the use of adjunctive therapy."	( Epoetin alfa protocol and multidisciplinary blood-conservation program for critically ill patients. Martin, BS; Pell, LJ; Shirk, MB, 2005)	2.01
" Several studies have been carried out to determine the optimum schedule of dosing to obtain maximum patient benefit."	( Phase III clinical trials with darbepoetin: implications for clinicians. Glaspy, J, 2005)	0.33
" In case of patients with Hb level exceeding > 14 g/dL or in case of non-response, the dosage was reconsidered."	( The impact of weekly dosing of epoetin alfa on the haematological parameters and on the quality of life of anaemic cancer patients. Argyriou, AA; Argyriou, K; Heras, P; Karagiannis, S; Mitsibounas, D; Papapetropoulos, S, 2005)	0.61
" Activity varied with treatment regimen (1 microg darbepoetin alfa congruent with 800 U for 3 times weekly dosing to 8,000 U for a single injection)."	( Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice. Begley, CG; Browne, JK; Egrie, JC; Elliott, S; Hartley, C; Khaja, R; McElroy, P; Molineux, G; Sasu, BJ; Schultz, H, 2005)	0.94
"We performed a phase I study of two fixed dosing schemes of cisplatin, a DNA cross-linker, with intravenous escalating topotecan, a DNA-topoisomerase I inhibitor."	( Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Briasoulis, E; Karavassilis, V; Mauri, D; Pavlidis, N; Pentheroudakis, G; Rammou, D; Tzamakou, E, 2005)	0.33
" There are five major considerations for the 'optimal' route of epoetin administration: efficacy; dosing frequency; convenience; safety and tolerability; and cost."	( Optimizing anaemia management with subcutaneous administration of epoetin. Besarab, A, 2005)	0.33
"The effectiveness of extended dosing of epoetin alfa beyond once-weekly (QW) has not been well explored in patients being treated for anaemia of chronic kidney disease (CKD)."	( Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Bhaduri, S; Curzi, M; Germain, M; Klausner, M; Ram, CV; Tang, KL, 2005)	1.01
"A retrospective chart review was conducted to assess the efficacy of extended epoetin alfa dosing in patients being treated for CKD-related anaemia."	( Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Bhaduri, S; Curzi, M; Germain, M; Klausner, M; Ram, CV; Tang, KL, 2005)	0.97
"5 years; 79% white, 54% female) who received extended epoetin alfa dosing for a mean of 10."	( Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Bhaduri, S; Curzi, M; Germain, M; Klausner, M; Ram, CV; Tang, KL, 2005)	0.99
"Data from private community nephrology practices showed that extended epoetin alfa dosing effectively maintained Hb > or =11."	( Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review. Bhaduri, S; Curzi, M; Germain, M; Klausner, M; Ram, CV; Tang, KL, 2005)	0.98
"The purpose of this study was to compare erythropoietin dosage requirements during subcutaneous versus intravenous administration in a hemodialysis population."	( Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. Collins, DM; Penner, SB; Vercaigne, LM, 2005)	0.33
"To determine whether extended epoetin alfa dosing schedules of up to once every four weeks are as effective as weekly dosing in maintaining hemoglobin (Hb) levels in patients with anemia of chronic kidney disease (CKD)."	( Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Bhaduri, S; Provenzano, R; Singh, AK, 2005)	1.03
" Patients were randomized to one of four subcutaneously administered epoetin alfa dosing regimens: 10,000 units (U) once weekly (QW), 20,000 U every two weeks (Q2W), 30,000 U every three weeks (Q3W) or 40,000 U every four weeks (Q4W)."	( Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Bhaduri, S; Provenzano, R; Singh, AK, 2005)	0.98
" Quality of life was maintained or improved from baseline to final within each dosing group."	( Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Bhaduri, S; Provenzano, R; Singh, AK, 2005)	0.75
"Approximately 90% of patients dosed once every two weeks and over 75% of patients dosed once every three or four weeks maintained mean Hb levels > or = 11."	( Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Bhaduri, S; Provenzano, R; Singh, AK, 2005)	0.75
"African-American non-smokers exhibit a diminished response to standard epoetin alfa dosing than non-smokers in other races."	( Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking. Brown, J; Fink, JC; Hsu, VD; Jones-Burton, C; Seliger, SL; Stackiewicz, L, 2005)	0.82
" These cost-savings are largely due to reduced utilization of these expensive biotechnology products with implementation of a dosing protocol."	( Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis. Brophy, DF; Kockler, DR; Lee, S; Proeschel, LA; Ripley, EB, 2005)	0.89
" This study examined dosing and hematologic outcomes with these agents in community oncology clinics."	( Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Fastenau, J; Mark, TL; McKenzie, RS; Piech, CT, 2005)	0.33
" Eleven patients required erythropoietin; their mean ribavirin dosage was higher but mean ribavirin concentration was lower compared to the 11 patients who did not require erythropoietin factor."	( Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection. Fung, J; Jain, A; Kashyap, R; Marcos, A; Vekatramanan, R; Yelochan, B, 2005)	0.33
" Head-to-head trials are comparing erythropoietic agents in a randomised setting; other trials are evaluating optimal dosage schedules."	( Evaluating erythropoietic agents for the treatment of anaemia in the oncology setting. Gascón, P, 2005)	0.33
"We compared the erythropoietin-alpha dosage requirements during subcutaneous administration (3 months pre-switch) and intravenous administration (months 4-6 post-switch)."	( Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration. Bernstein, KN; Collins, DM; Raymond, CB; Skwarchuk, DE; Vercaigne, LM, 2006)	0.33
" However, the optimal epoetin dosing schedule is unknown."	( Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia. , 2005)	0.89
" Three large, open-label, community studies of epoetin alfa for the treatment of chemotherapy-related anemia were retrospectively analyzed to assess the association of early hemoglobin response to subsequent transfusion requirements, subsequent hemoglobin response, quality of life, and epoetin alfa dosage administered over the study."	( Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. Campos, SM; Duh, MS; Lefebvre, P; Rosberg, J, 2005)	0.83
" All children required dosage increases to 900 IU/kg due to no response."	( Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Burghen, E; Freeman, BB; Hinds, P; Iacono, LC; Razzouk, BI; Stewart, CF, 2006)	0.58
" In myeloid disorders such as myelodysplasia, response to single-agent recombinant human erythropoietin is disappointing but significant synergism with granulocyte colony stimulating factor has been demonstrated and different dosing regimens may also improve response."	( Epoetin alfa: basic biology and clinical utility in cancer patients. Collins, G; Littlewood, T, 2005)	1.77
" These data warrant a randomized prospective trial in gynecologic oncology patients with careful attention to the timing of initiation of treatment, dosing regimens, and titration of growth factor."	( Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies. Barnes, MN; Case, AS; Kilgore, LC; Rocconi, RP, 2006)	0.65
" Use of this drug in existing patients treated with rHu-EPO (epoetin alfa; EPO) requires conversion dosing and the potential for serious alterations in previously stable and satisfactory hemoglobin levels."	( Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa. Capelli, JP; Kushner, H, 2006)	0.81
" At the end of six months, there was an analysis of the data to determine if the results warranted an adjustment in the DPO dose and if so, what the adjusted dosing factor should be."	( Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa. Capelli, JP; Kushner, H, 2006)	0.57
" The approved 30,000 IU once-weekly dosing regimen (as opposed to the 10,000 IU three-times weekly regimen) provides greater convenience and may result in improved treatment compliance."	( Epoetin beta in oncology: examining the current evidence. Ludwig, H, 2006)	0.33
" Neither epoetin dosage nor hemoglobin level was associated with cardiovascular adverse events or death."	( Effect of early correction of anemia on the progression of CKD. Fouqueray, B; Frei, D; Gassmann-Mayer, C; Hörl, WH; Levin, A; McClellan, WM; Roger, SD; Rossert, J, 2006)	0.33
" The objective of this study was to investigate dosing patterns, hematologic outcomes, and intervention costs with EPO and DARB in anemic CKD patients treated in an ambulatory care setting."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. McKenzie, RS; Mody, SH; Papatheofanis, FJ; Piech, CT; Suruki, RY, 2006)	0.33
" Once-weekly and extended dosing (> or = Q2W) was common in both groups."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. McKenzie, RS; Mody, SH; Papatheofanis, FJ; Piech, CT; Suruki, RY, 2006)	0.33
"Extended dosing (Q2W) was common in EPO- and DARB-treated patients with CKD-related anemia, with EPO-treated patients experiencing a significantly greater hematologic response (at Weeks 4, 8, and 12)."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. McKenzie, RS; Mody, SH; Papatheofanis, FJ; Piech, CT; Suruki, RY, 2006)	0.33
" Less frequent dosing offers potential benefits for patients, caregivers and health care providers."	( Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. Boccia, RV; Bosserman, L; Glaspy, J; Hu, E; Lloyd, RE; Patel, R; Rossi, G; Tomita, D; Vadhan-Raj, S, 2006)	0.6
" The open-label dosing and the patient attrition rate did not appear to influence overall study results."	( Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Charu, V; Gordan, LN; Henry, DH; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2006)	0.61
"Extended dosing (80 000 U Q2W) and once-weekly dosing (40 000 U QW) of EPO provided comparable safety and efficacy for chemotherapy-induced anemia."	( Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Charu, V; Gordan, LN; Henry, DH; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2006)	0.61
"We performed a prospective multicentre clinical trial in iron-replete haemodialysis patients to evaluate the efficacy of weekly low-dose (50 mg) intravenous iron sucrose administration for 6 months to maintain the iron status, and to examine the effect on epoetin dosage needed to maintain stable haemoglobin values in these patients."	( Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Ambühl, PM; Binet, I; Dickenmann, M; Keusch, G; Lüthi, L; Schiesser, D; Schmidli, M; Tsinalis, D; Wüthrich, RP, 2006)	0.33
"A regular 50 mg weekly dosing schedule of iron sucrose maintains stable iron stores and haemoglobin levels in haemodialysed patients and allows considerable dose reductions for epoetins."	( Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Ambühl, PM; Binet, I; Dickenmann, M; Keusch, G; Lüthi, L; Schiesser, D; Schmidli, M; Tsinalis, D; Wüthrich, RP, 2006)	0.33
" Darbepoetin alfa effectively alleviates CKD-associated anaemia with less frequent dosing than recombinant human erythropoietin (EPO)."	( Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients. Boquinhas, H; Carrera, F; Jorge, C; Lucas, C; Pais, MJ, 2006)	1.14
"Lower doses of darbepoetin alfa at extended dosing interval is as safe and effective as EPO-alfa for treating anaemia, suggesting that darbepoetin alfa is a more cost-effective therapeutic alternative to EPO-alfa in the management of anaemia associated with HIV infection in subjects receiving haemodialysis."	( Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients. Boquinhas, H; Carrera, F; Jorge, C; Lucas, C; Pais, MJ, 2006)	0.96
"We conclude that a higher initial dosing of epoetin alpha appears to be an efficient schedule for treating anemia in cancer patients undergoing chemotherapy, conferring higher response rates than those seen with standard doses."	( An induction dose of epoetin alpha of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Ceccherini, R; Dellach, C; Foladore, S; Leita, M; Milani, S; Mustacchi, G; Sisto, M, 2006)	0.33
"Post hoc subset analyses were conducted for 2 studies: a prospective, multicenter survey evaluating the prevalence of anemia in patients with CKD (the Prevalence of Anemia in Early Renal Insufficiency [PAERI] study) and a prospective, multicenter, open-label trial evaluating the efficacy and safety of QW epoetin alfa for the treatment of anemia associated with CKD (the Clinical Evaluation of Procrit Dosed Once Weekly in Patients With Anemia Due to Early Renal Insufficiency [POWER] study)."	( Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease. Lorber, DL; McClellan, W; Provenzano, R, )	0.56
"AMPS (Aranesp Monthly Preference Study) consisted of two studies of similar design, each with a 2-week screening/baseline period, a 20-week QM darbepoetin alfa dosing period, and an 8-week follow-up period."	( Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Audhya, P; Crouch, T; Hoggard, J; Levine, M; McMurray, S; Prathikanti, R; Scarlata, D, 2006)	0.83
" Of the patients converted from once-weekly Epoetin alfa, 86% (138/161) preferred darbepoetin alfa QM, and of all patients who expressed a preference, regardless of previous Epoetin alfa dosing frequency, 96% (305/319) preferred QM darbepoetin alfa."	( Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Audhya, P; Crouch, T; Hoggard, J; Levine, M; McMurray, S; Prathikanti, R; Scarlata, D, 2006)	0.89
"This study investigated dosing patterns and costs associated with the use of erythropoietic-stimulating therapy (EST) in patients with CKD not on dialysis who were newly starting EPO or DARB therapy in managed care organizations."	( Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Duh, MS; Gosselin, A; Lefebvre, P; Mody, SH; Scott McKenzie, R; Tak Piech, C, 2006)	0.33
" The mean dosing interval was determined for both groups."	( Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Duh, MS; Gosselin, A; Lefebvre, P; Mody, SH; Scott McKenzie, R; Tak Piech, C, 2006)	0.33
" Use of extended dosing (> or =q2wk) was common in both groups (63."	( Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Duh, MS; Gosselin, A; Lefebvre, P; Mody, SH; Scott McKenzie, R; Tak Piech, C, 2006)	0.33
"The majority of these CKD patients newly started on EST in managed care organizations received extended dosing regimens (> or =q2wk) of EPO or DARB."	( Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Duh, MS; Gosselin, A; Lefebvre, P; Mody, SH; Scott McKenzie, R; Tak Piech, C, 2006)	0.33
" Extended dosing of ESP has potential advantages for the patient and may also improve resource utilization."	( Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. Agarwal, AK, 2006)	0.33
"To investigate dosing patterns and drug costs of erythropoietic agents and assess the frequency of outpatient nephrologist visits in an elderly population with pre-dialysis chronic kidney disease (pCKD) newly initiated on epoetin alfa (EPO) or darbepoetin alfa (DARB)."	( Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Bookhart, BK; Duh, MS; Gosselin, A; Lefebvre, P; McKenzie, RS; Mody, SH; Piech, CT, 2006)	0.52
" The average dosing interval for both EPO and DARB was calculated and classified as once weekly (qw), every 2 weeks (q2w) or every 3 weeks or less frequently (> or = q3w)."	( Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Bookhart, BK; Duh, MS; Gosselin, A; Lefebvre, P; McKenzie, RS; Mody, SH; Piech, CT, 2006)	0.33
" Extended dosing (every 2 weeks or less frequently: > or = q2w) during treatment was observed in both groups (EPO: qw 49."	( Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Bookhart, BK; Duh, MS; Gosselin, A; Lefebvre, P; McKenzie, RS; Mody, SH; Piech, CT, 2006)	0.33
"Based on this analysis of claims data from more than 30 US healthcare plans, extended dosing (> or = q2w) of EPO and DARB was common in elderly pCKD patients treated with erythropoietic agents, with significantly higher weekly drug costs observed in the DARB group compared with the EPO group."	( Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Bookhart, BK; Duh, MS; Gosselin, A; Lefebvre, P; McKenzie, RS; Mody, SH; Piech, CT, 2006)	0.33
"This analysis was a post hoc evaluation of epoetin alfa dosage requirements in a subgroup of patients from the Effect of early Correction of Anemia on the Progression of CKD study."	( Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Frei, D; Gassmann-Mayer, C; McClellan, W; Rossert, J, 2007)	0.6
"Of the 93 patients evaluated in this subgroup analysis, 14 (15%) were hyporesponsive to epoetin (maximum dosage >100 IU/kg/week during stabilization)."	( Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Frei, D; Gassmann-Mayer, C; McClellan, W; Rossert, J, 2007)	0.34
" Front loading with weekly doses of either erythropoietic agent followed by a three-week-long dosing interval for maintenance treatment may be used to quickly correct anemia, improve convenience, and reduce costs."	( Anemia in cancer and critical care patients: pharmacoeconomic considerations. Reeder, CE, 2007)	0.34
" Moreover, studies suggest consistently that a 'front-loading' dosing regimen with epoetin alfa does not convey improved speed of Hb response over epoetin beta administered according to current clinical practice guidelines."	( Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. Oberhoff, C, 2007)	0.56
" Data from randomised, double-blind, placebo-controlled studies, and large, non-randomised, open-label, community-based studies, along with almost 15 years of practical experience, support the assertion that epoetin alfa administered at a dosage of 150-300 U/kg three times weekly or 40,000-60,000U once weekly, both of which are US FDA-approved dose administration schedules, can effectively and safely achieve anaemia treatment goals for the majority of patients with lymphoid malignancies."	( Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies. Henry, DH, 2007)	0.53
" We reviewed data showing the feasibility and effectiveness of treatment with the erythropoiesis-stimulating protein darbepoetin alfa at extended dosing intervals to treat anemia in patients with cancer receiving multicycle chemotherapy."	( Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. Natale, JJ; Stevenson, JG, 2007)	1.11
") dosage requirements is a notable characteristic of darbepoetin-alpha (DPO), as opposed to other epoetins (EPOs)."	( Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients. Icardi, A; Romano, U; Sacco, P; Salvatore, F, )	0.13
" DPO weekly mean dosage decreased from 40."	( Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients. Icardi, A; Romano, U; Sacco, P; Salvatore, F, )	0.13
" Of these patients, 806 had dosing data for at least 1 month before switch through to 6 months post switch (6 month cohort)."	( Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Pussell, BA; Walker, R, 2007)	0.77
" Centre and dosing frequency of epoetin alfa before switch were determinants of increased dose."	( Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration. Pussell, BA; Walker, R, 2007)	1.06
" The frequency of dosing was higher in the epoetin alfa group (1."	( Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? Pussell, BA; Walker, R, 2007)	0.86
" The type of facility (profit, chain, and affiliation status) at which a patient receives dialysis might affect epoetin dosing patterns and has implications for future epoetin policies."	( Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. Cotter, D; Dong, F; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2007)	0.34
" Dosing adjustments also differed by type of facility."	( Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. Cotter, D; Dong, F; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2007)	0.34
"Dialysis facility organizational status and ownership are associated with variation in epoetin dosing in the United States."	( Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. Cotter, D; Dong, F; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2007)	0.34
" Initial dose of drug was 150 units/kg/week subcutaneously, two or three times a week and dosage was adjusted to maintain the Hb at 10-12g%."	( 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis. Tasanarong, A; Thitiarchakul, S, 2007)	0.34
" Mean weekly of Espogen dosage was 8390 +/- 2452."	( 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis. Tasanarong, A; Thitiarchakul, S, 2007)	0.34
" With the introduction of the longer-acting erythropoiesis-stimulating agent darbepoetin alfa, there has been growing interest in longer dosing intervals for erythropoiesis-stimulating agents."	( Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Carrera, F; Disney, A; Molina, M, 2007)	0.57
"The purpose of this study was to evaluate the safety and efficacy of epoetin alfa (EPO) at an initial dose of 60,000 Units (U) once weekly (QW) followed by extended dosing of 80,000 U every 3 weeks (Q3W) in patients with chemotherapy-induced anemia (CIA)."	( An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Montoya, VP; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2007)	0.84
"Anemic patients (hemoglobin [Hb] < or = 11 g/dl) receiving Q3W chemotherapy for nonmyeloid malignancy were enrolled in this prospective, open-label, single-arm study to receive EPO 60,000 U subcutaneously (SC) QW (initial dosing phase [IDP]) until a target Hb level of 12 g/dl was reached (maximum 12 weeks)."	( An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Montoya, VP; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2007)	0.6
"These results suggest that initiation of EPO 60,000 U SC QW is effective in the treatment of CIA and that EPO 80,000 U SC Q3W can be an effective extended dosing option."	( An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Montoya, VP; Wilhelm, FE; Williams, D; Woodman, RC; Xie, J, 2007)	0.6
" Extended dosing of darbepoetin alfa and the new agent continuous erythropoiesis receptor activator appears effective."	( Pharmacist's role in managing anemia in patients with chronic kidney disease: potential clinical and economic benefits. Gilmartin, C, 2007)	0.65
"The NKF recommendations for ESA use are general and include dosing based on the measured and target hemoglobin concentrations, the rate of increase in hemoglobin, and clinical circumstances, with the route and frequency of administration determined by the CKD stage, treatment setting, efficacy, and ESA class."	( Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease. Grabe, DW, 2007)	0.34
" Variable costs were those which varied with dosing frequency."	( Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Attard, C; Churchill, DN; Goeree, R; Kallich, J; Macarios, D, 2007)	0.34
"66, if patients were converted to less frequent dosing using darbepoetin alfa."	( Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Attard, C; Churchill, DN; Goeree, R; Kallich, J; Macarios, D, 2007)	0.58
" Less frequent monitoring of iron therapy and less frequent dosing could decrease costs by CAD 678."	( Costs associated with erythropoiesis-stimulating agent administration to hemodialysis patients. Attard, C; Churchill, DN; Goeree, R; Kallich, J; Macarios, D, 2007)	0.34
"To compare the efficacy of extended epoetin alfa dosing in maintaining hemoglobin (Hb) concentrations in patients with and without diabetes as the primary cause of chronic kidney disease."	( Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Provenzano, R; Singh, AK, )	0.65
" Patients received 1 of 4 epoetin alfa dosing regimens administered subcutaneously for up to 16 weeks: 10,000 U once weekly (QW), 20,000 U every 2 weeks (Q2W), 30,000 U every 3 weeks (Q3W), or 40,000 U every 4 weeks (Q4W)."	( Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Provenzano, R; Singh, AK, )	0.68
" The percentage of patients achieving Hb maintenance, stratified by epoetin alfa dosing regimen, was similar in patients with and those without diabetes: QW (90."	( Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Provenzano, R; Singh, AK, )	0.62
" These results demonstrated that patients with diabetes responded in a similar manner as patients without diabetes to extended dosing of epoetin alfa up to Q4W."	( Hemoglobin maintenance with use of extended dosing of epoetin alfa in patients with diabetes and anemia of chronic kidney disease. Provenzano, R; Singh, AK, )	0.58
" Here we have investigated the dose-response to rhEPO and compared the effects of rhEPO with those of carbamylated rhEPO (CEPO) in a model of cerebral stroke in rats."	( Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Chopp, M; Heavner, G; Kapke, A; Lu, M; Pool, C; Renzi, M; Rhodes, K; Wang, Y; Zhang, RL; Zhang, ZG, 2007)	0.34
"To evaluate the effectiveness, the safety, and the quality of life by using once weekly dosing of Epoetin alfa (Eprex, Janssen-cilag) 40,000 units in the treatment of anemia in cancer patients receiving chemotherapy."	( Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy. Sriuranpong, V; Suwanrusme, H; Voravud, N, 2007)	0.82
"Once weekly dosing of Epoetin alfa 40,000 units therapy is safe and effective in remodeling anemia and significantly improves the quality of life in cancer patients receiving chemotherapy."	( Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy. Sriuranpong, V; Suwanrusme, H; Voravud, N, 2007)	0.92
"To compare real-world dosing patterns, drug costs, and hematologic outcome in anemic chronic kidney disease (CKD) patients, not receiving dialysis, who switched from darbepoetin alfa (DARB) to epoetin alfa (EPO) in a community practice setting."	( Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Bickimer, T; Bookhart, BK; Hymes, J; Jackson, JH; Mody, SH; Tak Piech, C, 2007)	0.74
" The goal of this study was to assess and compare EPO- and DARB-treated CKD patients with respect to dosing patterns, hematologic outcomes, and associated costs."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Bookhart, B; McKenzie, RS; Mody, S; Papatheofanis, F; Piech, CT; Smith, C, )	0.13
" Selection criteria included patients newly initiated on EPO or DARB between July 2002 and December 2003 who had at least 24 weeks of dosing and hematologic laboratory data available."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Bookhart, B; McKenzie, RS; Mody, S; Papatheofanis, F; Piech, CT; Smith, C, )	0.13
" Extended dosing (defined as > or =Q2W) was common in both groups."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Bookhart, B; McKenzie, RS; Mody, S; Papatheofanis, F; Piech, CT; Smith, C, )	0.13
"Extended dosing frequency (> or = Q2W) was common in both groups."	( Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Bookhart, B; McKenzie, RS; Mody, S; Papatheofanis, F; Piech, CT; Smith, C, )	0.13
"There are limited data suggesting that initiation of epoetin alfa at extended dosing intervals of every 2, 3, or 4 wk may be efficacious for treating anemia in patients who have chronic kidney disease and are not on dialysis (CKD-NOD)."	( Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Benz, R; Kelly, K; Schmidt, R; Wolfson, M, 2007)	2.03
" Dosage was adjusted to maintain Hb +/-1."	( Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Balla, J; Beyer, U; Csiky, B; Ehrhard, P; Harris, K; Locatelli, F; Ryckelynck, JP; Sulowicz, W, 2007)	0.34
"The inpatient dosing patterns and treatment costs in cancer and predialysis chronic kidney disease (CKD) patients treated with erythropoietic agents from a hospital pharmacy perspective were studied."	( Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Duh, MS; Lefebvre, P; McKenzie, RS; Mody, SH; Piech, CT; Vekeman, F; Watson, SH, 2007)	0.34
"To demonstrate the effectiveness of once-weekly (QW) rHuEPO dosing to effect improved hemoglobin levels, decreased transfusion use, and improved functional outcomes and QOL in pediatric leukemic patients (ALL) receiving maintenance chemotherapy."	( Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Abdelrazik, N; Fouda, M, 2007)	0.34
"EPO administration to renal patients is much more costly in Sweden than in the UK, primarily due to the higher dosage of EPO and iron supplementation used in Sweden."	( Cost-effectiveness analysis of treatment with epoietin-alpha for patients with anaemia due to renal failure: the case of Sweden. Glenngård, AH; Persson, U; Schön, S, 2008)	0.35
" More frequent dosing with epoetin alfa is recommended by the labeled administration guidelines because it has a shorter half-life than darbepoetin alfa."	( Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Coyne, DW; Wish, JB, 2007)	0.64
" Dosage was adjusted to maintain patients' Hb within +/-1."	( C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. Adamis, H; Azer, M; Beyer, U; Coyne, DW; Dalal, S; Fraticelli, M; Lok, CE; Rosansky, S; Spinowitz, B; Villa, G, 2008)	0.35
" We estimated the dose-response relationship for the average epoetin dose and hematocrit during a 3-month initiation and subsequent 3-month maintenance phase using a marginal structural model to adjust for measured time-dependent confounding by indication."	( The effect of epoetin dose on hematocrit. Cotter, D; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2008)	0.35
" The erythropoietin dosage regimes in different types of hepatic resections in living kindred donors were proposed."	( [Application of recombinant erythropoietin during preparation for hepatic transplantation operation from the living kindred donor]. Dykhovichnaia, NIu; Gusev, AV; Kotenko, OG; Mazur, AP; Popov, AO, 2007)	0.34
" Erythropoietic drug costs were calculated using unit wholesale acquisition cost multiplied by the number of units or micrograms while comparing the following dosing regimens: EPO 3 times weekly, EPO once weekly, and DARB once weekly."	( Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen. Decter, A; Duh, MS; Greco, T; Kang, YJ; Mody, SH; Naeem, A; Piech, CT; Sikand, H; Watson, SH, 2008)	0.35
" The approved dosing interval for currently available erythropoiesis-stimulating agents (ESAs) is 2 to 3 times weekly for epoetin alfa (EPO) and every 1 to 2 weeks for darbepoetin alfa (DARB)."	( Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Dennis, VW; Law, A; Nurko, S; Spirko, R, 2007)	0.76
"This study investigated patterns of actual ESA use (doses and dosing intervals) and hemoglo- bin (Hb) control in adult outpatients with CKD not requiring dialysis at the Cleveland Clinic Foundation anemia clinic."	( Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Dennis, VW; Law, A; Nurko, S; Spirko, R, 2007)	0.55
"The clinical charts and electronic records of adult outpatients with CKD who initiated ESA therapy before March 2005 were reviewed to identify the initial, dominant (used for the longest consecutive period), and final dosing intervals and mean weekly doses of EPO and DARB."	( Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Dennis, VW; Law, A; Nurko, S; Spirko, R, 2007)	0.55
" The most common initial dosing intervals were qwk for EPO (66."	( Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Dennis, VW; Law, A; Nurko, S; Spirko, R, 2007)	0.55
"The patterns of ESA usage in adult outpatients with CKD at this center indicated that clinicians extended dosing intervals beyond those in the approved prescribing information."	( Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study. Dennis, VW; Law, A; Nurko, S; Spirko, R, 2007)	0.55
" However, in the Phase III trial providing the basis for this new dosage recommendation, more than 70% of patients required a 40% reduction in the dosage, resulting in an average dose of 375 microg every three weeks."	( Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. Baribeault, D; Muller, RJ, 2007)	0.34
"This analysis was limited to prevalent hemodialysis patients, and inhospital EPO dosing information was unavailable."	( Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Acquavella, JF; Bradbury, BD; Critchlow, CW; Heagerty, P; Keen, M; Rothman, KJ; Wang, O, 2008)	0.63
" The subsequently introduced epoetin analogue, darbepoetin alpha, with a prolonged serum half-life, allowed for extended dosing intervals and less frequent administration."	( Darbepoetin alpha coming of age. Cinieri, S; Gamucci, T; Lorusso, V; Pedrazzoli, P; Secondino, S; Silvestris, N, )	0.13
"To report the design, methodology, implementation and initial results of the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) Registry, the first US patient registry to collect and report on practice patterns and outcomes associated with erythropoiesis-stimulating therapy (EST) for anaemia management in oncology patients."	( Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients. Bookhart, B; Larholt, K; McKenzie, RS; Pashos, CL; Piech, CT; Wang, Q, 2008)	0.35
" Results from this registry should provide patients, clinicians and healthcare decision makers with a better understanding of the relationship between EST dosage and outcomes in the clinical setting."	( Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) : a registry for characterizing anaemia management and outcomes in oncology patients. Bookhart, B; Larholt, K; McKenzie, RS; Pashos, CL; Piech, CT; Wang, Q, 2008)	0.35
" Although the clinical approach tested in this study is not consistent with current prescribing recommendations, the results confirm the efficacy of prolonged dosing intervals (every 2-4 weeks) in maintaining optimal Hb levels and QOL in anemic HIV-infected patients."	( Efficacy of epoetin alfa administered every 2 weeks to maintain hemoglobin and quality of life in anemic HIV-infected patients. Leitz, GJ; Levine, AM; Salvato, P, 2008)	0.72
"The objective of this study was to examine, from the perspective of a third-party payer, patterns of use and costs of DA and EA in patients with CRA, using episode-based methodology to account for differences in assumed duration of effect and frequency of dosing with these products."	( Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia. Berger, A; Edelsberg, J; Kallich, J; Oster, G, 2008)	0.74
" Dosing was titrated individually to achieve a stable, target Hb concentration of 11-12 g/dL."	( Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Czekalski, S; Koytchev, R; Krivoshiev, S; Manitius, J; Scigalla, P; Todorov, VV, 2008)	0.35
" This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis."	( Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Beaver, JS; Massarella, J; McGowan, T; Vaccaro, NM; Wolfson, M, 2008)	0.78
"Extended dosing interval regimens of epoetin alfa yielded modest pharmacokinetic differences but a similar pharmacodynamic response, suggesting that less frequent, higher dosages of epoetin alfa may be as effective as the current three-times-weekly regimen in anemic patients who have chronic kidney disease and are not on dialysis."	( Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis. Beaver, JS; Massarella, J; McGowan, T; Vaccaro, NM; Wolfson, M, 2008)	0.86
" Renal programs across Canada should consider dosage conversion ratios in addition to drug acquisition costs when considering a formulary decision about erythropoiesis stimulating agents."	( Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios. Bernstein, KN; Lesperance, EM; Raymond, CB; Skwarchuk, DE; Vercaigne, LM; Wazny, LD, )	0.48
" The revisions include revised safety information, new Epoetin alfa dosing recommendations, and revised information on health-related quality of life (HRQoL)."	( Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis. Hayslip, D, )	0.64
" The choice of ESA should consider safety of subcutaneous administration, cost-effectiveness, and dosing frequency, all of which may affect compliance with ESA administration."	( Latest strategy in renal anemia management in peritoneal dialysis patients. Lo, WK, 2008)	0.35
") dosing schedules."	( Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Cannella, G; Conte, F; De Ferrari, G; Filippini, A; Formica, M; Locatelli, F; Lombardi, L; Messa, P; Naso, A; Rossi, E; Rotolo, U; Villa, G, )	0.39
" epoetin alfa with conventional dosing regimens."	( Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. Cannella, G; Conte, F; De Ferrari, G; Filippini, A; Formica, M; Locatelli, F; Lombardi, L; Messa, P; Naso, A; Rossi, E; Rotolo, U; Villa, G, )	1.3
" Prospective studies are needed to confirm this relationship and determine safe dosing algorithms for patients unable to achieve target hemoglobin."	( Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Barnhart, HX; Califf, RM; Inrig, JK; Patel, UD; Reddan, DN; Sapp, S; Singh, AK; Szczech, LA, 2008)	0.35
" Recombinant human erythropoietin was administered intraperitoneally at 6 hours and at 3 and 7 days post-TBI (5000 U/kg body weight, total dosage 15,000 U/kg)."	( Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice. Chopp, M; Goussev, A; Lu, D; Mahmood, A; Qu, C; Schallert, T; Xiong, Y, 2008)	0.35
" Study variables by setting included ESA use, prescriber specialty, and dosage regimen."	( Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. Audhya, P; Brophy, DF; Comstock, T; Feng, A; Johnson, PE; Jorgenson, J; Siegel, J, 2008)	0.35
" The dosage of epoetin zeta was stable throughout the course of the trial."	( Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Baldamus, C; Bronn, A; Koytchev, R; Krivoshiev, S; Siebert-Weigel, M; Wolf-Pflugmann, M, 2008)	0.35
" In March 2007, the FDA changed the labeling of the ESAs to add boxed warnings, updated in November 2007, to include the following key points: (a) ESAs should be used only to treat anemia that occurs in patients with cancer while they are undergoing chemotherapy; (b) treatment with ESAs should be stopped when chemotherapy ends; and (c) dosing ESAs to an Hb target of 12 gm per dL or greater has resulted in more rapid cancer progression or shortened overall survival in patients with breast, head and neck, lymphoid, cervical, and non-small cell lung malignancies."	( Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. Fraeman, K; Luo, W; Nordstrom, BL; Nordyke, RJ; Whyte, JL, )	0.13
" The Centers for Medicare & Medicaid Services has decreased ESA dosing recommendations in the Medicare claims policy for ESAs."	( The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now? Singh, AK, 2008)	0.35
"157 prevalent-hemodialysis subjects were analyzed from an open-label, randomized study that compared the intravenous to the subcutaneous route of epoetin with identical weight-based dosing algorithm."	( Route of epoetin administration influences hemoglobin variability in hemodialysis patients. Hirter, A; Kaufman, J; Keithi-Reddy, SR; Patel, T; Reda, D; Singh, A, 2009)	0.35
" Data on ESA doses, dosing frequencies, hemoglobin levels, and red blood cell (RBC) transfusions were abstracted from electronic medical records."	( A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Audhya, P; Brophy, GM; Lottenberg, L; Scarlata, D; Shapiro, MJ; Sheehan, V, 2008)	0.35
" The most commonly prescribed dosing frequency with darbepoietin alfa was once weekly (88."	( A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. Audhya, P; Brophy, GM; Lottenberg, L; Scarlata, D; Shapiro, MJ; Sheehan, V, 2008)	0.35
" We wished to evaluate the effect of protocol adherence to EPO and intravenous iron dosing on achieving the desired range of hemoglobin levels."	( Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Chan, K; Hlatky, M; Lafayette, R; Moran, J, 2009)	0.35
"A cohort of hemodialysis patients was studied to evaluate the rate of adherence to EPO and iron dosing protocols over a 5 month period."	( Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Chan, K; Hlatky, M; Lafayette, R; Moran, J, 2009)	0.35
"Among 2114 patients, we found that adherence to both the EPO and iron dosing protocol resulted in the greatest probability of achieving the target hemoglobin range (56 +/- 5% in anemia protocol adherent patients versus 42 +/- 7% in non adherent patients)."	( Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Chan, K; Hlatky, M; Lafayette, R; Moran, J, 2009)	0.35
"To describe the pharmacokinetic profiles of six different dosing regimens for epoetin alfa, and whether more rapid and robust reticulocytosis can be elicited with more frequent administration of epoetin alfa in anemic critically ill patients."	( Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Arroliga, AC; Beaver, JS; Guntupalli, KK; Kelly, K; Langholff, W; Marino, K, 2009)	0.84
" Erythropoietin exposure was approximately ten times greater for IV dosing than for subcutaneous dosing."	( Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Arroliga, AC; Beaver, JS; Guntupalli, KK; Kelly, K; Langholff, W; Marino, K, 2009)	0.61
"In this study of anemic critically ill patients treated with epoetin alfa, all dosing regimens were well tolerated and appeared to effect reticulocytosis, with a peak at day 11 or 15 in most patients."	( Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Arroliga, AC; Beaver, JS; Guntupalli, KK; Kelly, K; Langholff, W; Marino, K, 2009)	0.85
"The common finding that low achieved hemoglobin in observational studies and high target hemoglobin in randomized trials each were associated with increased mortality and high epoetin dosage has suggested the possibility that high epoetin dosage might explain the increased mortality risk."	( Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Cotter, D; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2009)	0.35
" We estimated the association between cumulative average epoetin dosage and survival through the subsequent 9 mo by using inverse probability weighting to adjust for time-dependent confounding by indication."	( Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Cotter, D; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2009)	0.35
"Survival was similar throughout the entire follow-up period for the three hypothetical treatment regimens selected: Low dosage 15,000 U/wk, medium dosage 30,000 U/wk, and high dosage 45,000 U/wk."	( Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Cotter, D; Hernán, MA; Kaufman, J; Thamer, M; Zhang, Y, 2009)	0.35
" Dosing regimens were obtained from registration clinical trials."	( Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. Adams, JL; Glaspy, JA; Kallich, JD; Mafilios, MS; Rubin, RJ; Viswanathan, HN; Wang, SM, 2008)	0.63
"The difference in risk estimates between the adjusted linear regression and the IV regression suggests that the short-term mortality related to EPO dosing may be largely attributable to confounding-by-indication for higher doses."	( Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. Bradbury, BD; Brookhart, MA; Critchlow, CW; Do, TP; Winkelmayer, WC, 2009)	0.79
"To reduce the risk of potential bias, DCB and different patient characteristics should be taken into account when using retrospective claims data to conduct cost comparisons between agents that have significant differences in dosing schedule."	( The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Kallich, J; Long, SR; Marder, WD; Song, X; Sullivan, SD, 2009)	0.59
" These data lack clinical variables, such as baseline haemoglobin (Hb) level, which are likely to influence choice of ESA, dosing and costs."	( The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia. Eremina, D; Hess, G; Hill, J; Hulnick, S; Kallich, J; Polsky, D; Roumm, A; Whyte, JL, 2009)	0.35
"A 16-week dose-response study and a 32-week follow-Up study were combined."	( Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Akaishi, M; Akiba, T; Akizawa, T; Aonuma, K; Fukuhara, S; Gejyo, F; Hada, Y; Hirakata, H; Hiroe, M; Iino, Y; Inaguma, D; Morita, S; Nishi, S; Saito, A; Suzuki, M; Tsubakihara, Y; Watanabe, Y, 2010)	0.36
"In clinical practice, physicians often use once-weekly (QW) and biweekly (Q2W) dosing of epoetin alfa to treat anemia in patients with chronic kidney disease (CKD)."	( A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Rao, S; Wolfson, M, 2009)	0.81
"Administration of epoetin alfa at QW and Q2W intervals are potential alternatives to TIW dosing for the treatment of anemia in stage 3 to 4 CKD subjects."	( A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Rao, S; Wolfson, M, 2009)	0.93
" Clinical experience demonstrates that the dose conversion ratio (DCR) between epoetin alfa and darbepoetin alfa is nonproportional across the dosing spectrum."	( Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. Agarwal, A; Cangialose, CB; Gandra, SR; Gitlin, M; Horowitz, J; Huang, F, )	0.36
"Extended-interval dosing of epoetin alfa (EPO) is commonly used to treat anemia in patients with chronic kidney disease (CKD)."	( A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Sun, S; Wolfson, M, 2010)	0.87
"430 anemic subjects with stage 3 to 4 CKD receiving a stable QW dose of EPO were randomized 1:1:2 to QW, Q2W, and Q4W dosing for 36 weeks."	( A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Sun, S; Wolfson, M, 2010)	0.58
"Both the Q2W and Q4W dosing groups were noninferior to the QW group."	( A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Sun, S; Wolfson, M, 2010)	0.58
"Q2W and Q4W EPO dosing maintained Hb levels in subjects with stage 3 to 4 CKD."	( A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in CKD patients with anemia. Bowers, P; Fu, M; Gartenberg, G; Pergola, PE; Sun, S; Wolfson, M, 2010)	0.58
", a continuous erythropoietin receptor activator, offers once-monthly dosing without compromising haemoglobin control."	( Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Backs, W; Dellana, F; Dellanna, F; Fassbinder, W; Fliser, D; Kleophas, W; Kraatz, U; Strack, G; Winkler, RE; Wizemann, V, 2010)	0.36
"9%) of the 354 evaluable patients, respectively, with no differences observed between patients formerly receiving epoetin or darbepoetin or different dosing frequencies."	( Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Backs, W; Dellana, F; Dellanna, F; Fassbinder, W; Fliser, D; Kleophas, W; Kraatz, U; Strack, G; Winkler, RE; Wizemann, V, 2010)	0.36
" administration using pre-filled syringes was shown to be practical, convenient and offer good control of haemoglobin levels, regardless of the previous type of therapy or dosing frequency."	( Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study. Backs, W; Dellana, F; Dellanna, F; Fassbinder, W; Fliser, D; Kleophas, W; Kraatz, U; Strack, G; Winkler, RE; Wizemann, V, 2010)	0.36
" Primary endpoints were the mean Hb level and the mean weekly epoetin dosage during the last 4 weeks of treatment."	( Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Bronn, A; Czekalski, S; Koytchev, R; Krivoshiev, S; Pljesa, S; Schiller, A; Siebert-Weigel, M; Wizemann, V; Wolf-Pflugmann, M, 2010)	0.36
" The mean weekly epoetin dosage per body weight over the last 4 weeks of treatment was 97."	( Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Bronn, A; Czekalski, S; Koytchev, R; Krivoshiev, S; Pljesa, S; Schiller, A; Siebert-Weigel, M; Wizemann, V; Wolf-Pflugmann, M, 2010)	0.36
"3% higher than baselines for the two dosing regimen."	( Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats. Ait-Oudhia, S; Krzyzanski, W; Scherrmann, JM, 2010)	0.36
" Ribavirin dosage was reduced in 12 patients, and peginterferon dosage was reduced in 2 patients."	( Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection. Black, M; Burke, M; Jain, AB; Singhal, A, 2010)	0.36
" EPO and darbepoetin alfa have a non-proportional dose conversion relationship across the dosing spectrum."	( Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Gandra, SR; Khan, I; Petersen, J; Sharma, A; Yee, J, 2010)	1.01
"The management of anaemia in chronic kidney disease (CKD) to achieve current guideline goals is difficult and is hindered by multiple factors, including problems with the scheduling and adjustment of dosing of erythropoiesis-stimulating agents (ESAs) and the frequency of required ESA administration to achieve target haemoglobin (Hgb) levels."	( Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Cernii, A; Finkelstein, FO; Gobin, J; McLean, R; Simon, DB, 2011)	0.72
"To analyse the impact of dosing decisions for continuous erythropoietin receptor activator (C."	( Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study. Bockreiss, N; Bozkurt, F; Dellanna, F; Fliser, D; Graf, S; Schettler, V; Winkler, RE, 2011)	0.37
"To assess the clinical and economic outcomes among patients with chemotherapy-induced anemia (CIA) treated with United States Food and Drug Administration-approved fixed dosing regimens of erythropoiesis-stimulating agents (ESA)."	( Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Fraser, KA; Larholt, K; McKenzie, RS; Pashos, CL; Piech, CT; Senbetta, M, 2012)	0.38
"Data were employed from the Dosing and Outcomes Study of Erythropoiesis-Stimulating Therapies (DOSE) registry to evaluate CIA patients who were initiated on either epoetin alfa (EPO) 40,000 Units (U) or darbepoetin alfa (DARB) 500 micrograms (mcg) between January 1, 2006 and May 8, 2009."	( Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Fraser, KA; Larholt, K; McKenzie, RS; Pashos, CL; Piech, CT; Senbetta, M, 2012)	0.57
" Although widely believed that the dosage requirements are the same, we undertook a retrospective analysis to investigate whether the dosage requirements in chronic renal failure patients were comparable for both preparations."	( Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients. Abeygunasekara, SC; Ali, GR; Loughnan, A, 2011)	0.61
" Dosing was based on the Hb concentration measurement obtained by HemoCue Hb201+System (Quest Diagnostics; Madison, NJ) at the time of the scheduled dose."	( An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Langholff, W; McGowan, T; Patel, M; Thimons, DG; Winston, JL, 2012)	0.62
"0 g/dL at any time during the study); the time to the Hb response; the proportion of subjects who received a transfusion and the number of units of transfused; the proportion of epoetin alfa-treated subjects converting to Q4W dosing; and the proportion of subjects who converted to Q4W dosing and remained on Q4W dosing through the end of the study."	( An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. Langholff, W; McGowan, T; Patel, M; Thimons, DG; Winston, JL, 2012)	0.81
" We investigated Epo dosage effect (up to 1000 U/kg) on hematocrit, body weight, body composition, glucose metabolism, food intake, and physical activity, during high-fat diet-induced obesity."	( The effects of erythropoietin dose titration during high-fat diet-induced obesity. Alnaeeli, M; Foskett, A; Noguchi, CT; Teng, R; Wang, L, 2011)	0.37
"Frequent dosing and requirements for dose adjustments of erythropoiesis-stimulating agents (ESAs) create significant burdens for healthcare providers and have been associated with hemoglobin (Hb) cycling, hampering maintenance of target Hb levels."	( Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Canaud, B; de Francisco, A; Mann, JF; Nassar, G, 2011)	0.37
" Dosage was adjusted to maintain Hb ± 1 g/dl of baseline and 10 - 13."	( Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Canaud, B; de Francisco, A; Mann, JF; Nassar, G, 2011)	0.37
" q4w and 572 with comparator ESA at their usual dosing interval."	( Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease. Canaud, B; de Francisco, A; Mann, JF; Nassar, G, 2011)	0.37
" Uptake of (14)C-2-deoxy-D-glucose indicated that animals dosed with CNTO 530 transported more glucose into skeletal muscle and heart relative to control animals."	( A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Bugelski, PJ; Deutsch, HA; Dubell, WH; Havekes, LM; James, IE; Makropoulos, DA; Ort, TA; Picha, KM; Pieterman, EJ; Scully, MS; van den Hoek, AM; Wertheimer, JD, 2011)	0.37
"Randomized trials of hemoglobin targeting in chronic kidney disease suggest that erythropoiesis-stimulating agent (ESA) dosing increases mortality risk, but dosing intensity is confounded by hemoglobin concentration."	( Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Collins, AJ; Gilbertson, DT; Weinhandl, ED, 2011)	0.67
"Using Medicare claims, we conducted a retrospective cohort study of mortality risk associated with epoetin alfa (EPO) dosing in prevalent hemodialysis patients (n = 137,918), 2000-2004."	( Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Collins, AJ; Gilbertson, DT; Weinhandl, ED, 2011)	0.88
"ESA dosing may be directly associated with risk of death, but the nature of the association likely varies according to hemoglobin concentration."	( Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients. Collins, AJ; Gilbertson, DT; Weinhandl, ED, 2011)	0.67
" We evaluated a dosing algorithm and potential confounders' effect on Hb and blood pressure (BP) in a clinical trial."	( A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction. Altincatal, A; Helmke, S; Macarthur, RB; Maurer, MS; Teruya, S, 2013)	0.39
"The currently employed dosing algorithm, which adjusts the administration of ESA based on the absolute hemoglobin and weekly change in hemoglobin increases Hb with relatively a low weekly dose of ESA without significant effects on BP."	( A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction. Altincatal, A; Helmke, S; Macarthur, RB; Maurer, MS; Teruya, S, 2013)	0.39
" These agents are a mainstay in MDS therapy, but many issues are still open in terms of the initiation of therapy, the optimal dosage of erythropoietic stimulating agents (ESAs), the most efficient type of ESA, and the duration and outcome of such treatments."	( Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Santini, V, 2011)	0.37
" Despite widespread usage of these agents, there is no generally accepted "standard dosing algorithm" for treating anemia in HDD-CKD patients."	( Anemia management in patients receiving chronic hemodialysis. Diaz-Buxo, JA; Mullon, C; Ofsthun, NJ; Thakuria, M, )	0.13
" Further simulations suggested that once-weekly and thrice-weekly subcutaneous dosing regimens would result in similar efficacy."	( Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575. Balser, S; Berghout, A; Fink, M; Krzyzanski, W; Lowe, PJ; Yan, X, 2012)	0.59
" Efficacy endpoints were mean absolute change in Hb from baseline to end of Week 13 and mean weekly epoetin dosage in Weeks 11 - 13."	( Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study. Eckardt, KU; Haag-Weber, M; Hörl, WH; Roger, SD; Roth, K; Vetter, A, 2012)	0.38
" Indication of use and prescribed dosage of epoetins were derived by the therapeutic plans filled in by specialists and linked to drug dispensing records."	( How much are biosimilars used in southern Italy?: a retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011. Arcoraci, V; Cananzi, P; Cannata, A; Caputi, AP; Coppolino, S; Ferrara, R; Loiacono, C; Savica, V; Schuemie, M; Sgroi, C; Trifirò, G, 2012)	0.38
" In 2006, a 500-μg dose and new dosing schedule was approved for DA in the United States."	( Utilization and cost in clinical practice of darbepoetin alfa and epoetin alfa for anemia concomitant with chemotherapy. Berger, A; Corey-Lisle, PK; Lord, C; Oster, G; Williams, GR, 2012)	0.63
" We monitored hemoglobin, feritin, saturation of transferin (TSAT), dose of LSE, number of change in dosage and number of transfusion."	( [Treatment of renal anemia in hemodialysis patients in General Hospital Bjelovar from 2007 to 2010]. Basić-Jukić, N; Dzapo, M; Janković, RI; Kurtović, I; Lovcić, P; Lovcić, V; Vujić, J, 2011)	0.37
" Further examination of the use and dosing of erythropoietin-stimulating agents and intravenous iron, their impact on haemoglobin levels related to patient comorbidities and subsequent cost effectiveness of protocols is required."	( Anaemia management protocols in the care of haemodialysis patients: examining patient outcomes. MacLeod, ML; MacMillan, PD; Ogborn, MR; Salyers, V; Saunders, S, 2013)	0.39
" The ESA dosage was recorded monthly."	( Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5. Boonyapapong, P; Rianthavorn, P, 2013)	0.39
"The erythropoiesis-stimulating agents (ESAs), darbepoetin alfa (DA), and epoetin alfa (EA) differ with respect to dosing schedule in chemotherapy-induced anemia."	( Synchronization of administrations of chemotherapy and erythropoiesis-stimulating agents and frequency of associated healthcare visits. Corey-Lisle, PK; De, AP; Hess, GP; Hill, JW; McGarvey, N; Shreay, S, 2013)	0.64
" No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment."	( The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients. Djukanović, L; Ležaić, V; Marić, I; Miljković, B; Pejovic, V; Petković, N; Simić-Ogrizović, S; Vučićević, K, 2013)	0.39
" Side effects of anemia treatment, considering frequency and dosage of treatment as well as targeted hemoglobin levels when utilizing ESAs, greatly impact overall well-being and the quality of life."	( Emerging drugs for treatment of anemia of chronic kidney disease. Bennett, CL; Chen, B; Kessler, S; Lebby, A; Magwood, JS; Norris, L, 2013)	0.39
" Despite equivocal longer-term outcomes in clinical studies investigating EPO as a renoprotective agent in AKI, optimal clinical dosing and administration have not been established."	( Remote conditioning or erythropoietin before surgery primes kidneys to clear ischemia-reperfusion-damaged cells: a renoprotective mechanism? Devonald, MA; Dunford, LJ; Gardner, DS; Hodi, Z; McCulloch, TA; O'Sullivan, S; Sleeman, P; Welham, SJ, 2014)	0.4
" Consistent with national data, the findings from this study indicate that from 2010 to 2013, HBDCs modified anemia management practices for dialysis patients, as evidenced by reductions in mean monthly Hb levels and ESA dosing and by increases in iron biomarkers and dosing."	( Anemia management trends in hospital-based dialysis centers (HBDCs), 2010 to 2013. Acharya, A; Chang, CL; Coritsidis, GN; Gitlin, M; Hill, J; Lafayette, RA; Maglinte, GA; Saxena, A, 2014)	0.4
" Comparisons of differing dosing schedules and routes of administration were compared in small numbers of participants and studies."	( Darbepoetin for the anaemia of chronic kidney disease. Craig, JC; Navaneethan, SD; Palmer, SC; Saglimbene, V; Strippoli, GF, 2014)	0.4
"For consumers, clinicians and funders, considerations such as drug cost and availability and preferences for dosing frequency might be considered as the basis for individualising anaemia care due to lack of data for comparative differences in clinical benefits and harms."	( Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Craig, JC; Mavridis, D; Palmer, SC; Saglimbene, V; Salanti, G; Strippoli, GF; Tonelli, M; Wiebe, N, 2014)	0.4
" Our aim was to determine changes in epoetin dosing and hematocrit levels in response to PPS by different types of dialysis providers."	( Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. Cotter, D; Hernán, MA; Kaufman, J; Kshirsagar, O; Thamer, M; Zhang, Y, 2014)	0.4
"Major declines in epoetin use, dosing and achieved hematocrit levels were observed after PPS."	( Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. Cotter, D; Hernán, MA; Kaufman, J; Kshirsagar, O; Thamer, M; Zhang, Y, 2014)	0.4
" The PD model described 2 subpopulations, one whose Hb response reflected epoetin alfa dosing and a second whose response was unrelated to epoetin alfa dosing."	( Assessment of hemoglobin responsiveness to epoetin alfa in patients on hemodialysis using a population pharmacokinetic pharmacodynamic model. Doshi, S; Mould, DR; Perez Ruixo, JJ; Wu, L, 2015)	0.91
" Further, in the polaprezinc group, ESA dosage and ERI were significantly decreased at 10 months and nine months, respectively, as compared with the baseline value."	( Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis. Abe, M; Higuchi, T; Kikuchi, F; Kobayashi, H; Maruyama, N; Okada, K; Soma, M; Tei, R, 2015)	0.42
" Extended-interval ESA dosing (administration less than once weekly) is common with DA, but previous studies suggested that EA might also be administered less often than weekly."	( A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Anderson, DM; Dakhil, SR; Johnson, DB; Loprinzi, CL; Mattar, BI; Moore, DF; Nikcevich, D; Novotny, PJ; Sloan, JA; Steensma, DP, 2015)	0.69
"Previous research suggests that erythropoiesis stimulating agent (ESA) administration in dialysis is a time-consuming task and switching to less frequently dosed ESAs may offer operational efficiencies."	( Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients. Anderson, ER; Ashfaq, A; Caloyeras, JP; Emerson, LC; Reitan, JF; Spry, LA; Stephens, JM, 2016)	0.43
"Results should not be generalized to other countries, ESAs and/or dosing frequencies."	( Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients. Anderson, ER; Ashfaq, A; Caloyeras, JP; Emerson, LC; Reitan, JF; Spry, LA; Stephens, JM, 2016)	0.43
" An abrupt decline in erythropoietin dosing and hemoglobin concentration began in late 2010."	( Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. Ashfaq, A; Beaubrun, AC; Bradbury, BD; Brookhart, MA; Chertow, GM; Collins, AJ; Gilbertson, DT; Herzog, CA; Liu, J; Monda, KL; Pollock, A; Rothman, KJ; Sturmer, T; Winkelmayer, WC, 2016)	1.88
"Little is known about epoetin alfa (EPO) dosing at dialysis centers after implementation of the US Medicare prospective payment system and revision of the EPO label in 2011."	( Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. Beaubrun, AC; Bradbury, BD; Collins, AJ; Gilbertson, DT; Li, S; Molony, JT; Monda, KL, 2016)	1.14
"Approximately 412,000 adult hemodialysis patients with Medicare Parts A and B as primary payer in 2009 to 2012 to describe EPO dosing and hemoglobin patterns; of these, about 70,000 patients clustered in about 1,300 dialysis facilities to evaluate facility-level EPO titration practices and patient-level outcomes in 2012."	( Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. Beaubrun, AC; Bradbury, BD; Collins, AJ; Gilbertson, DT; Li, S; Molony, JT; Monda, KL, 2016)	0.82
"Facility EPO titration practices when hemoglobin levels were <10 and >11g/dL (grouped treatment variable) determined from monthly EPO dosing and hemoglobin level patterns."	( Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates. Beaubrun, AC; Bradbury, BD; Collins, AJ; Gilbertson, DT; Li, S; Molony, JT; Monda, KL, 2016)	0.82
" One subject in each treatment group had a positive recombinant human erythropoietin antibody result by radioimmunoprecipitation assay before dosing and throughout study conduct with negative immunoglobulin M and neutralizing antibodies and with no evidence of clinical deterioration or of impact on PD, PK, or safety profile."	( Pharmacodynamic and Pharmacokinetic Equivalences of Epoetin Hospira and Epogen(®) After Multiple Subcutaneous Doses to Healthy Male Subjects. Kumbhat, S; Martin, N; Ramaiya, A; Reid, S; Stalker, D; Zhang, J, 2016)	0.43
" One subject had a positive anti- recombinant human erythropoietin antibody result by radioimmunoprecipitation assay before dosing and throughout the conduct of the study with negative neutralizing antibodies and with no evidence of clinical deterioration or impact on the pharmacokinetics, pharmacodynamics, or safety."	( Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects. Martin, NE; Ramaiya, A; Reid, S; Stalker, D; Wisemandle, WA, 2016)	0.43
" There were no significant differences in final haemoglobin (Hb) levels when dosing every two weeks was compared with weekly dosing (4 studies, 785 participants: MD -0."	( Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Elserafy, N; Esezobor, CI; Hahn, D; Hodson, EM; Webster, AC, 2017)	0.46
"Epoetin alpha given at higher doses for extended intervals (two or four weekly) is non-inferior to more frequent dosing intervals in maintaining final Hb levels with no significant differences in adverse effects in non-dialysed CKD patients."	( Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Elserafy, N; Esezobor, CI; Hahn, D; Hodson, EM; Webster, AC, 2017)	0.46
" Approved epoetin and darbepoetin dosing schedules were three times per week and weekly, respectively, although off-label, less frequent scheduling was common."	( Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. Bennett, CL; Chen, B; Cotter, D; Dickson, M; Hikmet, N; Hrushesky, W; Knopf, KB; Lebby, AA; Norris, LB; Noxon, V; Qureshi, ZP; Schooley, B; Thamer, M; Yang, YT; Yarnold, PR, 2017)	0.46
" Per-patient dosing of darbepoetin, but not epoetin, increased steadily between 2003 and 2010, and monthly per-patient epoetin costs decreased 3% while the per-patients costs of darbepoetin increased 30% between 2003 and 2010."	( Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. Bennett, CL; Chen, B; Cotter, D; Dickson, M; Hikmet, N; Hrushesky, W; Knopf, KB; Lebby, AA; Norris, LB; Noxon, V; Qureshi, ZP; Schooley, B; Thamer, M; Yang, YT; Yarnold, PR, 2017)	0.46
"We explicitly emulated a target trial of three ‎erythropoietin dosing strategies (aimed at achieving a low, middle, or high hematocrit) and estimated the observational analog of the per-protocol effect."	( Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. Hernán, MA; Thamer, M; Young, JG; Zhang, Y, 2018)	0.48
" Different dosing requirements and molecular characteristics of CERA compared with other ESAs may lead to different health outcomes (mortality, cardiovascular events, quality of life) in people with anaemia and chronic kidney disease (CKD)."	( Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Craig, JC; Natale, P; Palmer, SC; Ruospo, M; Saglimbene, VM; Strippoli, GF, 2017)	0.46
" HD patients treated for up to 24 months showed stable dosing patterns and Hb outcomes."	( Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study . Abraham, I; Combe, C; Dellanna, F; Goldsmith, D; Hoebel, N; Krendyukov, A; London, G; MacDonald, K; Mann, J; Zaoui, P, 2018)	0.48
" Dosing was adjusted according to the epoetin alfa prescribing information."	( Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease. Fishbane, S; Kumbhat, S; Martin, NE; Singh, B; Wisemandle, WA, 2018)	1.13
"For patients with anemia undergoing hemodialysis, erythropoiesis-stimulating agents (ESAs) are typically dosed via precise algorithms."	( Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. Ahuja, A; Guilatco, R; Hymes, J; Maddux, FW; Thadhani, R, 2018)	0.83
"Switching to RetacritTM was non-inferior to continuing -Epogen® in maintaining hemoglobin levels in patients receiving hemodialysis, when both ESAs were dosed using a specified algorithm (ClinicalTrials."	( Switching from Epoetin Alfa (Epogen®) to Epoetin Alfa-Epbx (RetacritTM) Using a Specified Dosing Algorithm: A Randomized, Non-Inferiority Study in Adults on Hemodialysis. Ahuja, A; Guilatco, R; Hymes, J; Maddux, FW; Thadhani, R, 2018)	0.83
" The primary endpoints of this study were to assess the mean hemoglobin (Hb) change during the last 4 weeks of treatment from baseline along with the evaluation of the mean weekly epoetin dosage per kilogram of body weight that was necessary to maintain the Hb level within 10-12 g/dL during the last 4 weeks of treatment."	( Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients. Abbasi, MR; Amini, S; Azmandian, J; Ezzatzadegan Jahromi, S; Nasiri, AA; Ossareh, S; Pourfarziani, V; Sanadgol, H; Shahvaroughi Farahani, A, 2018)	0.72
" Further, the controller satisfactorily handles the following challenging problems in simulations: bleedings, missed administrations and dosing errors."	( Optimal EPO dosing in hemodialysis patients using a non-linear model predictive control approach. Fuertinger, DH; Kappel, F; Kotanko, P; Rogg, S; Volkwein, S, 2019)	0.51
"The ability to control dosage regimens of erythropoiesis-stimulating agents (ESAs) to maintain a desired hemoglobin (HGB) target is still elusive."	( Population Pharmacodynamic Modeling of Epoetin Alfa in End-Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach. Krzyzanski, W; Meaney, CJ; Nguyen, LM; Panesar, M; Rao, GG, 2020)	0.83
"Our study showed that DPA was more effective and well tolerated in achieving and maintaining Hb levels with lower dosing frequency compared to EPA."	( Comparative Efficacy and Safety Study of Darbepoetin Alfa El-Ashmawy, NE; Ibrahim, AO; Khedr, EG; Kotb, NS; Salem, F, 2022)	0.98
"This study has confirmed the therapeutic equivalence between PDA10 and Eprex® in terms of efficacy, dosage requirement and safety profile in haemodialysis patients with renal anaemia."	( A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure. Chang, JH; Goh, BL; Jeon, JS; Kim, SG; Kim, SH; Lim, CS; Lim, SK; Morad, Z; Visvanathan, R, 2021)	0.62
"The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels."	( Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. Desai, R; Goodin, A; Gopal, S; Henry, L; Hincapie-Castillo, J; Liu, X; Mohandas, R; Park, H; Pepine, CJ; Smith, SM, 2022)	0.72
"Anemia Studies in Chronic Kidney Disease: Erythropoiesis via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Three Times Weekly Dosing in Dialysis (ASCEND-TD), NCT03400033."	( Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients: ASCEND-TD: A Phase 3 Randomized, Double-Blind, Noninferiority Trial. Bailey, CK; Cobitz, AR; Connaire, J; Coyne, DW; DiMino, TL; Huang, C; Kim, SG; Lopes, RD; Orias, M; Patel, V; Rastogi, A; Shah, S; Singh, AK; Wanner, C, 2022)	0.72
" A blinded placebo cohort followed the same dosing pattern, administering saline instead of EPO."	( EPO and the athlete biological passport: Hematological results from a placebo-controlled, boosting and microdose EPO administration in male recreational athletes. Crouch, AK; Eichner, D; Husk, J; Miller, GD, 2022)	0.72
" Primary endpoints were mean absolute change in hemoglobin level and mean absolute change in weekly epoetin dosage from baseline to 6 months after treatment with EPIAO®/EPREX® in parallel groups."	( Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. Alexandrov, IV; Davydkin, IL; Isachkina, AN; Khadikova, NG; Kvitkova, LV; Li, M; Li, X; Miao, B; Mironova, TP; Omelchenko, AM; Perlin, DV; Selyutin, AA; Shilo, VY; Shutov, EV; Solovyova, OM; Tutin, AP; Vareesangthip, K; Vetchinnikova, ON; Zuev, AV, 2022)	0.72
" There were no significant differences in the epoetin dosage of the 2 groups compared with the baseline."	( Biosimilar erythropoietin in anemia treatment (BEAT)-Efficacy and safety of a 1:1 dose conversion from EPREX® to EPIAO® in patients with end-stage renal disease on hemodialysis: A prospective, randomized, double blind, parallel group study. Alexandrov, IV; Davydkin, IL; Isachkina, AN; Khadikova, NG; Kvitkova, LV; Li, M; Li, X; Miao, B; Mironova, TP; Omelchenko, AM; Perlin, DV; Selyutin, AA; Shilo, VY; Shutov, EV; Solovyova, OM; Tutin, AP; Vareesangthip, K; Vetchinnikova, ON; Zuev, AV, 2022)	0.72
" The current treatments for anemia include iron therapy and erythropoiesis-stimulating agents (ESAs); however, the relatively short half-lives of the ESAs epoetin alfa/beta or darbepoetin alfa may require more frequent dosing and hospital visits compared with the ESA known as continuous erythropoietin receptor activator (C."	( Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study. Drozdz, D; Meyer Reigner, S; Tirodkar, C; Warady, BA, 2023)	1.11
"To determine the effectiveness of pharmacy consultation in managing epoetin alfa-epbx dosing for inpatients on hemodialysis."	( Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients. Heierman, T; Linn, E; Morrison, H; Sanchez, M, 2023)	1.48
"Pharmacist-driven ESA dosing was associated with significant decreases in ESA average acquisition cost and average total dose per patient."	( Pharmacist-driven epoetin alfa-epbx dosing for hospitalized patients. Heierman, T; Linn, E; Morrison, H; Sanchez, M, 2023)	1.24
"We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0-43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model."	( Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients. Chiu, YL; Hsu, SP; Lin, MC; Pai, MF; Pan, SY; Peng, YS; Shu, KH; Tsai, WC; Tung, KT; Wang, SH; Wu, HY; Yang, CW; Yang, JY, 2023)	1.11
" The primary endpoints were to demonstrate the Hb level change between baseline and evaluation period in both treatment groups, while the secondary endpoints were the mean change in weekly dosage per kg body weight and the instability rate of Hb level during maintenance and evaluation period."	( Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients. Angginy, N; Dwitanto, K; Sutandar, W, 2023)	0.91
"05), also for the mean changes of weekly dosage between groups (1091."	( Comparative Study of Recombinant Human Erythropoietin (rhEPO) Products on CKD (Chronic Kidney Disease) Patients. Angginy, N; Dwitanto, K; Sutandar, W, 2023)	0.91

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	273 (15.64)	18.7374
1990's	109 (6.25)	18.2507
2000's	853 (48.88)	29.6817
2010's	413 (23.67)	24.3611
2020's	97 (5.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	388 (20.54%)	5.53%
Reviews	324 (17.15%)	6.00%
Case Studies	94 (4.98%)	4.05%
Observational	19 (1.01%)	0.25%
Other	1,064 (56.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (506)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar. [NCT02049346]	Phase 4	327 participants (Actual)	Interventional	2012-03-31	Completed
A Randomized, Controlled, Open-label, Multi-center, Parallel-group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Intravenously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialysi [NCT00077610]	Phase 3	673 participants (Actual)	Interventional	2004-02-29	Completed
An Open Label, Multicenter, Randomized, Controlled Study to Evaluate Efficacy and Safety of PROCRIT in Subjects Undergoing Elective Major Abdominal and/or Pelvic Surgery [NCT00350519]	Phase 4	37 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to The study was stopped due to slow enrollment)
An Open, Randomized, Multi-centre Trial to Investigate the Effect of Anemia Correction on Cardiac Structure and Function in Patients With Early Diabetic Nephropathy [NCT00354341]	Phase 3	170 participants (Actual)	Interventional	2002-09-30	Completed
Effect of Erythropoietin on Neurodevelopmental Outcomes in Very Preterm Infants With Intraventricular Hemorrhage [NCT03914690]	Phase 2	316 participants (Actual)	Interventional	2014-07-31	Completed
Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction [NCT00367991]	Phase 2	44 participants (Actual)	Interventional	2006-11-30	Completed
An Open-label, Randomized, Multi-centre, Multiple Dose Trial to Investigate the Efficacy and Safety of Subcutaneous Injections of RO0503821 at Different Dosing Intervals in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy [NCT00048048]	Phase 2	65 participants (Actual)	Interventional	2002-03-31	Completed
Prospective Study Evaluating the Quality of Life in Dialysis Patients With End Stage Renal Disease [NCT01105494]		6,000 participants (Actual)	Observational	2008-12-31	Completed
A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) and Single-Blind Placebo-Controlled, Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis [NCT01147666]	Phase 2	161 participants (Actual)	Interventional	2010-05-17	Completed
A Phase 1 Clinical Research of Erythropoietin Therapy for Children With Cerebral Palsy: Safety and Efficacy [NCT01586052]	Phase 1	11 participants (Actual)	Interventional	2012-06-30	Completed
Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT [NCT03308448]	Phase 3	93 participants (Actual)	Interventional	2018-01-06	Completed
A Phase 1 Study Comparing the Pharmacokinetics of Epoetin Hospira and Epoetin Alfa (Amgen) When Administered Intravenously in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment [NCT01170078]	Phase 1	107 participants (Actual)	Interventional	2010-07-31	Completed
Randomized Placebo-controlled Trial to Assess the Efficacy of Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO) in the Survival of Patients With Acute-on-chronic Liver Failure (ACLF) [NCT01383460]	Phase 3	55 participants (Actual)	Interventional	2011-07-31	Completed
Effects of the Dose of Erythropoiesis Stimulating Agents on Cardiac-cerebrovascular Outcomes Quality of Life and Costs in Hemodialysis Patients. The Clinical Evaluation of the DOSe of Erythropoietins (C.E. DOSE) Trial [NCT00827021]	Phase 3	656 participants (Actual)	Interventional	2009-07-31	Completed
A Single Arm Open Label Interventional Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous Methoxy-polyethylene Glycol-epoetin Beta for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic [NCT01066000]	Phase 4	33 participants (Actual)	Interventional	2009-10-31	Terminated
A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat [NCT03400033]	Phase 3	407 participants (Actual)	Interventional	2018-09-05	Completed
Colorado-Oregon Altitude Study [NCT05734716]	Phase 4	121 participants (Actual)	Interventional	2021-02-17	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Epoetin Alfa Versus Placebo in Anemic Patients With IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes [NCT01381809]	Phase 3	130 participants (Actual)	Interventional	2011-10-31	Completed
EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT) [NCT02802592]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to Loss of funding)
A Randomized, Open-label Study Comparing the Pharmacoeconomic (Time and Motion) Benefit of Mircera and Epoetin Alfa in Patients With Chronic Kidney Disease (Stage V) on Dialysis. [NCT00422513]	Phase 3	260 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Strategic decision unrelated to safety or efficacy)
A Phase 4 Study in the Treatment of Anemia With Weekly Epoetin Alfa Doses in Patients With Solid Tumors or Lymphoma Receiving Chemotherapy [NCT01374373]	Phase 4	30 participants (Actual)	Interventional	2011-06-30	Completed
Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study [NCT02140736]		2,333 participants (Actual)	Observational	2009-09-30	Completed
Exosome Proteomics to Detect Eyrthropoietin (EPO) Use in Athletes [NCT03700515]		72 participants (Anticipated)	Interventional	2019-09-04	Recruiting
A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent [NCT03029247]	Phase 2	105 participants (Actual)	Interventional	2017-07-27	Completed
Single High Dose Erythropoietin Obviates Transfusions: an Independent, Blinded, Prospective Randomized Study in Heart Surgery Population. [NCT01265680]		600 participants (Actual)	Interventional	2012-02-29	Completed
A Phase Ⅱ Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Polyethylene Glycol Recombinant Human Erythropoietin Injection (CHO Cell) in Optimal Dose and Administration Regimen for Maintenance Therapy in Patients With Regula [NCT05629598]	Phase 2	150 participants (Anticipated)	Interventional	2022-04-13	Recruiting
Epoetin Alfa in the Treatment of Post-Transplant Anemia: A Randomized Controlled Trial [NCT01290328]		100 participants (Anticipated)	Interventional	2011-02-28	Terminated(stopped due to low enrollment, termination of funding)
Use of Erythropoietin to Expand Regulatory T Cells in Autoimmune Liver Disease [NCT03842254]	Early Phase 1	6 participants (Actual)	Interventional	2019-01-25	Completed
The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Preterm Infants 401-1250 Grams: Two Multi-Center, Randomized, Double-Masked, Placebo Controlled Studies [NCT01203514]	Phase 2/Phase 3	318 participants (Actual)	Interventional	1997-08-31	Completed
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers [NCT03822884]	Phase 1	24 participants (Actual)	Interventional	2016-09-30	Completed
A Phase I Single Centre Open Label Trial to Investigate the Bioequivalence of a Single Subcutaneous Dose of Epoetin Beta (NeoRecormon®) in Healthy Japanese and Caucasian Male Subjects [NCT01085552]	Phase 1	23 participants (Actual)	Interventional	2007-11-30	Completed
Evaluation of the Diagnostic/Therapeutic Course of Patients With Autoimmune Cytopenias (Autoimmune Hemolytic Anemia AIHA, Immune Thrombocytopenia ITP, Chronic Idiopathic/Autoimmune Neutropenia CIN/AIN) and Identification of Predictive and Prognostic Marke [NCT05931718]		200 participants (Anticipated)	Observational	2021-06-01	Recruiting
Documentation of Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction (BEAT-STEMI Pilot) [NCT01093820]	Phase 2	8 participants (Actual)	Interventional	2010-04-30	Completed
An Open-label, Multi-center Study to Document the Efficacy, Safety, and Tolerability of Long-term Administration of RO0503821 in Patients With Chronic Renal Anemia [NCT00090753]	Phase 3	1,228 participants (Actual)	Interventional	2004-10-31	Completed
Cost-Utility Analysis of Erythropoietin for Anemia Treatmentin Thai End-Stage Renal Disease Patients With Hemodialysis [NCT01049711]		152 participants (Actual)	Observational	2009-11-30	Completed
Treatment of Anemia of Chronic Disease With True Iron Deficiency in Pregnancy [NCT03317210]	Phase 4	50 participants (Actual)	Interventional	2002-09-01	Completed
Pre-operative Treatment With Erythropoietin and Iron Supplement for Prevention of Perioperative Blood Transfusion in Cardiac Surgery [NCT02210949]	Phase 4	7 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to Low inclusion rate)
The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial [NCT03882060]		60 participants (Actual)	Interventional	2019-04-08	Active, not recruiting
Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA [NCT02547454]		393 participants (Actual)	Observational	2008-12-31	Completed
The Effect of Local Erythropoietin 3000 and 6000 Units on the Treatment of Conjunctival and Scleral Avascular Lesions: A Multicenter Clinical Trial [NCT05476042]	Phase 2/Phase 3	60 participants (Anticipated)	Interventional	2022-08-14	Enrolling by invitation
Combined ErythroPoietin and Iron Therapy for AnemiC Patients With Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve REplacement- The EPICURE Trial A Prospective Double Blind Randomized Trial [NCT02390102]	Phase 3	117 participants (Actual)	Interventional	2012-06-30	Completed
Optimized EPO Treatment of Neonatal Anemia [NCT02075970]	Phase 2	62 participants (Actual)	Interventional	2014-06-30	Completed
Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial [NCT00654992]	Phase 2/Phase 3	71 participants (Actual)	Interventional	2006-09-30	Completed
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies [NCT05301517]	Phase 3	159 participants (Actual)	Interventional	2022-03-16	Completed
A Randomized, Controlled Trial of Costs Associated With Anemia Therapy in Hemodialysis Patients Treated With Intravenous Darbepoetin Alfa Versus Epoetin Alfa [NCT02817555]	Phase 4	50 participants (Actual)	Interventional	2010-09-30	Completed
[NCT02036073]	Phase 4	490 participants (Actual)	Interventional	2009-01-31	Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT02251041]	Phase 2	72 participants (Actual)	Interventional	2014-09-30	Completed
A Phase II Trial of Progressive Resistance Training (PRT) Plus Procrit for the Treatment of Anemia-Related Fatigue in Cancer Patients [NCT00004914]	Phase 2	0 participants	Interventional	2000-01-31	Completed
A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia [NCT03528564]	Phase 2	4 participants (Actual)	Interventional	2019-07-01	Terminated(stopped due to The primary reasoning is that we were unable to demonstrate feasibility, prior to and because of the impact of COVID on our research programs.)
Compare the Hemoglobin and Hematocrit Variability Between Once & Three Times Weekly Erythropoietin Therapy for the Anemia in Patients With Maintenance Dialysis [NCT01111630]	Phase 4	60 participants (Anticipated)	Interventional	2009-10-31	Completed
A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis [NCT02947438]	Phase 3	207 participants (Actual)	Interventional	2015-12-31	Completed
A Pilot Trial of Extended Interval Dosing of Epoetin Alfa (Procrit®) for the Treatment of Anemia in Oncology Patients [NCT00258440]		7 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Sponsor discontinued funding of the study)
An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in He [NCT00048035]	Phase 2	91 participants (Actual)	Interventional	2002-03-31	Completed
Phase 2, Randomized, Open-Label, Active-Controlled, Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Oral Vadadustat for the Treatment of Anemia in Hemodialysis Subjects Converting From Epoetin Alfa (FO2RWARD-2) [NCT03799627]	Phase 2	175 participants (Actual)	Interventional	2019-01-31	Completed
An Open Label Study of the Safety, Tolerability and Effect on Hemoglobin Levels of Once-monthly Subcutaneous Mircera in Predialysis Patients With Chronic Renal Anemia Not Currently Treated With ESA. [NCT00680563]	Phase 3	4 participants (Actual)	Interventional	2009-04-30	Terminated
Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid�) Alone and in Combination With Epoetin Alfa (Procrit�) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia [NCT00843882]	Phase 3	247 participants (Actual)	Interventional	2009-01-29	Active, not recruiting
Prevention of Contrast Induced Nephropathy by Erythropoietin in Patients With Diabetes Mellitus and eGFR<60 ml/Min/1.73m2 Undergoing Percutaneous Coronary Intervention [NCT01364402]	Phase 3	142 participants (Anticipated)	Interventional	2011-08-31	Recruiting
Double Blind, Placebo-controlled Study to Assess the Effects of Erythropoietin on Clinical Disability and Brain Pathology as Shown by Magnetic Resonance Imaging in Patients With Progressive Multiple Sclerosis [NCT01144117]	Phase 2	56 participants (Anticipated)	Interventional	2009-11-30	Recruiting
Multicenter Double-bind Randomized Trial of Ferric Carboxymaltose With or Without Erythropoietin for the Prevention of Red-cell Transfusion in Hip Fracture Perioperative Period. [NCT01154491]	Phase 3	303 participants (Actual)	Interventional	2010-06-30	Completed
Scientific Title: Efficacy of Oral Prednisolone and Erythropoietin Injection in Treatment of Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) [NCT03715881]	Phase 2	99 participants (Anticipated)	Interventional	2018-12-01	Recruiting
An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Biosimilar Epoetin Alfa [NCT01121237]		2,086 participants (Actual)	Observational	2010-02-28	Completed
A Phase III, Randomized, Two Armed, Parallel, Double Blind (Patient and Assessor Blinded), Active Controlled Non Inferiority Clinical Trial to Determine the Non Inferior Therapeutic Efficacy and Safety Between CinnaPoietin® (Beta Erythropoietin) and Eprex [NCT03408639]	Phase 3	156 participants (Actual)	Interventional	2016-06-22	Completed
Single Administration of Recombinant Human Serum Albumin/Erythropoietin Fusion Protein for Injection, Tolerance, Safety, Pharmacokinetics and Pharmacodynamic Clinical Trials of Increased Dosage [NCT03786289]	Phase 1	34 participants (Actual)	Interventional	2018-12-03	Completed
Effect of Erythropoietin on Red Blood Cell Requirement in Children With Hemolytic Uremic Syndrome: a Randomized Controlled Trial [NCT03776851]	Phase 4	24 participants (Actual)	Interventional	2019-01-01	Completed
Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients [NCT03867071]		60 participants (Actual)	Interventional	2005-10-31	Completed
A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Diseas [NCT01191983]	Phase 4	102 participants (Actual)	Interventional	2010-08-13	Completed
Identification of New Serum Markers for Detection of Abuse With Erythropoietin [NCT01320449]		35 participants (Actual)	Interventional	2011-08-31	Completed
A Randomised, Double-blind, Placebo-controlled Trial of Erythropoietin Alfa Versus Placebo in Mechanically Ventilated Critically Ill Patients Following Traumatic Injury [NCT04588311]	Phase 3	2,500 participants (Anticipated)	Interventional	2020-11-09	Recruiting
Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury A Follow-up Study of an International Randomised Controlled Trial [NCT03061565]		356 participants (Actual)	Observational	2017-08-01	Completed
A Randomised, Placebo-controlled Trial of Erythropoietin in ICU Patients With Traumatic Brain Injury [NCT00987454]	Phase 3	606 participants (Actual)	Interventional	2010-05-31	Completed
Multicentre, Blinded, Randomised, Controlled Study on the Efficacy and Safety of Early or Late Epoetin Beta Treatment in Premature Infants (500- 999g Birth Weight)for Prevention or Treatment of Anaemia of Prematurity [NCT00593801]		219 participants (Actual)	Interventional	1998-05-31	Completed
Phase I Open and Monocentric Clinical Trial With Pharmacokinetic and Pharmacodynamic Determination of Subcutaneous Recombinant Human Erythropoietin in Male Adults. [NCT04954989]	Phase 1	52 participants (Anticipated)	Interventional	2023-01-31	Not yet recruiting
The Effects of Erythropoietin on Depressive Symptoms and Neurocognitive Deficits in Patients With Treatment Resistant Depression and in Patients With Remitted Bipolar Disorder - a Proof of Concept Study [NCT00916552]	Phase 2	83 participants (Actual)	Interventional	2009-09-30	Completed
Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia [NCT01023035]	Phase 3	687 participants (Actual)	Interventional	2009-12-07	Completed
A Phase Ⅲ Randomized Double-Blind Placebo-Controlled Study of Epoetin Beta for the Treatment of Chemotherapy-Induced Anemia (CIA) in Cancer Patients [NCT00628043]	Phase 3	160 participants (Anticipated)	Interventional	2008-05-31	Completed
A One Year, Open Label, Multicenter Trial of LBH589 Alone or in Combination With ESA in Red Blood Cell Transfusion-dependent LOW and INT-1 MDS Patients Being Either Refractory to ESA or With a Low Probability of Response - the GErman PAnobinostat Low Risk [NCT01034657]	Phase 2	34 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to The study was terminated due to lack of efficacy of single agent LBH589 in the 4 month open label core phase and due to enrollment difficulties.)
Neonatal Erythropoietin in Asphyxiated Term Newborns: a Phase I Trial [NCT00719407]	Phase 1	24 participants (Actual)	Interventional	2010-01-31	Completed
An Open-Label, Randomized Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Subjects With Chronic Kidney Disease [NCT00641589]	Phase 1	40 participants (Actual)	Interventional	2006-01-31	Completed
Erythropoietin Therapy in Patients With Chronic Renal Failure: A Study of Time Dependent Activity [NCT00744445]	Phase 2	46 participants (Actual)	Interventional	1993-10-31	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous MIRCERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia [NCT00737464]	Phase 4	132 participants (Actual)	Interventional	2008-08-26	Completed
Single-Center, Open-Label, Sequential Trial to Test the Efficacy, Safety and Tolerability of Epoetin Alfa in Patients With Friedreich's Ataxia [NCT00631202]	Phase 2	10 participants (Anticipated)	Interventional	2008-02-29	Completed
Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders [NCT00776425]	Phase 4	117 participants (Actual)	Interventional	2007-01-31	Completed
AFX01-12: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin Alfa [NCT00597753]	Phase 3	803 participants (Actual)	Interventional	2007-09-30	Completed
Tracing Changed Production of Red Blood Cells [NCT05833477]		12 participants (Actual)	Interventional	2022-10-28	Completed
Post-authorization Safety Study to Prospectively Monitor the Incidence of Relevant Drug-related Adverse Events and EPO-related Lack of Efficacy Among CKD Subjects Receiving HX575 Recombinant Human Erythropoietin Alfa i.v. [NCT00632125]	Phase 4	1,695 participants (Actual)	Interventional	2008-07-31	Completed
NADIR: Multicentre, Open-Label Trial Evaluating a Simple NeoRecormon Regimen in Anemic Patients With Diabetes and Chronic Kidney Disease (Stage 2 to 5) Who Are Not on Dialysis [NCT02827266]	Phase 3	122 participants (Actual)	Interventional	2005-10-31	Completed
Randomized Clinical Study for Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax, Marketed by the Blausiegel Laboratory, Compared to Drug Eprex, Produced by Janssen-Cilag Laboratory, in Healthy Subjects. [NCT03572647]	Phase 1	40 participants (Actual)	Interventional	2012-11-30	Completed
Erythropoietin Gel as an Adjunct to Xenograft in the Surgical Management of Intrabony Periodontal Defects. A Randomized Controlled Clinical Study [NCT05360511]	Early Phase 1	24 participants (Anticipated)	Interventional	2022-07-01	Recruiting
Safety and Efficacy of Repetitive Erythropoietin Treatment for Cerebral Palsy [NCT03303573]		164 participants (Actual)	Observational	2013-01-01	Completed
Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study [NCT02076373]	Phase 3	120 participants (Actual)	Interventional	2014-03-31	Active, not recruiting
Comparison of Darbepoetin Alpha and Recombinant Human Erythropoietin as Erythropoietic Agents for Treatment of Anemia in Pediatric Chronic Kidney Disease Patients [NCT04959578]	Phase 4	50 participants (Actual)	Interventional	2018-02-01	Completed
Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI [NCT02148367]	Phase 2	0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to Publication of recent trials showing no effect of EPO in TBI.)
Prospective, Open-label, Multicenter Clinical Study for the Efficacy and Safety of Recombinant Human Erythropoietin in the Treatment of Anemia in Patients With Lymphoma [NCT04910594]	Phase 3	130 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy [NCT02767765]	Phase 3	61 participants (Actual)	Interventional	2003-06-30	Completed
Comparison of the Efficacy of Erythropoietin Produced in the Institute of Technology in Immunobiology of the Oswald Cruz Foundation (BioMaguinhos/FioCruz/MS) and Erythropoietin Industrialized in Patients With Chronic Renal Failure [NCT01184495]	Phase 3	74 participants (Actual)	Interventional	2008-04-30	Completed
Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. [NCT02031289]	Phase 4	1,003 participants (Actual)	Interventional	2013-12-31	Completed
An Open-Label (OL) Extension Study to Assess Safety of PROCRIT (Epoetin Alfa) in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis (RA) [NCT00123149]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
A Randomised, Controlled, Open-label, French Multicenter Parallel Group Study to Compare the Maintenance of Haemoglobin Level With Once Monthly Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) Versus Epoetin Beta or Darbepoetin Al [NCT00717821]	Phase 3	421 participants (Actual)	Interventional	2008-08-31	Completed
A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-dialysis Patients With Chronic Renal Anaemia [NCT00517881]	Phase 3	29 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to The study was terminated due to the slow recruitment rate.)
A Single-Arm Open-Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous and/or Subcutaneous C.E.R.A for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia [NCT00517413]	Phase 3	163 participants (Actual)	Interventional	2007-10-31	Completed
An Open-Label, Single-Arm Pilot Study of the Efficacy of Erythropoietin Alfa in Improving Peak Oxygen Consumption in Elderly Subjects With Unexplained Anemia [NCT00954486]		0 participants (Actual)	Interventional	2008-12-31	Withdrawn(stopped due to Difficulty in identifying interested subjects.)
A Randomized, Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Control in Patients Transitioning From Chronic Kidney Disease Stage 4 Through Dialysis [NCT00454246]	Phase 3	111 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Strategic decision unrelated to safety or efficacy)
Effect of Erythropoietin on Renal Function After Kidney Transplantation [NCT00425698]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2007-02-28	Completed
A Randomized, Controlled, Open-Label, Multi- Center, Parallel-Group Study to Demonstrate the Efficacy and Safety of RO0503821 When Administered Subcutaneously for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Dialy [NCT00077623]	Phase 3	572 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized, Open-Label, Comparative Study of Epoetin Alfa (PROCRIT) 80,000 Units or 120,000 Units Q3W (Every 3 Weeks) Versus Darbepoetin Alfa (ARANESP) 500 Mcg Q3W in Anemic Cancer Subjects Receiving Chemotherapy [NCT00386152]	Phase 2	235 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to No safety signals were noted. The study was stopped because it was no longer consistent with the company's scientific and strategic focus.)
A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia [NCT00660023]	Phase 3	124 participants (Actual)	Interventional	2008-08-31	Completed
A Single Arm Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Haemodialysis Patients With Chronic Renal Anaemia. [NCT00661505]	Phase 3	132 participants (Actual)	Interventional	2008-05-14	Completed
Effect of Epoetin Beta on Renal Function Within 30 Days Following a Kidney Transplant [NCT00815867]	Phase 3	108 participants (Actual)	Interventional	2007-10-31	Completed
An Open-Label, Phase IIIb, Multi-Centre, Randomised, Parallel-Group Study to Investigate the Efficacy and Safety of Three Dosing Schedules of Subcutaneous Dynepo in Adult Patients With Anaemia Associated With Chronic Kidney Disease Who Are Pre-Dialysis or [NCT00450333]	Phase 3	407 participants (Actual)	Interventional	2006-10-30	Terminated(stopped due to The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA)
Phase II Randomized Trial With A Modified Dose & Schedule of Subcutaneously Administered Azacitidine & Erythropoietin v Azacitidine Alone in Patients With Low-Risk Myelodysplastic Syndromes (Less Than 11% Marrow & Peripheral Blood Blasts) [NCT00379912]	Phase 2	15 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Insufficient response rate)
"Optimal Blood Management in Elective Orthopaedic Surgery: The Transfusion Op Maat (TOMaat) Study" [NCT00998088]	Phase 4	2,598 participants (Actual)	Interventional	2004-05-31	Completed
An Open Label Randomised Controlled Study to Compare the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. Versus Epoetin Alfa for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Ana [NCT00605293]	Phase 3	101 participants (Actual)	Interventional	2008-01-31	Completed
[NCT02745990]		440 participants (Anticipated)	Interventional	2016-05-31	Enrolling by invitation
Study Of Epoetin Alfa Vs Epoetin Alfa With Dexamethasone In Hormone Refractory Prostate Cancer Patients: Impact On Fatigue, Anemia, Functional Status And Quality Of Life [NCT00060398]	Phase 3	282 participants (Anticipated)	Interventional	2004-09-29	Completed
The Effect of Intravenous Erythropoietin Treatment on Cognition During Hypoglycemia in Patients With Type 1 Diabetes. [NCT00615368]		11 participants (Actual)	Interventional	2008-05-31	Completed
The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group [NCT00617474]	Phase 1	50 participants (Anticipated)	Interventional	2008-03-31	Not yet recruiting
An Open-label, Randomized, Multi-center, Parallel Group Study to Demonstrate Correction of Anemia Using Intravenous Injections of RO0503821 in Patients With Chronic Kidney Disease Who Are on Dialysis [NCT00546481]	Phase 3	80 participants (Actual)	Interventional	2007-11-30	Completed
A Phase 3, Randomized, Open-Label, Active-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease on Dialysis [NCT02652806]	Phase 3	305 participants (Actual)	Interventional	2015-12-31	Completed
Phase 1 Study of Recombinant Human Erythropoietin (rhEPO) in Parkinson's Disease (PD) [NCT01010802]	Phase 1	10 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease [NCT04036253]	Phase 3	120 participants (Anticipated)	Interventional	2018-02-28	Active, not recruiting
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery [NCT00513240]	Phase 1/Phase 2	62 participants (Actual)	Interventional	2006-09-30	Completed
A Phase II Study of Azacitidine (Vidaza®) Combined to Epoetin Beta (NeoRecormon®) in IPSS Low-risk and Intermediate-1 MDS Patients, Resistant to ESA [NCT01015352]	Phase 2	98 participants (Actual)	Interventional	2009-02-28	Completed
Augmentation of Medical Readiness and Physical Performance at High Altitude Using Pharmacological Countermeasures [NCT05300477]	Phase 4	18 participants (Anticipated)	Interventional	2022-05-27	Recruiting
An Open-label, Multi-center Study to Demonstrate Correction of Anemia and to Assess the Maintenance of Hemoglobin Levels Using Subcutaneous Once Monthly Injections of Mircera in Pre-dialysis Patients With Chronic Kidney Disease [NCT00462384]	Phase 3	39 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Strategic decision unrelated to safety or efficacy)
A Two-arm, Randomized, Open-label, Multicenter Study of Safety and Efficacy of Monthly Injections of RO0503821 Versus Epoetin Alfa in Peritoneal Dialysis Patients Who Self Inject or Receive In-center Injections. [NCT00442416]	Phase 3	80 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Strategic decision unrelated to safety or efficacy)
A Randomized, Open-label, Multicenter Study of Epoetin Alfa Comparing Two Extended Dosing Regimens, Once-every-two-weeks and Once-every-four-weeks, With the Once-weekly Dosing Regimen for Maintenance Treatment in Anemic Subjects With Chronic Kidney Diseas [NCT00440466]	Phase 3	430 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized, Masked, Placebo Controlled Study to Assess the Safety and Efficacy of Darbepoetin Alfa Administered to Preterm Infants [NCT00334737]	Phase 2	102 participants (Actual)	Interventional	2006-06-30	Completed
Multicenter Study for the Evaluation of Efficacy and Safety of NeoRecormon® Therapy Administered as 30000 IU Subcutaneously in Anemic Patients With Breast Cancer Treated With Chemotherapy [NCT02761642]	Phase 2	200 participants (Actual)	Interventional	2004-02-29	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia [NCT00642850]	Phase 3	188 participants (Actual)	Interventional	2007-11-30	Completed
Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [NCT00577096]		120 participants (Actual)	Interventional	2001-10-31	Completed
An Open-label Study of the Effect of Mircera on Hemoglobin Levels in Filipino Chronic Kidney Disease Patients [NCT00922610]	Phase 4	28 participants (Actual)	Interventional	2009-02-28	Completed
Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial) [NCT02603406]	Phase 2	44 participants (Actual)	Interventional	2016-07-15	Completed
Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers [NCT00687518]		14 participants (Anticipated)	Interventional	2008-03-31	Recruiting
A Single Arm, Open Label Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia [NCT00550680]	Phase 3	208 participants (Actual)	Interventional	2008-01-31	Completed
Perioperative Intravenous Iron With Erythropoietin for the Prevention of Postoperative Severe Anemia and Reduction of Transfusion in Bilateral Total Knee Replacement Arthroplasty [NCT01012063]		54 participants (Actual)	Interventional	2008-08-31	Completed
Phase 4, Multicenter, Randomized, Open-Lable, Active-Controlled Study of the Efficacy and Safty of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in Incident-Dialysis Patients [NCT04134026]	Phase 4	400 participants (Anticipated)	Interventional	2022-10-20	Not yet recruiting
A Single Arm Open Label Multicentre Study to Assess the Efficacy, Safety and Tolerability of Monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients, Not Currently Treated With ESA [NCT00576628]	Phase 3	133 participants (Actual)	Interventional	2008-05-31	Completed
Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as [NCT02624141]	Phase 4	10 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to The study was terminated due to low recruitment)
Infusion of a Single Dose of Erythropoietin to Prevent Injury in an Ischemia Reperfusion Forearm Model - A Randomised Cross-over Study to Evaluate if Infusion of a Single Dose of EPO Protects Against Ischemia-reperfusion Injury in Man [NCT00691613]		12 participants (Anticipated)	Interventional	2010-07-31	Not yet recruiting
A Non-Interventional, Post-Authorisation Study to Assess Adverse Events and Drug Utilisation Among Chronic Kidney Disease Patients Treated With DYNEPO [NCT00664066]		3 participants (Actual)	Observational	2008-04-25	Terminated(stopped due to The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA)
An Open-Label Study of the Safety Of NeoRecormon in Patients With Solid Tumors Being Treated With Platinum Capable of Inducing Anemia [NCT02554942]	Phase 4	28 participants (Actual)	Interventional	2004-06-30	Completed
A Randomized, Double-blind, Placebo-Controlled Study Evaluating Weekly Epoetin Alfa (PROCRIT�) Administration on Hemoglobin Response and Safety in Diabetic Subjects With the Anemia of Chronic Kidney Disease (CKD) [NCT00240734]	Phase 2	11 participants (Actual)	Interventional	2005-03-31	Terminated(stopped due to This study was stopped for slow enrollment after enrolling only 11 of 180 patients in six months time.)
An Open-Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Participants With Chronic Kidney Disease on Hemodialysis [NCT00717366]	Phase 2	64 participants (Actual)	Interventional	2008-07-31	Completed
''Erythropoietin Gel as an Adjunct to Split-Thickness Apically Positioned Flap in Augmentation of Attached Gingiva'' (A Randomized Controlled Clinical Study) [NCT05683782]	Phase 4	20 participants (Anticipated)	Interventional	2022-10-01	Recruiting
A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Pegolsihematide for the Correction of Anemia in Patients With CRF Undergoing Dialysis and Previously Treated With ESAs [NCT02586402]	Phase 2	60 participants (Anticipated)	Interventional	2015-10-31	Recruiting
An Open-Label Study of the Tolerability and Flexibility of Multi-Dose NeoRecormon Administered by Reco-Pen in Pre-Dialysis Patients With Chronic Renal Anemia. [NCT02569515]	Phase 4	58 participants (Actual)	Interventional	2004-10-31	Completed
A Single Arm Open Label Study to Assess Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneously C.E.R.A. for the Maintenance of Hemoglobin Levels in Patients With Chronic Renal Anemia Not on Dialysis [NCT00642304]	Phase 3	20 participants (Actual)	Interventional	2008-03-27	Completed
A Single-arm, Open Label Multicenter Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of C.E.R.A. for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia [NCT00576303]	Phase 3	200 participants (Actual)	Interventional	2008-04-30	Completed
German Multicenter EPO Stroke Trial (Phase II/III) [NCT00604630]	Phase 2/Phase 3	522 participants (Actual)	Interventional	2003-01-31	Completed
AFX01-15: A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Correction of Anemia in Patients With Chronic Renal Failure (CRF) Undergoing Hemodialysis and Not on Erythropoiesis Stimu [NCT00680043]	Phase 2	114 participants (Actual)	Interventional	2008-06-30	Completed
An Open Label Randomized Controlled Study to Compare the Efficacy and Safety of Once Every 4 Weeks Administration of Mircera Versus Short-acting Epoetin for the Maintenance of Hemoglobin Levels in Dialysis Patients With Chronic Renal Anemia. [NCT00773331]	Phase 3	281 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Open Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly Dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects With Chronic Kidney [NCT00440557]	Phase 3	375 participants (Actual)	Interventional	2006-09-30	Completed
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation [NCT05907499]	Phase 3	76 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
A Single Arm, Open Label, French Multi-centre Study to Assess the Maintenance of Hemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease Not on Dial [NCT00642967]	Phase 3	127 participants (Actual)	Interventional	2008-06-30	Completed
A Randomized, Controlled, Open-Label, Multi-Centre, Parallel-Group Study To Assess All-Cause Mortality And Cardiovascular Morbidity In Patients With Chronic Kidney Disease On Dialysis And Those Not On Renal Replacement Therapy Under Treatment With MIRCERA [NCT00773513]	Phase 4	2,825 participants (Actual)	Interventional	2008-12-12	Completed
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes [NCT00910858]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2005-01-31	Completed
Erythropoietin Monotherapy for Brain Regeneration in Neonatal Encephalopathy in Low and Middle-Income Countries [NCT05395195]	Phase 3	504 participants (Anticipated)	Interventional	2022-12-31	Recruiting
Effect of Ultra-short-term Treatment of Patients With Iron Deficiency or Anemia Undergoing Adolescent Scoliosis Correction [NCT04343170]		44 participants (Anticipated)	Interventional	2023-11-01	Active, not recruiting
Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial [NCT00476619]	Phase 4	17 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to The exclusion criteria were stringent and enrollment was slow.)
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Intravenous C.E.R.A. for the Maintenance of Haemoglobin Levels in Hemodialysis Patients With Chronic Renal Anaemia [NCT00699348]	Phase 3	351 participants (Actual)	Interventional	2008-07-31	Completed
Phase 4 Study of the Effect of Human Recombinant Erythropoietin at the Time of Reperfusion in Patients With Acute Myocardial Infarction [NCT00882466]	Phase 4	58 participants (Actual)	Interventional	2008-05-31	Completed
Double-blind Randomized Controlled Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Allogenic Umbilical Cord Blood and Erythropoietin for Children With Cerebral Palsy [NCT01193660]		105 participants (Actual)	Interventional	2010-05-31	Completed
Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly [NCT02564094]	Phase 4	54 participants (Actual)	Interventional	2005-02-28	Completed
Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone [NCT02731378]	Phase 4	603 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Early Treatment With Recombinant Erythropoietin for Neuroprotection in Very Preterm Infants: Comparison of High and Low Dose [NCT00910234]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2009-08-31	Not yet recruiting
A Randomized, Open Label Study to Compare the Effect of Once Monthly Administration of Subcutaneous Mircera Versus Epoetin Alfa on Maintenance of Hemoglobin Levels, Safety and Tolerability in Dialysis Patients With Chronic Renal Anemia. [NCT00560404]	Phase 3	233 participants (Actual)	Interventional	2008-04-30	Completed
An Open Label Study to Assess the Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Monthly Administration of Mircera in Hemodialysis Patients With Chronic Renal Anemia. [NCT00560547]	Phase 3	0 participants (Actual)	Interventional	2007-10-31	Withdrawn(stopped due to The study was cancelled before any patients were enrolled, due to operational reasons.)
A Randomized, Double Blind, Placebo Controlled, Multicenter Study Evaluating Epoetin Alfa Initiated at 40,000 IU Every Week or 80,000 IU Every Week Versus Placebo in Subjects With IPSS Low- or Intermediate-1 Risk Myelodysplastic Syndromes at Risk For Tran [NCT00695396]	Phase 3	25 participants (Actual)	Interventional	2008-06-30	Terminated(stopped due to The study was stopped due to low subject enrollment. No safety issue or other concern factored into this decision.)
A Prospective Randomised Controlled Trial to Study the Effects of Recombinant Human Erythropoietin on the Progression of Atherosclerosis, Cardiovascular Function, Nutrition and Residual Renal Function in Pre-dialysis Chronic Renal Failure Patients [NCT00563355]		66 participants (Actual)	Interventional	2001-02-28	Completed
The Effect of Erythropoietin on Platelet Activation Markers: a Prospective Study in Healthy Volunteers [NCT01392612]	Phase 4	12 participants (Actual)	Interventional	2006-11-30	Completed
Safety and Efficacy of Combined Administration of Erythropoietin in Umbilical Cord Blood Therapy for Stroke Patients [NCT04013646]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2019-05-02	Recruiting
Evaluation of CD71 Expression in a Dried Blood Spot Following rEPO Administration [NCT04073849]	Early Phase 1	24 participants (Actual)	Interventional	2019-07-15	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous Mircera® for the Maintenance of Haemoglobin Levels in Patients With Chronic Renal Anaemia Who Are Not on Dialysis [NCT00922116]	Phase 4	191 participants (Actual)	Interventional	2009-04-30	Completed
Erythropoietin for the Prevention of Postoperative Delirium in Elderly Patients Undergoing Total Joint Arthroplasty: Randomized Controlled Study [NCT06178835]	Phase 4	76 participants (Actual)	Interventional	2017-09-12	Completed
Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial [NCT00945789]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy. [NCT00321919]	Phase 3	605 participants (Actual)	Interventional	2000-07-31	Completed
Effect of Erythropoietin on Neonatal Hypoxic Ischemic Encephalopathy [NCT00808704]	Phase 1/Phase 2	167 participants (Actual)	Interventional	2003-08-31	Completed
Efficacy of Erythropoietin to Prevent Acute Kidney Injury in Chronic Kidney Disease Patients Undergoing Cardiac Surgery [NCT01066351]	Phase 3	200 participants (Anticipated)	Interventional	2010-01-31	Enrolling by invitation
Erythropoietin Prevention Trial of Coronary Restenosis and Cardiac Remodeling After Acute Myocardial Infarction (EPOC-AMI) [NCT00423020]	Phase 4	72 participants	Interventional		Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) on the Development of Peripheral Neuropathy in Patients Receiving Combination Taxane and Platinum-Based Ch [NCT00267007]	Phase 2	32 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Slow enrollment)
A Pilot Study to Evaluate the Response Rate of PROCRIT� (Epoetin Alfa) at 60,000 Units Every Two Weeks in Anemic Cancer Patients Not Receiving Chemotherapy Or Radiation Therapy [NCT00388336]	Phase 2	57 participants (Actual)	Interventional	2004-02-29	Completed
A Single Arm, Open Label, Interventional Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Once-Monthly Administration of Intravenous C.E.R.A. for the Maintenance of Hemoglobin Levels in Hemodialysis Patients With Chronic Renal Anemia [NCT00545571]	Phase 3	120 participants (Actual)	Interventional	2007-10-31	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anaemia in Pre-dialysis Patients Not Currently Treated With ESA. [NCT00661388]	Phase 3	75 participants (Actual)	Interventional	2008-08-31	Completed
The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia [NCT00524407]	Phase 4	273 participants (Actual)	Interventional	1996-07-31	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Two Weekly Administration of Intravenous Methoxy Polyethylene Glycol-epoetin Beta (MIRCERA) for the Treatment of Chronic Renal Anemia in Dialysis Patients Not Currently Trea [NCT00737711]	Phase 4	189 participants (Actual)	Interventional	2008-07-31	Completed
A Single Arm, Open-Label, Multicentre Study to Assess the Maintenance of Haemoglobin Levels With Once Monthly Subcutaneous Administration of C.E.R.A (Continuous Erythropoietin Receptor Activator) in Patients With Chronic Kidney Disease on Peritoneal Dialy [NCT00737477]	Phase 3	96 participants (Actual)	Interventional	2008-09-30	Completed
Subcutaneous Treatment of Anemia in Patients With a GFR Below 45 ml/Min/1.73m2 Through Injections With Mircera as Low Frequent as Once Monthly (STABILO) [NCT00642668]	Phase 4	35 participants (Actual)	Interventional	2008-06-30	Completed
Generation of Positive Biological Samples to Epoetin for Doping Control. [NCT02920372]	Phase 1	2 participants (Actual)	Interventional	2016-11-30	Completed
A Randomized, Open-Label Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and Epoetin Alfa Manufactured by Roller Bottle Technology in Subjects With Chronic Kidney Disease Not on Dialysis [NCT00156962]	Phase 3	850 participants (Anticipated)	Interventional	2005-04-30	Terminated(stopped due to Regulatory decision not to proceed)
An Open-Label, Randomized, Multi-center, Controlled Study of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease in the Long Term Care Setting [NCT00337935]	Phase 2	157 participants (Actual)	Interventional	2006-07-31	Completed
RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa [NCT00416624]	Phase 2	239 participants (Actual)	Interventional	2007-05-31	Completed
An Open Label Study of the Effect of Intravenous Mircera on Hemoglobin Levels in Anemic Patients With Chronic Kidney Disease Who Are on Dialysis, and Who Have Previously Received Epoetin Alfa or Beta or Darbepoetin Alfa Treatment. [NCT00413894]	Phase 3	424 participants (Actual)	Interventional	2007-03-31	Completed
Treatment Program for Anemia in AIDS Patients [NCT00002022]		0 participants	Interventional		Completed
Clinical and Biological Evaluation of Azacitidine in Transfusion-dependent Patients With Low and Intermediate-1 Risk MDS, and Low-risk CMML, Who Are Either Refractory to or Not Eligible for Treatment With Erythropoietin +/- G-CSF [NCT01048034]	Phase 2	30 participants (Actual)	Interventional	2010-01-31	Completed
An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Subcutaneous Epoetin Alfa or Beta to Maintenance Treatment With Subcutaneous RO050 [NCT00364832]	Phase 2	137 participants (Actual)	Interventional	2001-10-31	Completed
A Phase 1b, Randomized, Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease [NCT03992066]	Phase 1	46 participants (Actual)	Interventional	2019-05-28	Completed
Prevalence and Treatment of Anemia in Patients Admitted to Subacute Rehabilitation Hospital [NCT00511901]	Phase 4	22 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to Study enrollment was suspended in response to an FDA alert regarding the study drug. The study was subsequently terminated)
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy [NCT00338286]	Phase 3	2,098 participants (Actual)	Interventional	2006-03-02	Completed
Effects of Erythropoietin on Cerebral Vascular Dysfunction and Anemia in Traumatic Brain Injury [NCT00313716]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2006-04-30	Completed
An Open-Label, Randomized, Parallel-Group Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Subjects Undergoing Major Elective Spinal Surgery [NCT00211146]	Phase 3	680 participants (Actual)	Interventional	1998-04-30	Completed
Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study [NCT01886443]	Phase 1	10 participants (Actual)	Interventional	2013-08-31	Completed
[NCT01889056]	Phase 1/Phase 2	32 participants (Anticipated)	Interventional	2013-02-28	Active, not recruiting
[NCT01902511]		60 participants (Actual)	Interventional	2013-07-31	Completed
The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Chemotherapy [NCT00266617]	Phase 2	86 participants (Actual)	Interventional		Completed
An Open-label, Randomized Study to Evaluate the Effect of Early Treatment of Anemia With Epoetin Alfa on Hemoglobin, the Incidence of Blood Transfusions and Quality of Life in Patients Receiving Platinum-containing Chemotherapy [NCT00283465]	Phase 4	316 participants (Actual)	Interventional	1999-11-30	Completed
A Phase 2, Multicenter, Open-label, Randomized, Active-Controlled Study of Efficacy and Safety of AND017 in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis [NCT05265325]	Phase 2	120 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Pilot Study to Evaluate the Response Rate of Epoetin Alfa (PROCRIT) at 80,000 Units Every Three Weeks in Anemic Patients With Cancer Not Receiving Chemotherapy or Radiation Therapy [NCT00210587]	Phase 3	51 participants (Actual)	Interventional	2005-02-28	Completed
An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD) [NCT00210743]	Phase 2	67 participants (Actual)	Interventional	2004-05-31	Completed
Phase 2 Study Evaluating the Efficacy of Epoetin Beta (Neocormon®) For Fatigue and Quality of Life of Patients Receiving Palliative Care for a Solid Malignant Tumor [NCT00559195]	Phase 2	40 participants (Anticipated)	Interventional	2005-11-30	Completed
"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysp [NCT05949684]	Phase 3	360 participants (Anticipated)	Interventional	2023-10-24	Recruiting
Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial [NCT01962571]	Phase 3	108 participants (Actual)	Interventional	2014-11-25	Completed
Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy Combined With Erythropoietin in Children With Cerebral Palsy: a Double-blind, Randomized, Placebo-controlled Clinical Trial [NCT01991145]		92 participants (Actual)	Interventional	2013-11-26	Completed
Randomized Trial of Epoetin Alfa in Men With Hormone-refractory Prostate Cancer and Anemia. [NCT00364455]	Phase 3	56 participants (Actual)	Interventional	2002-12-31	Completed
Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial [NCT02002039]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2012-06-30	Completed
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery [NCT00254436]	Phase 3	50 participants (Actual)	Interventional	2001-10-31	Terminated
Randomized, Double-blind, Multicenter, Parallel-group, Equivalence Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients [NCT00666835]	Phase 3	478 participants (Actual)	Interventional	2004-04-30	Completed
A Prospective, Randomized, Double-Blinded Control Study of Procrit Versus Placebo to Determine Efficacy in Pre-Operative Patients Undergoing Major Surgical Oncology Operations [NCT00624312]	Phase 2	0 participants (Actual)	Interventional	2008-02-29	Withdrawn
[NCT00006136]	Phase 2	15 participants	Interventional	1999-03-31	Completed
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3) [NCT00390832]	Phase 3	138 participants (Actual)	Interventional	2006-12-31	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once-monthly Administration of Subcutaneous and Intravenous MIRCERA® for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anaemia [NCT01156363]	Phase 4	86 participants (Actual)	Interventional	2010-10-31	Completed
Pilot Study to Assess the Effect of Low Dose Epoetin Beta Administered for Six Month in Patients With Ischemic Heart Failure Subjected to Percutaneous Coronary Intervention (PCI) [NCT00568542]	Phase 4	28 participants (Actual)	Interventional	2006-05-31	Completed
Prognostic Value of Serum Erythropoietin Level,Ferritin Level and Fibrinogen in Adult Low Risk MDS [NCT04573686]		50 participants (Anticipated)	Observational	2021-01-01	Not yet recruiting
High-Dose Erythropoietin in Very Low Birth Weight Infants for the Potential Treatment of Prematurity-Related Cerebral Hemorrhagic-Ischemic Injury: A Phase II Safety/Tolerability Study [NCT00589953]	Phase 2	22 participants (Actual)	Interventional	2007-07-31	Terminated
A Randomized, Open Label Study to Evaluate the Effect of Subcutaneous Mircera, Versus no ESA Therapy, on Hemoglobin Levels in Chronic Kidney Disease Patients With Anemia After Kidney Transplant. [NCT00576602]	Phase 4	1 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to poor recruitment)
A Randomized Controlled, Single-blind, Proof-of-concept-study to Investigate the Protective Effects of Early Treatment With C.E.R.A. in Patients With Chronic Kidney Disease on Renal Disease Progression (PRIMAVERA-Study) [NCT01194154]	Phase 2	241 participants (Actual)	Interventional	2010-09-30	Completed
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once- Monthly Administration of Subcutaneous CERA for the Maintenance of Haemoglobin Levels in Dialysis Patients With Chronic Renal Anemia [NCT00882713]	Phase 3	202 participants (Actual)	Interventional	2009-02-28	Completed
Impact of Erythropoietin on Hematological Adaptations and Physical Performance [NCT05078138]	Phase 4	8 participants (Actual)	Interventional	2021-09-01	Completed
Erythropoietin as an add-on Treatment for Cognitive Side-effects of Electroconvulsive Therapy [NCT03339596]	Phase 2	60 participants (Actual)	Interventional	2017-06-26	Completed
A Single Arm, Open Label, Multicenter Phase IIIb/IV Clinical Trial to Assess the Efficacy, Safety and Tolerability of Monthly Administration of C.E.R.A. for the Treatment of Not on Dialysis Chronic Renal Anemia Not Currently Treated With ESA [NCT01342640]	Phase 4	70 participants (Actual)	Interventional	2011-07-18	Completed
Relationship Between Clinical Recovery and Oxidative Stress and Inflammation Following Usage of Erythropoietin in Admitted Traumatic Patient In Intensive Care Unit [NCT00622934]	Phase 2	20 participants (Anticipated)	Interventional	2007-07-31	Recruiting
A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers [NCT02580006]	Phase 1	42 participants (Anticipated)	Interventional	2015-11-30	Not yet recruiting
Insulin Resistance and Substrate Metabolism After Acute EPO Administration in Healthy Young Men [NCT00793767]		10 participants (Anticipated)	Interventional	2009-01-31	Completed
Topical Erythropoietin Hydrogel in Management of Oral Lichen Planus: A Randomized Controlled Clinical Trial [NCT06135259]	Phase 3	18 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
An Open Label, Single-arm, Baseline-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 Administered Once a Week (qw) and Once Every Two Weeks (q2w) in the Treatment of Anemia Associated With Chronic Kid [NCT00869856]	Phase 3	0 participants (Actual)	Interventional	2009-04-30	Withdrawn(stopped due to investigation of adverse events in a related clinical study)
Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria [NCT00697164]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2007-10-31	Recruiting
AFX01-14: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Peginesatide for the Maintenance Treatment of Anemia in Hemodialysis Patients Previously Treated With Epoetin [NCT00597584]	Phase 3	823 participants (Actual)	Interventional	2007-10-31	Completed
Pharmaco-epidemiological Observational Study of the Clinical Benefit of NeoRecormon® in Cancer Patients With Anemia, According to Early Response to Treatment [NCT01168349]		1,060 participants (Actual)	Observational	2010-01-31	Completed
EPO to Protect Renal Function After Cardiac Surgery. A Phase II Double Blind Randomized Controlled Study. [NCT01423955]	Phase 2	75 participants (Actual)	Interventional	2011-10-31	Completed
Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Usi [NCT02608060]	Phase 4	4 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Due to poor enrollment this study was terminated prematurely.)
A Single Arm, Open Label Study to Assess the Efficacy, Safety and Tolerability of Once Monthly Administration of Subcutaneous C.E.R.A. for the Maintenance of Haemoglobin Levels in Pre-Dialysis Patients With Chronic Renal Anaemia [NCT00773968]	Phase 3	140 participants (Actual)	Interventional	2008-09-30	Completed
Evaluation of the Tolerability and Efficacy of Erythropoietin (EPO) Treatment in Spinal Shock: Comparative Study VS Methylprednisolone (MP) [NCT00561067]	Phase 3	10 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Italian Medicines Agency decision)
The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial. [NCT00336466]	Phase 2	32 participants	Interventional	2004-09-30	Completed
Chronic Anemia And Fatigue In Elderly Patients: A Randomized Double-Blind Placebo-Controlled Cross-Over Study With Epoetin Alfa. [NCT00337441]	Phase 2	62 participants	Interventional	2003-01-31	Active, not recruiting
An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Weekly or Every Four Week Regimen [NCT00337948]	Phase 2	129 participants (Actual)	Interventional	2003-02-28	Completed
An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of PROCRIT� (Epoetin Alfa) in the Treatment of Patients With Cancer and Chemotherapy Induced Anemia (60,000 Units Weekly for Four Weeks Followed by 60,000 Units Every Two Weeks) [NCT00338299]	Phase 2	51 participants (Actual)	Interventional	2003-08-31	Completed
An Open-Labeled Pilot Study to Evaluate the Effects of High Dose PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy on a Every Three Week Regimen [NCT00338416]	Phase 2	115 participants (Actual)	Interventional	2003-03-31	Completed
The Possible Influence of Erythropoietin and Early Iron Supplements on the Prevalence and Severity of Retinopathy of Prematurity and Other Short Term Outcome of Prematurity [NCT00339001]		400 participants	Observational	2006-04-30	Recruiting
Comparative Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days [NCT00210756]	Phase 2	60 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Anemia of Chronic Disease (ACD) Receiving Epoetin Alfa (PROCRIT�) [NCT00210795]	Phase 2	12 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to This study was stopped due to slow enrollment after enrolling only 12 of 80 patients over 14 months time.)
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum [NCT00189371]	Phase 3	300 participants	Interventional	2004-02-29	Terminated
An Open-Label Study to Investigate Improvement in Heart Function After Complete Anemia Correction With NeoRecormon in Patients With End-Stage Renal Disease Already Receiving Sub-Optimal Doses of NeoRecormon [NCT00413101]	Phase 4	50 participants (Actual)	Interventional		Completed
A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease W [NCT01975818]	Phase 2	201 participants (Actual)	Interventional	2013-10-28	Completed
Effects of Recombinant Human Erythropoietin on Platelet Function in Healthy Subjects [NCT00368238]	Phase 2	96 participants	Interventional	2005-10-31	Completed
A Double-blind, Randomized, Placebo-controlled, Clinical Trial to Test the Efficacy of Epoetin Alfa on Physical Performance of Friedreich Ataxia Patients. [NCT01493973]	Phase 2	56 participants (Actual)	Interventional	2013-01-31	Completed
An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure [NCT00338000]	Phase 4	292 participants (Actual)	Interventional	2001-06-30	Completed
An Open-Label Pilot Study to Assess Disability in Anemic Elderly Patients With Chronic Kidney Disease Receiving PROCRIT (Epoetin Alfa) [NCT00338468]	Phase 4	13 participants (Actual)	Interventional	2003-11-30	Terminated(stopped due to The study was stopped early due to slow enrollment.)
A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy [NCT00350090]	Phase 3	98 participants (Actual)	Interventional	2002-09-30	Terminated(stopped due to This study was stopped early due to slow enrollment.)
Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid [NCT00437450]	Phase 2	99 participants	Interventional	2004-10-31	Active, not recruiting
A Randomized Study to Compare the Safety and Effectiveness of Two Monitoring Schedules to Maintain Hemoglobin Levels and Iron Parameters in Patients With Renal Anemia Receiving NeoRecormon [NCT00440063]	Phase 4	0 participants	Interventional		Terminated
Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta). [NCT00491868]	Phase 3	134 participants (Actual)	Interventional	2007-06-30	Completed
Treatment With Erythropoetin in Patients With Spinal Trauma With Neurological Deficit, Maximum Tolerated Dose Study. TETRAM2 [NCT00478517]	Phase 1	20 participants	Interventional	2007-05-31	Withdrawn
High-dose Erythropoietin for Asphyxia and Encephalopathy [NCT02811263]	Phase 3	500 participants (Actual)	Interventional	2017-01-31	Completed
Evaluation of Dose Conversion From Variable Dosing Intervals of Darbepoetin Alfa to Variable Dosing Intervals of Epoetin Alfa in Patients With the Anemia of Chronic Kidney Disease [NCT00495365]	Phase 4	8 participants (Actual)	Interventional	2003-06-30	Terminated(stopped due to This study was stopped due to slow enrollment)
An Open Label Study to Evaluate the Effect of Intravenous Erythropoietin on Erythropoietin Receptor Signaling and Markers for Apoptosis, Myocardial Damage and Renal Dysfunction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery [NCT00524901]	Phase 2	10 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Epoetin Alfa (Procrit) in the Treatment of HIV-associated Sensory Neuropathy [NCT00528593]	Phase 2	0 participants (Actual)	Interventional	2007-11-30	Withdrawn(stopped due to lack of pharmaceutical support)
Systemic Erythropoietin Injection in Patients Having Optic Atrophy [NCT04680143]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2020-09-01	Completed
Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients Using EPODURE Biopump [NCT00542568]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2008-08-31	Completed
"A Study in Early Renal Insufficiency Patients to Assess the Effect of Maintaining Three Different Hemoglobin Levels With the Use of Erythropoetin Alpha on Left Ventricular Hypertrophy and Dilation and Quality if Life; The Cardiac Results of Early Treatme [NCT00446576]	Phase 3	176 participants (Actual)	Interventional	1999-11-30	Completed
A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disea [NCT02064426]	Phase 2	88 participants (Actual)	Interventional	2014-03-13	Completed
A Phase 3, Multicenter, Open-label, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Desidustat Tablet Versus Epoetin Alfa Injection for the Treatment of Anemia in Patients With Chronic Kidney Disease (CKD) on Dialysis (DREAM-D) [NCT04215120]	Phase 3	392 participants (Actual)	Interventional	2020-01-04	Completed
Serum Erythropoietin Level for Detection of Kidney and Brain Injuries in Asphyxiated Neonates in Neonatal Intensive Care Unit. [NCT05018364]		80 participants (Actual)	Observational	2020-08-01	Completed
A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter, Non-Inferiority Study to Evaluate the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Non-Dialysis-Dependent Chronic Kidney Disease [NCT03903809]	Phase 3	175 participants (Actual)	Interventional	2019-06-20	Active, not recruiting
A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy [NCT00003600]	Phase 3	344 participants (Actual)	Interventional	1998-12-31	Completed
A Study to Determine the Impact of Hemoglobin Maintenance and Other Interventional Strategies to Prevent or Delay the Progression of Left Ventricular Mass Growth in Subjects With Early Renal Insufficiency. [NCT00364260]	Phase 3	172 participants (Actual)	Interventional	1997-12-31	Completed
A Randomized, Open-Label Study Assessing the Efficacy of Initiating PROCRIT (Epoetin Alfa) Dosing at Q2W vs. PROCRIT Dosing at QW in Anemic HIV-infected Subjects [NCT00246298]	Phase 2	31 participants (Actual)	Interventional	2005-10-31	Terminated(stopped due to OBI business decision not to complete any additional research in HIV.)
Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA) [NCT00104169]	Phase 2	0 participants (Actual)	Interventional	2004-08-31	Terminated(stopped due to No subject accrual)
A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemoth [NCT00070382]	Phase 3	14 participants (Actual)	Interventional	2003-08-31	Completed
An Open Label, Randomized, Multicenter, Phase II Study To Determine Hemoglobin Dose Response, Safety And Pharmacokinetic Profile Of Ro 50-3821 Given Subcutaneously Once Weekly Or Once Every 3 Weeks To Anemic Patients With Stage IIIB or IV Non-Small Cell L [NCT00072059]	Phase 2	0 participants	Interventional	2003-07-31	Completed
Erythropoietin Protect the Cerebral Blood Flow and Oxygenation During Simulated Dive? [NCT00265486]		12 participants (Anticipated)	Observational	2005-08-31	Recruiting
A Parallel Group Placebo-Controlled Study to Determine an Effective Dose Regimen for EPREX� (Epoetin Alfa) Sterile Solution to Reduce Transfusion Requirements in Patients Undergoing Major Elective Orthopedic Surgery [NCT00269971]	Phase 3	0 participants (Actual)	Interventional	1996-05-31	Withdrawn
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00270010]	Phase 2	72 participants (Actual)	Interventional		Completed
The Effect of Subcutaneous r-HuEPO in Patients With Chronic Lymphocytic Leukemia [NCT00270049]	Phase 2	195 participants (Actual)	Interventional	1990-11-30	Completed
A Double-Blind, Placebo-Controlled Study to Determine Whether Procrit� (Epoetin Alfa) Can Reduce Peri-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery [NCT00270088]	Phase 3	316 participants (Actual)	Interventional	1993-04-30	Completed
Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving Non-Platinum-Containing Chemotherapy [NCT00270127]	Phase 3	375 participants (Actual)	Interventional	1996-08-31	Completed
A Placebo-Controlled Study on the Effect of Epoetin Alfa in Patients With Malignancy Receiving Chemotherapy [NCT00270166]	Phase 3	201 participants (Actual)	Interventional	1995-02-28	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00270283]	Phase 2	102 participants (Actual)	Interventional	1988-07-31	Completed
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia [NCT00270478]	Phase 1	7 participants (Actual)	Interventional	2005-12-21	Completed
Assessment of Efficacy & Safety of Recombinant Human Erythropoietin -Alpha, (rHu-EPO-Alpha) in Patients With Anemia of Chronic Renal Failure. [NCT00399269]	Phase 3	100 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease [NCT00077597]	Phase 3	182 participants (Actual)	Interventional	2004-02-29	Completed
Influence of G-CSF and EPO on Associative Learning and Motor Skills [NCT00298597]	Phase 2	180 participants (Anticipated)	Interventional	2006-03-31	Completed
[NCT00083486]	Phase 3	0 participants	Interventional	2004-02-29	Terminated
Effect of Early Correction of Anemia on the Progression of Chronic Renal Insufficiency (ECAP) [NCT00312871]	Phase 4	217 participants (Actual)	Interventional	2001-02-28	Terminated(stopped due to Study was stopped due to restrictions in labeling for the subcutaneous route of administration of EPREX.)
A Multicenter, Randomized, Open Label Dose Finding Study of Mircera in Anemic Patients With Stage IIIB or IV Non-small Cell Lung Cancer Receiving First Line Myelosuppressive Chemotherapy [NCT00327535]	Phase 2	153 participants (Actual)	Interventional	2006-05-31	Completed
An Open-Label Study to Evaluate The Effect of Every Other Week PROCRIT (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients [NCT00317902]	Phase 4	292 participants (Actual)	Interventional	2002-10-31	Completed
Resistance to ErythroPoietin Effectiveness Algorithm Trial [NCT00319150]	Phase 3	6 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to New evidence and trouble recruiting)
The Practical Anemia Bundle for SusTained Blood Recovery (PABST-BR) Clinical Trial [NCT05167734]	Phase 2	100 participants (Anticipated)	Interventional	2021-11-30	Recruiting
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Epoetin Alfa in Critically Ill Subjects [NCT00091910]	Phase 3	1,460 participants (Actual)	Interventional	2003-09-30	Completed
Switch and Maintenance Study of Subcutaneous or Intravenous Injections of R744 to Predialysis Patients ( Phase Ⅲ Study ). [NCT00433615]	Phase 3	124 participants (Actual)	Interventional	2007-02-28	Completed
Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn [NCT01732146]	Phase 3	120 participants (Actual)	Interventional	2013-03-28	Completed
A Phase 2, Randomized, Open-Label Study To Assess The Safety And Efficacy Of Weekly (QW) Or Once Every Two Week (Q2W) Dosing Of Epoetin Alfa (PROCRIT) in Anemic Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [NCT00446602]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Due to company decision to focus resources on a larger, controlled study in this patient population.)
A Prospective, Randomised, Clinical Study to Examine the Effects of a Single Bolus Erythropoietin on Left Ventricular Function in Patients With an Acute Myocardial Infarction [NCT00449488]	Phase 2	529 participants (Actual)	Interventional	2007-01-31	Completed
A Phase II Trial Using Intravenous Iron in Advanced Lung Cancer Patients With Chemotherapy-Induced Anemia Treated With 120,000 Units Epoetin Alfa Every Three Weeks [NCT00481624]	Phase 2	0 participants (Actual)	Interventional	2007-05-31	Withdrawn(stopped due to The study was stopped because of lack of funding.)
Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia [NCT00482716]	Phase 3	80 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Female Breast Cancer Patients Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy [NCT00120692]	Phase 2	0 participants	Interventional	2002-10-31	Completed
High Dose Erythropoietin for Neonates With Asphyxia [NCT00491413]	Phase 1	15 participants (Anticipated)	Interventional		Not yet recruiting
Correction and Maintenance Study of Subcutaneous Injections of R744 to Predialysis Patients ( Phase III, Comparative Study in Comparison With Epoetin Beta) [NCT00492427]	Phase 3	187 participants (Actual)	Interventional	2007-06-30	Completed
A Multicenter, Non-Randomized, Open-Label Study to Evaluate Efficacy and Safety of Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Red Cell Transfusion Dependent With Low or Intermediate -1 Risk. [NCT00495547]	Phase 2	16 participants (Actual)	Interventional	2009-02-28	Terminated
Effects of Systemic Erythropoietin Therapy on Cerebral Autoregulation and Incidence of Delayed Ischemic Deficits in Patients With Aneurysmal Subarachnoid Hemorrhage [NCT00140010]	Phase 2	80 participants (Actual)	Interventional	2005-04-30	Completed
A Multicenter, Open-Label Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy [NCT00144495]	Phase 3	104 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized, Double-Blind Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy [NCT00144482]	Phase 3	122 participants (Actual)	Interventional	2003-12-31	Completed
A Phase II Randomised Trial to Investigate the Safety and Efficacy of Recombinant Human Erythropoietin on Infarct Size in Patients Undergoing Primary Percutaneous Coronary Angioplasty for ST-Segment Elevation Myocardial Infarction [NCT00149058]	Phase 2	124 participants	Interventional	2005-10-31	Not yet recruiting
A Single Institution, Open-Label, Nonrandomized Pilot Study of High Dose Epoetin Alfa Administered Once a Week in Patients With Multiple Myeloma: Its Effects on Hemoglobin, Blood Transfusion Requirements and Quality of Life [NCT00400686]		31 participants (Actual)	Interventional	2003-09-30	Completed
Erythropoietin and Pediatric Cardiac Surgery [NCT00451698]		9 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Inadequate patient enrollment)
A Double Blinded, Placebo Controlled, Pilot Study to Evaluate the Safety of Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa [NCT00626574]	Phase 4	3 participants (Actual)	Interventional	2007-07-31	Terminated(stopped due to This study is terminated as a result of data from a study that showed increased mortality in stroke patients.)
Randomized Study of Procrit vs no Procrit in Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Undergoing Frontline Myelosuppressive Induction/Consolidation Chemotherapy [NCT00656448]	Phase 3	51 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized Multi-Center Study to Determine the Safety and Efficacy of Erythropoietin Plus Pentoxifylline Versus Erythropoietin Alone for the Treatment of Anemia in Subjects With End Stage Renal Disease on Maintenance Hemodialysis [NCT01102218]	Phase 2	48 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Lack of statistical difference between both arms of the trial.)
A Study of Darbepoetin Alfa Administered Once Every 2 Weeks (Q2W) Compared With Epoetin Alfa Administered Once Every Week (QW) for the Treatment of Anemia in Subjects With Non-myeloid Malignancies Receiving Multicycle Chemotherapy. [NCT00148421]	Phase 3	0 participants	Interventional		Completed
A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) To Evaluate Hematologic Response Rate In Anemic Cancer Patients Receiving Chemotherapy [NCT00315484]	Phase 4	358 participants (Actual)	Interventional	2003-02-28	Completed
A Randomized, Masked Study of Weekly Erythropoietin Dosing in Preterm Infants [NCT01235923]	Phase 2	20 participants (Actual)	Interventional	2006-04-30	Completed
Assessment of Early and Standard Intervention With PROCRIT (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy. [NCT00210600]	Phase 2	186 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized, Open-Label Study Of Epoetin Alfa (PROCRIT) Initiated At 40,000 Units Every Week Versus 80,000 Units Every Two Weeks In Anemic Patients With Cancer Receiving Chemotherapy [NCT00210834]	Phase 2	310 participants (Actual)	Interventional	2004-05-31	Completed
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Impact of Maintaining Hemoglobin Using Eprex (Epoetin Alfa) in Metastatic Breast Carcinoma Subjects Receiving Chemotherapy [NCT00211133]	Phase 3	939 participants (Actual)	Interventional	2000-06-30	Completed
A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer [NCT00246597]	Phase 3	37 participants (Actual)	Interventional	2002-12-31	Terminated(stopped due to Study stopped to avoid treating enrolled subjects to hemoglobin levels higher than those specified in current labeling.)
A Phase II Randomized, Open-Label, Multiple-Rising Dose Clinical Trial to Study the Efficacy and Safety of MK2578 for the Maintenance of Anemia Treatment in Patients With Chronic Kidney Disease Who Are on Hemodialysis. [NCT00924781]	Phase 2	39 participants (Actual)	Interventional	2009-06-30	Terminated
An Open-Label Study to Investigate the Effect of NeoRecormon on Hemoglobin Level and Renal Function in Patients With Chronic Kidney Disease, Stage 2-4 [NCT00437723]	Phase 4	90 participants (Actual)	Interventional		Completed
A Randomized, Open Label Study Comparing the Effect of Mircera and Epoetin Beta on Hemoglobin Response in Patients With Chronic Kidney Disease Who Are on Dialysis [NCT00442793]	Phase 3	265 participants (Actual)	Interventional	2007-05-31	Completed
Retrospective Review of Alternate PROCRIT Dosing In Patients With Chemotherapy Related Anemia [NCT00495378]	Phase 4	25 participants (Actual)	Interventional	2002-11-30	Terminated(stopped due to This study was stopped due to slow enrollment after enrolling 25 of 200 patients.)
A Randomized Phase II Study Of Gemcitabine Plus Radiotherapy Vs. Gemcitabine, 5-Fluorouracil And Cisplatin Followed By Radiotherapy And 5-Fluoraracil For Patients With Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma [NCT00049348]	Phase 2	0 participants	Interventional	2003-10-13	Completed
Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients With Chronic Kidney Disease [NCT03277183]	Phase 4	5 participants (Actual)	Interventional	2017-11-02	Terminated(stopped due to Lack of enrollment)
The Effect of PROCRIT on Hemoglobin and Hematocrit and the Relationship to Postoperative Function, Vigor and Strength in Patients Undergoing Primary Total Joint Arthroplasty: A Randomized, Parallel Group, Open-Label Trial [NCT00401869]	Phase 4	289 participants (Actual)	Interventional	1999-02-28	Completed
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patient With Non-Small Cell Lung Cancer Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy [NCT00120679]	Phase 2	0 participants	Interventional	2002-10-31	Completed
An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy [NCT00121030]	Phase 2	0 participants	Interventional	2002-10-31	Completed
Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) [NCT00355095]	Phase 2	40 participants (Actual)	Interventional	2006-08-31	Completed
A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing Preoperative Chemoradiation Followed by Surgery [NCT00036400]	Phase 3	60 participants (Actual)	Interventional	2001-12-31	Completed
Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer [NCT00017004]	Phase 3	114 participants (Actual)	Interventional	2001-08-31	Completed
A Phase III Double-Blind, Randomized, Placebo-Controlled Study of Erythropoietin When Used as an Adjuvant to Radiation Therapy in Patients With Head and Neck Squamous Cell Carcinoma [NCT00017277]	Phase 3	47 participants (Actual)	Interventional	2001-03-31	Terminated(stopped due to low accrual)
Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 [NCT00398749]		1,927 participants (Actual)	Observational	2005-10-31	Completed
A Randomized, Open-label Study of the Effect of Maintenance Mircera Administered With Pre-filled Syringes on Hemoglobin Levels in Anemic Dialysis Patients With Chronic Kidney Disease [NCT00081484]	Phase 3	336 participants (Actual)	Interventional	2004-06-30	Completed
Phase II Multicenter Study of Amifostine in Patients With Myelodysplastic Syndromes at Relatively Low Risk of Developing Acute Leukemia [NCT00003681]	Phase 2	50 participants (Anticipated)	Interventional	1998-08-31	Active, not recruiting
[NCT00083434]	Phase 3	0 participants	Interventional	2004-02-29	Terminated(stopped due to This study was stopped because of an inadequate rate of enrollment.)
The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome [NCT05857891]		40 participants (Anticipated)	Interventional	2023-05-20	Recruiting
An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer [NCT00022386]	Phase 4	0 participants	Interventional		Completed
Erythropoietin to Improve Critical Care Patient Outcomes: Feasibility Study of a Multicenter, Randomized, Placebo-controlled Trial of Subcutaneous Erythropoietin Injection for Intensive Care Patients [NCT05080049]	Phase 3	42 participants (Actual)	Interventional	2022-01-28	Active, not recruiting
Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery [NCT02984111]		97 participants (Actual)	Interventional	2016-01-31	Completed
A Phase III Randomized Trial Evaluating the Effect of Epoetin Alfa (Procrit) on Local Control in Patients Undergoing Concurrent Chemotherapy and Radiation Therapy for Non-Small Cell Lung Cancer [NCT00028938]	Phase 3	1 participants (Actual)	Interventional	2002-01-01	Completed
Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Patients With Bipolar Disorder or Recurrent Depressive Disorder and Healthy People: Study Protocol for a Randomized, Controlled Trial [NCT03315897]	Phase 2	103 participants (Actual)	Interventional	2017-07-05	Completed
A Placebo Controlled Trial Of Short-Term, High-Dose Epoetin Alfa In Advanced Cancer Outpatients With Mild Fatigue [NCT00052221]		0 participants (Actual)	Interventional	2003-05-20	Withdrawn
A Phase II Study on the Effectiveness of Thalomid (Thalidomide) Combined With Procrit (Erythropoietin) for the Treatment of Anemia in Patients With Low and Intermediate Risk-1 (IPSS Score Less Than or Equal to 1.5) Myelodysplastic Syndromes [NCT00053001]	Phase 2	0 participants	Interventional	2001-06-30	Completed
An Open Label Randomized Study To Evaluate The Response Rate Of Epoetin Alfa (PROCRIT�) Versus No/Delayed PROCRIT Treatment In Patients With Cancer And Persistent Chemotherapy-Induced Myelosuppression (Anemia) [NCT00210730]	Phase 3	2 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to This study was stopped early due to slow enrollment.)
Correction of Hemoglobin and Outcomes In Renal Insufficiency [NCT00211120]	Phase 4	1,432 participants (Actual)	Interventional	2002-03-31	Terminated(stopped due to Stopped by the DSMB due to a trend toward more adverse events in the higher hemoglobin (Hb) arm and <5% chance that the study would show benefit for higher Hb.)
An Open-Label, Randomized, Multicenter Study of the Initiation of Four Dosing Regimens of PROCRIT (Epoetin Alfa) for the Treatment of Anemia of Chronic Kidney Disease (CKD). Protocol Addendum: Due to Space Constraints, See Detailed Description for Full Ti [NCT00212875]	Phase 2	267 participants (Actual)	Interventional	2005-09-30	Completed
Randomised Study to Evaluate the Effect of Early Intervention to Treat Anemia With Epoetin Alfa Versus Standard Use on Hemoglobin Levels and the Incidence of Blood Transfusions in Cancer Patients Receiving Chemotherapy [NCT00216541]	Phase 4	110 participants (Actual)	Interventional	2003-08-31	Completed
Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study [NCT00220675]	Phase 2/Phase 3	7 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Insufficient accrual)
A Randomized, Double-Blind, Equivalence Study of the Efficacy of Epoetin Alfa Manufactured by Deep Tank Bioreactor Technology and Epoetin Alfa Manufactured by Roller-Bottle Technology for the Treatment of Anemia in Patients With Chronic Kidney Disease (CK [NCT00146224]	Phase 3	420 participants (Anticipated)	Interventional	2005-09-30	Completed
An Open-Label, Single-Arm Study to Assess the Safety of Epoetin Alfa Manufactured by a Deep Tank Technology in Subjects With Chronic Kidney Disease Receiving Dialysis [NCT00156949]	Phase 3	580 participants (Actual)	Interventional	2005-04-30	Completed
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation [NCT00157300]	Phase 4	92 participants (Actual)	Interventional	2005-07-31	Completed
A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer [NCT00058331]	Phase 3	365 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized Clinical Trial Comparing Two Management Strategies for Treatment of Neutropenia and Anemia Associated With Pegylated Interferon Plus Ribavirin Treatment of Compensated Chronic Hepatitis C in Adult Subjects Infected With HIV. [NCT00194857]	Phase 4	0 participants	Interventional	2002-02-28	Terminated
Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. [NCT00535925]	Phase 4	850 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of Recombinant Human Erythropoietin (Epoetin Alfa (PROCRIT®)) on Functional Outcomes in Anemic, Critically Ill, Trauma Subjects [NCT00210626]	Phase 2	192 participants (Actual)	Interventional	2005-08-31	Terminated
Research Factors Predictive of Treatment Failure With Erythropoietin Beta (NeoRecormon®) in Patients With Solid Tumors Treated With Chemotherapy [NCT00875004]		27 participants (Actual)	Interventional	2007-12-07	Terminated(stopped due to After two years of trial initiation, only 27 out of 300 patients were included. During this period, the international recommendations for the use of COOL were modified.)
The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia in Hematological Patients [NCT03683810]	Phase 1	50 participants (Anticipated)	Interventional	2019-01-14	Recruiting
Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: a Prospective Randomized Controlled Trial (ERECT) [NCT00737893]	Phase 2	56 participants (Actual)	Interventional	2017-07-01	Completed
Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome [NCT00356733]	Phase 3	62 participants (Actual)	Interventional	2007-01-31	Completed
Randomized, Double-blind, Safety and Efficacy of Recombinant Human Erythropoietin in Amyotrophic Lateral Sclerosis [NCT03835507]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2016-06-20	Recruiting
A Randomized, Double-blinded, Active Controlled, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics, Pharmacodynamics and Safety of GBPD002 and Eprex® After Subcutaneous Administration in Healthy Adult Volunteers. [NCT05585658]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2021-10-16	Completed
A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Idiopathic Anemia of Aging (IAA) Receiving Epoetin Alfa (PROCRIT�) [NCT00228995]	Phase 2	9 participants (Actual)	Interventional	2004-06-30	Terminated(stopped due to This study was stopped due to slow enrollment after enrolling only 9 of 80 patients over 14 months time.)
Neuroprotective Effect of High Dose Erythropoietin in Very Preterm Infants [NCT00413946]	Phase 2	420 participants (Actual)	Interventional	2006-01-31	Completed
Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis [NCT00236964]	Phase 3	78 participants	Interventional	2001-02-28	Completed
Phase II Study of the Effects of Erythropoietin on Neuronal Cell Death in Traumatic Brain Injury Patients [NCT00260052]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2003-07-31	Withdrawn(stopped due to PI has left institution)
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of of PROCRIT� (Epoetin Alfa) on Short-Term Outcomes in Orthopedic Subjects Undergoing Primary Unilateral Knee Arthroplasty [NCT00236405]	Phase 2	6 participants (Actual)	Interventional	2005-03-31	Terminated(stopped due to The study was terminated due to poor enrollment.)
A Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With Anemia of Chronic Disease (ACD) Due to Rheumatoid Arthritis Receiving PROCRIT� (Epoetin Alfa) [NCT00236678]	Phase 2	29 participants (Actual)	Interventional	2004-07-31	Terminated(stopped due to This study was terminated due to slow enrollment, despite protocol amendments to change the entrance criteria.)
A Double-Blind, Phase II, Placebo-Controlled Study to Determine the Safety and Efficacy of r-HuEPO in Reducing Transfusion Requirements in Patients Undergoing Total Hip Joint Replacement Surgery [NCT00269958]	Phase 2	208 participants (Actual)	Interventional		Completed
The Effect of Subcutaneous r-HuEPO in Patients With Chronic Anemia Secondary to Cisplatin Chemotherapy [NCT00269997]	Phase 2	72 participants (Actual)	Interventional		Completed
A Double-Blind, Placebo-Controlled Study to Determine the Safety of r-HuEPO and Whether r-HuEPO Can Reduce Post-Operative Transfusion Requirements in Subjects Undergoing Major Orthopedic Surgery [NCT00270036]	Phase 2	1 participants (Actual)	Interventional	1991-04-30	Completed
[NCT00238043]	Phase 3	2,000 participants (Anticipated)	Interventional	2005-08-31	Active, not recruiting
Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation [NCT05669079]	Phase 3	100 participants (Anticipated)	Interventional	2023-08-01	Not yet recruiting
EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE). [NCT00264108]		492 participants (Actual)	Observational	2005-06-30	Completed
Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study. [NCT01685359]	Phase 1	80 participants (Actual)	Interventional	2013-02-28	Completed
[NCT00284271]	Phase 2	65 participants (Actual)	Interventional	2004-01-31	Completed
An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection [NCT00248339]	Phase 3	150 participants (Actual)	Interventional	2002-05-31	Completed
Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels (110- 129 g/L and 130 - 149 g/L) on Progression of Chronic Kidney Disease in Patients With Type 2 Diabetes and With Chronic Kidney Disease [NCT00279084]		204 participants	Interventional	2004-01-31	Active, not recruiting
Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Orthopedic or Cardiovascular Surgery, to Facilitate Presurgical Autologous Blood Donation (A Double-blind, Randomized, Dose Finding Study) [NCT00270075]	Phase 2/Phase 3	80 participants (Actual)	Interventional	1990-01-31	Completed
Recombinant Human Erythropoietin (r-HuEPO) in Patients With Low Hematocrit Levels to Facilitate Presurgical Autologous Blood Donation in Patients Undergoing Orthopedic Surgery (An Open-label Dose Finding Study) [NCT00270114]	Phase 2/Phase 3	55 participants (Actual)	Interventional		Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00270270]	Phase 2	63 participants (Actual)	Interventional		Completed
Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy [NCT00255749]	Phase 2	89 participants (Actual)	Interventional	2005-08-31	Completed
Double-blind Study to Assess the Impact of Normalization of Hemoglobin Compared to Partial Correction of Hemoglobin With EPREX�/ERYPO� on Left Ventricular Structure in Early Hemodialysis Patients (RWJ-22512) [NCT00261521]	Phase 3	596 participants (Actual)	Interventional	2000-02-29	Completed
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) on Anemia and Quality of Life in Children With Cancer Undergoing Myelosuppressive Chemotherapy [NCT00261677]	Phase 3	224 participants (Actual)	Interventional	2000-08-31	Completed
Phase 4 Study on the Efficacy of Erythropoietin Treatment in Patients With Systolic Left Ventricular Dysfunction, Mild Anemia and Normal Renal Function [NCT00418119]	Phase 4	10 participants	Interventional	2007-01-31	Not yet recruiting
Multicenter Study, Randomized and Pragmatic, Comparing Two Therapeutic Strategies : Use or Non-use of Epoetin Beta in Patients Infected by Chronic Hepatitis C and Treated by Combination Therapy Peginterferon Alfa-2a Plus Ribavirin [NCT00262379]	Phase 3	229 participants (Actual)	Interventional	2005-12-31	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-up to Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00269945]	Phase 2	60 participants (Actual)	Interventional		Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of r-HuEPO, Administered Subcutaneously, in Chronic Anemia Induced by Advanced Cancer [NCT00269984]	Phase 2	56 participants (Actual)	Interventional		Completed
Recombinant Human Erythropoietin (R-HuEPO) in Non-Anemic Patients Scheduled for Selective Orthopedic and Vascular Surgery or Reductive Mammoplasty to Facilitate Presurgical Autologous Blood Donation Combined With Normo-Volemic Hemodilution (NVHD) [NCT00270023]	Phase 2/Phase 3	112 participants (Actual)	Interventional		Completed
A Double-Blind, Placebo-Controlled Study to Determine Whether R-HuEPO Can Facilitate Presurgical Autologous Blood Donation in Patients With Low Hematocrit Levels [NCT00270062]	Phase 3	77 participants (Actual)	Interventional	1989-05-31	Completed
A Placebo-Controlled Study on the Effect of r-huEPO in Patients With Multiple Myeloma Followed by an Open-Label Extension [NCT00270101]	Phase 3	156 participants (Actual)	Interventional	1995-01-31	Completed
A Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Multiple Doses of R-HuEPO in Facilitating Presurgical Autologous Blood Donation [NCT00270140]	Phase 3	17 participants (Actual)	Interventional	1989-09-30	Completed
A Double-Blind, Placebo-Controlled Study to Determine Whether R-huEPO Can Facilitate Presurgical Autologous Blood Donation and to Determine Its Safety for This Purpose [NCT00270179]	Phase 3	17 participants (Actual)	Interventional		Completed
Double-blind Phase II Pilot Monocentric Randomized Clinical Trial Evaluating the Effect of a Preliminary Administration of Erythropoietin on Different Markers of Cardiac Ischemia Induced by Cardiopulmonary Bypass [NCT00273767]	Phase 2	50 participants (Actual)	Interventional	2006-01-31	Completed
Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa [NCT00322413]	Phase 3	80 participants	Interventional	1997-01-31	Completed
Erythropoietin Role in Acute Kidney Injury (EAKI): a Pragmatic Clinical Trial [NCT03401710]		134 participants (Actual)	Interventional	2018-04-16	Terminated(stopped due to For very slow recruitment)
Placebo-Controlled Pilot Study to Assess the Post-Operative Administration of Epoetin Alfa on Patients Undergoing Abdominal or Pelvic Surgery for Malignancy [NCT00294203]	Phase 1	40 participants (Actual)	Interventional	2006-02-28	Completed
A Pilot Study to Evaluate the Safety and Efficacy of PROCRIT (Epoetin Alfa) 80,000 Units Once Every Four Weeks (Q4W) vs. 40,000 Units Once Every Two Weeks (Q2W) in Cancer Subjects With Non-Chemotherapy Anemia (NCA) [NCT00306267]	Phase 2	61 participants (Actual)	Interventional	2006-03-31	Terminated(stopped due to Study stopped as it would not address important survival concerns raised in other recently conducted clinical studies.)
The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® During Maintenance Period Until Evaluation Period On CKD (Chronic Kidney Disease) Patients: An Open Label, Randomized, Active Drug-Comparative, Parallel-Designed, Multi-Center Clinical [NCT05373303]		82 participants (Actual)	Interventional	2019-11-07	Completed
A Randomized, Open-Label Clinical Evaluation of PROCRIT (Epoetin Alfa) for Maintenance Phase Treatment of Patients With Anemia Due to Chronic Kidney Disease [NCT00307814]	Phase 2	519 participants (Actual)	Interventional	2002-01-31	Completed
A Pilot Study to Evaluate the Hematologic Response Rate of PROCRIT� (Epoetin Alfa) at 80,000 Units Once Weekly in Anemic Cancer Patients Receiving Chemotherapy [NCT00341055]	Phase 3	69 participants (Actual)	Interventional	2003-06-30	Completed
Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) [NCT00310232]	Phase 3	70 participants (Actual)	Interventional	2001-02-28	Terminated(stopped due to Recommendation of DSMB for safety issue, increased mortality with study drug.)
Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation [NCT00425126]	Phase 4	76 participants (Actual)	Interventional	2007-02-28	Completed
The Influence of the Pre-Therapeutic Increase in the Hemoglobin Level in the Blood Through Erythropoietin to the Therapy Results of the Primary Radiation Therapy for Carcinoma of the Cervix [NCT00348738]	Phase 3	300 participants (Anticipated)	Interventional	2000-07-31	Active, not recruiting
Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind [NCT01650415]	Phase 2	11 participants (Actual)	Interventional	2014-09-30	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS and Advanced ARC Patients With Anemia [NCT00002042]		0 participants	Interventional		Completed
Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Study. [NCT01664195]	Phase 1	28 participants (Anticipated)	Interventional	2013-02-28	Not yet recruiting
Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study. [NCT01664221]	Phase 1	80 participants (Anticipated)	Interventional	2013-02-28	Not yet recruiting
Randomized, Controlled Trial of Erythropoietin in the Prevention of Acute Mountain Sickness [NCT01665781]	Phase 4	39 participants (Actual)	Interventional	2012-08-31	Completed
Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Compared to Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease. [NCT01695759]	Phase 3	92 participants (Actual)	Interventional	2013-12-31	Terminated
A Non-interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Patients Not in Dialysis Treated With Mircera® [NCT01756612]		551 participants (Actual)	Observational	2012-11-21	Completed
[NCT01823029]		387 participants (Actual)	Interventional	2012-11-30	Completed
Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) [NCT01783847]	Phase 1/Phase 2	117 participants (Actual)	Interventional	2015-02-28	Completed
Single-arm, Open Study to Investigate the Efficacy, Safety and Tolerability of Monthly Subcutaneously Administered C.E.R.A. in Patients With Renal Anemia Not Yet Subject to Dialysis and Not Yet Permanently Treated With ESAs [NCT00559637]	Phase 3	184 participants (Actual)	Interventional	2008-01-31	Completed
An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes.¿ [NCT00551291]	Phase 2	10 participants (Actual)	Interventional	2007-08-31	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00002073]		0 participants	Interventional		Completed
Induction Chemotherapy With Taxotere, Cisplatin and 5-Fluorouracil Followed by Concomitant Cetuximab and Radiation for Locoregionally Advanced Squamous Cell Cancer of the Head and Neck: A Phase II Trial [NCT01467115]	Phase 2	1 participants (Actual)	Interventional	2010-03-31	Completed
Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents [NCT03140722]	Phase 2	2 participants (Actual)	Interventional	2017-05-02	Terminated(stopped due to Revised study design.)
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics for Healthy Subjects in the Phase Ⅰ Clinical Study [NCT02356419]	Phase 1	40 participants (Anticipated)	Interventional	2014-09-30	Recruiting
A Randomized, Active Comparator-Controlled, Parallel-Group, Single-Blind, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) in the Treatment of Anemia Associated With Chroni [NCT03521713]	Phase 3	214 participants (Anticipated)	Interventional	2016-03-01	Recruiting
The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema [NCT03821168]	Phase 2/Phase 3	58 participants (Anticipated)	Interventional	2019-03-01	Recruiting
Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic Congenital Heart Disease - A Prospective Randomized Control Trial [NCT02564796]	Phase 2	4 participants (Actual)	Interventional	2016-11-30	Terminated(stopped due to COVID)
Evaluation of the Effect of Subcutaneous Injection of Erythropoietin on Visual Functions in Patients With Late Onset Optic Neuropathy [NCT04469777]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2019-04-01	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Efficacy of Subcutaneous Doses of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00002302]		0 participants	Interventional		Completed
Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation [NCT03010579]	Phase 4	70 participants (Anticipated)	Interventional	2016-10-31	Recruiting
A Phase III Adjuvant Trial Of Sequenced EC + Filgrastim + Epoetin Alfa Followed By Paclitaxel Versus Sequenced AC Followed By Paclitaxel Versus CEF As Therapy For Premenopausal Women And Early Postmenopausal Women Who Have Had Potentially Curative Surgery [NCT00014222]	Phase 3	2,104 participants (Actual)	Interventional	2000-12-04	Completed
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial) [NCT01378273]	Phase 3	941 participants (Actual)	Interventional	2013-12-31	Completed
Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients [NCT05325073]	Phase 4	20 participants (Anticipated)	Interventional	2022-02-18	Recruiting
Proliferative Effects of Erythropoietin on Human Endometrium [NCT03060603]		14 participants (Actual)	Observational	2017-02-23	Completed
Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients [NCT03004209]	Phase 4	0 participants (Actual)	Interventional	2016-12-31	Withdrawn
A Phase III Randomized Controlled Study Comparing Iron Sucrose Intravenously to No Iron Treatment of Anemia in Cancer Patients Undergoing Chemotherapy and Erythropoietin Therapy [NCT00236951]	Phase 3	224 participants (Actual)	Interventional	2003-02-28	Completed
Effect of Intravenous Methylprednisolone and Intravenous Erythropoietin in Toxic Optic Neuropathies: Randomized Clinical Trial. [NCT05748561]	Phase 2/Phase 3	18 participants (Anticipated)	Interventional	2022-04-05	Recruiting
A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled, Multicenter, Dose Escalation Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients (REGENESIS-LED) [NCT00938314]	Phase 2	96 participants (Actual)	Interventional	2009-08-31	Terminated(stopped due to Slow Enrollment)
The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury [NCT03007537]		101 participants (Actual)	Interventional	2015-10-01	Terminated(stopped due to lack of funds)
Non-Interventional Observation Trial to Investigate the Efficacy, Safety and Usability of Mircera in PD Patients in Daily Use [NCT02596945]		223 participants (Actual)	Observational	2009-07-31	Completed
Non-interventional, Observational Study to Investigate the Efficiency and Safety of Mircera in Patients With a Kidney Transplant [NCT02538107]		290 participants (Actual)	Observational	2007-09-30	Completed
Assessing Combination Hydroxyurea and Exogenous Erythropoietin in Sickle Cell Disease [NCT05451940]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2023-05-25	Recruiting
Renal Effects of Erythropoietin in Humans [NCT01584921]	Phase 1	16 participants (Actual)	Interventional	2012-03-31	Completed
A Phase 2, Randomized, Open-Label Active-Comparator (Epoetin Alfa) Dose-Ranging Safety and Exploratory Efficacy Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD) [NCT01596855]	Phase 2	96 participants (Actual)	Interventional	2011-09-30	Completed
Phase III Study, Multi-center, Open, Randomized, to Assess the Impact of Early Starting Erythropoetin in the Reduction of Transfusions Blood and Improvement of Quality of Life and Fatigue in Children Under Chemotherapy Treatment. [NCT05704894]	Phase 3	320 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status [NCT00286182]	Phase 2	56 participants (Actual)	Interventional	2007-07-31	Completed
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) ESA in Native Subj [NCT03682536]	Phase 3	363 participants (Actual)	Interventional	2019-01-02	Active, not recruiting
Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Thoracic Aorta Surgery With Hypothermic Cardiac Arrest [NCT01369732]	Phase 4	66 participants (Actual)	Interventional	2011-05-31	Completed
An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome. [NCT01868477]	Phase 2	28 participants (Actual)	Interventional	2014-01-28	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00002072]		0 participants	Interventional		Completed
A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Patients on Stable Dialysis [NCT02278341]	Phase 3	838 participants (Actual)	Interventional	2014-11-21	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy [NCT00002071]		0 participants	Interventional		Completed
Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Crossover Study. [NCT01685333]	Phase 1	28 participants (Actual)	Interventional	2013-02-28	Completed
A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in Patients With AIDS or Advanced ARC and Anemia [NCT00002303]		0 participants	Interventional		Completed
An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or [NCT00002255]	Phase 1	0 participants	Interventional		Completed
Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy With Erythropoietin: A Phase III Randomised Placebo Controlled Multicentre Clinical Trial [NCT03079167]	Phase 3	313 participants (Actual)	Interventional	2016-05-14	Active, not recruiting
Phase III Evaluation of EPO With or Without G-CSF Versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes [NCT00003138]	Phase 3	118 participants (Actual)	Interventional	1998-03-04	Completed
A Randomized Phase III Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiotherapy for Carcinoma of the Head and Neck [NCT00004917]	Phase 3	0 participants	Interventional	2000-06-30	Completed
Ex Vivo Expanded Peripheral Blood Mononuclear Cells for the Elimination of Neutropenia Associated With High Dose Chemotherapy [NCT00005787]	Phase 1	3 participants (Actual)	Interventional	1999-09-30	Terminated(stopped due to Per PI due to poor/inadequate accrual.)
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis [NCT02253654]	Phase 4	216 participants (Actual)	Interventional	2015-04-01	Completed
Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya [NCT03162588]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2010-05-01	Completed
A Therapeutic-equivalence Study Comparing The Efficacy And Safety Of Intravenous Epoetin Hospira And Epoetin Alfa (Amgen) In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment [NCT01473407]	Phase 3	612 participants (Actual)	Interventional	2012-01-31	Completed
A Phase 3b Single-Arm, Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis [NCT01478971]	Phase 3	184 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q [NCT03223961]	Phase 3	124 participants (Anticipated)	Interventional	2018-03-26	Recruiting
An Open Label Phase I/II Study of Recombinant Granulocyte Colony-Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With AIDS or ARC [NCT00002281]		24 participants	Interventional		Completed
Effect of Erythropoietin and Hypothermia on Management of Neonatal Hypoxic Ischemic Encephalopathy [NCT03163589]	Phase 3	40 participants (Anticipated)	Interventional	2017-12-01	Not yet recruiting
Erythropoietin in Methanol Associated Optic Neuropathy [NCT02376881]	Phase 3	24 participants (Anticipated)	Interventional	2015-03-31	Active, not recruiting
A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Incident-Dialysis Patients [NCT02052310]	Phase 3	1,043 participants (Actual)	Interventional	2014-02-11	Completed
A Prospective, Observational, Non-inferiority Study to Assess the Effectiveness of a Biosimilar Epoetin Alfa in Maintaining Haemoglobin Levels in Stable 'End Stage Renal Failure' Patients on Haemodialysis [NCT02341547]		44 participants (Anticipated)	Observational	2015-02-28	Not yet recruiting
An Observational, Non-Interventional Cohort Study to Observe the Efficacy and Use of MIRCERA in the Treatment of Chronic Renal Anaemia in Patients With Chronic Kidney Disease Stage V on Haemodialysis [NCT01940484]		98 participants (Actual)	Observational	2009-08-31	Completed
[NCT00000587]	Phase 2	0 participants	Interventional	1988-09-30	Completed
Prospective, Multicenter, Single-blind, Randomized, Controlled Clinical Trial on Safety and Efficacy of a Novel Topical Formulation Containing Erythropoietin for the Treatment of Diabetic Foot Ulcers [NCT02361931]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2016-03-21	Completed
Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia: a Multicenter Randomized Controlled Study [NCT05911438]		419 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome [NCT03110341]	Phase 3	400 participants (Anticipated)	Interventional	2017-04-10	Recruiting
A Randomized Study of Procrit Versus No Procrit in Patients With Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy [NCT01099202]		109 participants (Actual)	Interventional	2003-03-31	Completed
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis [NCT01737879]	Phase 4	41 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted prematurely and will not resume; participants are no longer being treated)
Biological Predictive Factors of Response to Erythropoiesis Stimulating Agent (ESA) in Low Risk Myelodysplastic Syndromes (MDS) Patients [NCT03598582]	Phase 4	70 participants (Actual)	Interventional	2013-01-01	Completed
Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease [NCT01693029]	Phase 3	435 participants (Actual)	Interventional	2012-09-30	Completed
Non-Interventional Study to Evaluate Treatment of Symptomatic Anemia in Patients With Malignancies Receiving Chemo- and NeoRecormon-Therapy [NCT01809314]		1,167 participants (Actual)	Observational	2008-03-31	Completed
Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of HX575 Epoetin Alfa in the Treatment of Anemia Associated With Chronic Kidney Disease in Pre-dialysis and Dialysis Patients [NCT01576341]	Phase 3	417 participants (Actual)	Interventional	2012-04-30	Completed
The Benefits of a Preoperative Anemia Management Program [NCT01888003]		51 participants (Actual)	Interventional	2013-04-30	Terminated
Iron Sucrose Combined With rHuEPO and Ascorbic Acid on Perioperative Allogeneic Red Blood Cell Infusion in Patients Undergoing Elective Major Cardiac Surgery [NCT05353348]		370 participants (Anticipated)	Interventional	2023-02-15	Recruiting
Efficacy and Safety of Venofer (Iron Sucrose Injection USP) in Patients Receiving Peritoneal Dialysis [NCT00236938]	Phase 3	121 participants (Actual)	Interventional	2002-07-31	Completed
Comparative Study to Evaluate the Effect of the Altitude on Dosage Requirements of Methoxy Polyethylene Glycol-Epoetin Beta to Correct Hemoglobin Levels in Chronic Renal Anemia in Pre-Dialysis and Dialysis Patients [NCT01519947]	Phase 4	87 participants (Actual)	Interventional	2012-05-30	Completed
Effects of Erythropoietin on Infarct Size and Left Ventricular Remodeling in Survivors of Large Myocardial Infarctions [NCT00378352]	Phase 2	223 participants (Actual)	Interventional	2005-09-30	Completed
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS [NCT00520468]	Phase 2	15 participants (Actual)	Interventional	2004-06-30	Completed
A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects With Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia [NCT01394991]	Phase 4	504 participants (Actual)	Interventional	2006-01-31	Completed
Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy [NCT01736215]		33 participants (Actual)	Observational	2010-11-30	Terminated(stopped due to This study was terminated regarding to slow enrollment.)
The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial [NCT00003341]	Phase 3	275 participants (Anticipated)	Interventional	1997-12-31	Completed
Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes Study [NCT01913340]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2013-09-30	Completed
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients [NCT00701714]	Phase 3	337 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to investigation of adverse events)
A Therapeutic-equivalence Study Comparing The Efficacy And Safety Of Subcutaneous Epoetin Hospira And Epoetin Alfa (Amgen) In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment [NCT01473420]	Phase 3	320 participants (Actual)	Interventional	2012-01-17	Completed
Evaluation of the Effect of Zinc Supplementation on the Health Status of Hemodialysis Patients [NCT02335593]	Phase 2	64 participants (Actual)	Interventional	2014-12-31	Completed
The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis [NCT02504294]	Phase 3	432 participants (Actual)	Interventional	2015-07-13	Completed
A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO® With the Standard Treatment EPREX® in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis [NCT02522975]	Phase 4	16 participants (Actual)	Interventional	2015-08-31	Terminated
A Phase 1, Open-label, Randomized, Single Dose, Crossover Study Evaluating The Pharmacokinetics Of Epoetin Following Administration Of Epoetin Hospira Multiple Dose Vial (Mdv) Product Compared To Epoetin Hospira Single Dose Vial (Sdv) Product As Subcutane [NCT03398473]	Phase 1	68 participants (Actual)	Interventional	2018-01-25	Completed
Effect of Iron Sucrose Combined With Human Erythropoietin and Vitamin C on Perioperative Allogeneic Red Blood Cell Infusion in Major Cardiac Surgery [NCT06012760]		480 participants (Anticipated)	Interventional	2023-08-30	Recruiting
A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS) [NCT02145026]	Phase 4	100 participants (Actual)	Interventional	2014-08-06	Completed
A Phase 3, Open-label, Multicenter, Long-term Safety Study Of Subcutaneous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment [NCT01628120]	Phase 3	170 participants (Actual)	Interventional	2012-05-31	Completed
The Effect of High Dose Erythropoietin in Acute Renal Failure [NCT03102021]	Phase 2	25 participants (Actual)	Interventional	2006-03-31	Completed
A Prospective Cohort Study of Roxadustat for Anemia in Patients With Chronic Kidney Disease [NCT04502537]		200 participants (Anticipated)	Observational	2021-02-01	Recruiting
Comparison of Preoperative Haemoglobin Level After Administration of Epoetin Alfa Associated With an Oral Versus Intravenous Iron Supplementation [NCT02496377]		100 participants (Actual)	Interventional	2014-08-29	Completed
Inflammatory Markers and Mircera® Prospective Assessment of Correlation (IMPACT): A Multi-Center Observational Study Investigating the Correlation Between Inflammatory Marker Levels and ESA Dosage in CKD Patients on Dialysis Treated With Mircera® [NCT02238080]		197 participants (Actual)	Observational	2009-12-31	Completed
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome With Analysis of the Impact on Quality of Life and Functional Capacity of Patients [NCT02428686]	Phase 2	50 participants (Actual)	Interventional	2010-06-30	Completed
A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis [NCT02273726]	Phase 3	741 participants (Actual)	Interventional	2015-01-15	Completed
A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients [NCT02174731]	Phase 3	2,133 participants (Actual)	Interventional	2014-07-01	Completed
A Phase III, Open-label, Multicenter, Long-term Safety Study Of Intravenous Epoetin Hospira In Patients With Chronic Renal Failure Requiring Hemodialysis And Receiving Epoetin Maintenance Treatment [NCT01628107]	Phase 3	406 participants (Actual)	Interventional	2012-07-16	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003138 (3) [back to overview]	Overall Survival
NCT00003138 (3) [back to overview]	Proportion of Patients Free of Transfusion at 4 Months
NCT00003138 (3) [back to overview]	Quality of Life- Total Functional Assessment of Cancer Therapy - General (FACT-G) Score at 4 Months
NCT00014222 (2) [back to overview]	Disease Free Survival
NCT00014222 (2) [back to overview]	Overall Survival
NCT00048035 (6) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00048035 (6) [back to overview]	Number of Participants With Any Adverse Events, Any Serious Adverse Events, And Deaths
NCT00048035 (6) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Before and After Dialysis
NCT00048035 (6) [back to overview]	Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen
NCT00048035 (6) [back to overview]	Median Change From Baseline in Hematocrit Levels to End of Initial Treatment Under Constant Dosing Regimen
NCT00048035 (6) [back to overview]	Mean Change in Pulse Rate
NCT00048048 (7) [back to overview]	Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes Over Time
NCT00048048 (7) [back to overview]	Heart Rate Over Time
NCT00048048 (7) [back to overview]	Number of Participants With Any Serious Adverse Events and Any Adverse Events
NCT00048048 (7) [back to overview]	Hematocrit Levels at End of Initial Treatment Under Constant Dosing Regimen
NCT00048048 (7) [back to overview]	Reticulocyte Count at End of Initial Treatment Under Constant Dosing Regimen
NCT00048048 (7) [back to overview]	The Change in Hemoglobin Over Time Between Baseline and End of Initial Treatment Based on Individual Regression Slopes
NCT00048048 (7) [back to overview]	Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
NCT00077610 (8) [back to overview]	Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration.
NCT00077610 (8) [back to overview]	The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods
NCT00077610 (8) [back to overview]	Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death
NCT00077610 (8) [back to overview]	Mean Change in Blood Pressure From Baseline at Week 36 and Week 52
NCT00077610 (8) [back to overview]	Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52
NCT00077610 (8) [back to overview]	Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC)
NCT00077610 (8) [back to overview]	Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period
NCT00077610 (8) [back to overview]	Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes
NCT00077623 (9) [back to overview]	Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths
NCT00077623 (9) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants
NCT00077623 (9) [back to overview]	Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants
NCT00077623 (9) [back to overview]	Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods
NCT00077623 (9) [back to overview]	Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration
NCT00077623 (9) [back to overview]	Number of Participants With Red Blood Cell Transfusions
NCT00077623 (9) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00077623 (9) [back to overview]	Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants
NCT00077623 (9) [back to overview]	Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants
NCT00090753 (2) [back to overview]	Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation
NCT00090753 (2) [back to overview]	Percentage of Patients Who Had at Least 1 Adverse Event
NCT00210626 (2) [back to overview]	Return to Usual Activity (RTUA)
NCT00210626 (2) [back to overview]	SF-36 PF Score
NCT00236938 (4) [back to overview]	The Mean Change From Baseline to the Highest Reticulocyte Count up to Day 71
NCT00236938 (4) [back to overview]	The Mean Change From Baseline to the Highest Ferritin up to Day 71
NCT00236938 (4) [back to overview]	Mean Change From Baseline to the Highest Hemoglobin up to Day 71
NCT00236938 (4) [back to overview]	The Mean Change From Baseline to the Highest Serum Transferrin Saturation (TSAT) up to Day 71
NCT00236951 (1) [back to overview]	Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21).
NCT00258440 (2) [back to overview]	Number of Adverse Events (AEs) Experienced as Measure of Safety and Tolerability.
NCT00258440 (2) [back to overview]	Number of Subjects That Maintained Target Hemoglobin Level (11-12 g/dL) Maintenance Weekly for 12 Weeks
NCT00267007 (2) [back to overview]	The Number of Patients Who Developed Peripheral Sensory Neuropathy (National Cancer Institute Common Toxicity Criteria (NCI CTC) Score >= 1) at Week 12.
NCT00267007 (2) [back to overview]	The Number of Patients Who Developed Peripheral Sensory Neuropathy (National Cancer Institute Common Toxicity Criteria (NCI CTC) Score >= 2) at Week 12.
NCT00286182 (1) [back to overview]	Change in Left Ventricular End-diastolic Volume
NCT00313716 (5) [back to overview]	Glasgow Outcome Scale
NCT00313716 (5) [back to overview]	Disability Rating Scale
NCT00313716 (5) [back to overview]	Incidence of Adult Respiratory Distress Syndrome (ARDS)
NCT00313716 (5) [back to overview]	Incidence of Infection
NCT00313716 (5) [back to overview]	Mortality Rate
NCT00321919 (18) [back to overview]	Number of Participants on Blood Pressure/Anti-Hypertensive Treatment According to Class Of Drugs
NCT00321919 (18) [back to overview]	Number of Participants Experiencing Worsening of New York Heart Association (NYHA) Class (CL) of Chronic Heart Failure From Baseline (BL)
NCT00321919 (18) [back to overview]	Mean Values of Echocardiography Parameters
NCT00321919 (18) [back to overview]	Mean Values of Body Surface Area
NCT00321919 (18) [back to overview]	Mean Change From Baseline in the Scores of Each of The Eight Health Scales of Quality of Life Based on Short Form-36 (SF-36) Questionnaire
NCT00321919 (18) [back to overview]	Mean Change From Baseline in Left Ventricular Volume (LV Volume )
NCT00321919 (18) [back to overview]	Mean Change From Baseline in Left Ventricular Mass Index (LVMI)
NCT00321919 (18) [back to overview]	Mean Change From Baseline in Left Ventricular Ejection Fraction (LVEF) and Fractional Myocardial Shortening (FS)
NCT00321919 (18) [back to overview]	Total Number of Cardiovascular Intervention
NCT00321919 (18) [back to overview]	Median Time to First Hospitalization Due to Cardiovascular Events
NCT00321919 (18) [back to overview]	Median Time to First Cardiovascular Intervention
NCT00321919 (18) [back to overview]	Median Time to First Cardiovascular Event
NCT00321919 (18) [back to overview]	Median Time to Death Due to All Causes
NCT00321919 (18) [back to overview]	Duration of Hospitalization for Cardiovascular Events
NCT00321919 (18) [back to overview]	Median Time to Death Due to Cardiovascular Events
NCT00321919 (18) [back to overview]	Number of Participants Who Died Due to All Causes
NCT00321919 (18) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00321919 (18) [back to overview]	Number of Participants Who Died Due to Cardiovascular Events
NCT00334737 (9) [back to overview]	Volume of Transfusions
NCT00334737 (9) [back to overview]	Object Permanence Scores at 18-22 Months
NCT00334737 (9) [back to overview]	Overall Neurodevelopmental Impairment at 18-22 Months (Visual Impairment, Hearing Impariment, Cerebral Palsy, or Cognitive Score <85/<70 (NDI/Moderate NDI)
NCT00334737 (9) [back to overview]	Hematocrit
NCT00334737 (9) [back to overview]	Incidence of Retinopathy of Prematurity Stage 3 or Greater
NCT00334737 (9) [back to overview]	Reticulocyte Count
NCT00334737 (9) [back to overview]	Number of Transfusions During Hospitalization
NCT00334737 (9) [back to overview]	Composite Cognitive Score at 18-22 Months Corrected Age
NCT00334737 (9) [back to overview]	Epo Concentrations
NCT00337935 (3) [back to overview]	The Number of Patients Achieved a Hemoglobin Response.
NCT00337935 (3) [back to overview]	Time to Hemoglobin Response
NCT00337935 (3) [back to overview]	Mean Change in Hemoglobin Level From Baseline to the End of Study (26 Weeks)
NCT00338286 (5) [back to overview]	Overall Survival
NCT00338286 (5) [back to overview]	Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)
NCT00338286 (5) [back to overview]	Progression Free Survival
NCT00338286 (5) [back to overview]	Time to Tumor Progression
NCT00338286 (5) [back to overview]	Overall Response Rate (ORR)
NCT00350519 (4) [back to overview]	Hemoglobin Change From Baseline to End of Study
NCT00350519 (4) [back to overview]	Hospital Length of Stay
NCT00350519 (4) [back to overview]	Number of Participants Receiving pRBC (Packed Red Blood Cell) Transfusions
NCT00350519 (4) [back to overview]	Number of pRBC Units Transfused During Study
NCT00354341 (6) [back to overview]	Change From Baseline in Left Ventricle Mass Index (LVMI) at Month 15
NCT00354341 (6) [back to overview]	Percentage of Participants With Stable Hb Levels Between 13 to 15 g/dL
NCT00354341 (6) [back to overview]	Fractional Myocardial Shortening (FS)
NCT00354341 (6) [back to overview]	Left Ventricular Ejection Fraction (LVEF)
NCT00354341 (6) [back to overview]	Left Ventricular End Diastolic Volume Index (LVEDVI)
NCT00354341 (6) [back to overview]	Left Ventricular End Systolic Volume Index (LVESVI)
NCT00364832 (6) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00364832 (6) [back to overview]	Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen
NCT00364832 (6) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Before and After Dialysis
NCT00364832 (6) [back to overview]	Mean Change in Pulse Rate
NCT00364832 (6) [back to overview]	Number of Participants With Any Adverse Events, Any Serious Adverse Events, And Deaths
NCT00364832 (6) [back to overview]	Median Change From Baseline in Hematocrit Levels to End of Initial Treatment Under Constant Dosing Regimen
NCT00367991 (4) [back to overview]	Bleeding Time
NCT00367991 (4) [back to overview]	Platelet Function Assay Closure Time
NCT00367991 (4) [back to overview]	Serum Markers of Myocyte Damage
NCT00367991 (4) [back to overview]	Serum Markers of Apoptosis
NCT00378352 (9) [back to overview]	Vital Signs
NCT00378352 (9) [back to overview]	Hemoglobin Levels
NCT00378352 (9) [back to overview]	Infarct Size in the Territory of the Infarct Related Artery
NCT00378352 (9) [back to overview]	Infarct Size in the Territory of the Infarct Related Artery
NCT00378352 (9) [back to overview]	LV Volume Indexed to BSA
NCT00378352 (9) [back to overview]	LV Mass Indexed to BSA
NCT00378352 (9) [back to overview]	LV Ejection Fraction
NCT00378352 (9) [back to overview]	Number of Participants With Clinical Events
NCT00378352 (9) [back to overview]	Reticulocyte Counts
NCT00379912 (6) [back to overview]	Overall Response After Cycle 3
NCT00379912 (6) [back to overview]	Percent Apoptosis in 34+36+71+ Cells at Baseline, Three Cycles and Six Cycles
NCT00379912 (6) [back to overview]	BclXL Expression
NCT00379912 (6) [back to overview]	Analysis of CD34, CD71, CD36 Cells in Aspirated Bone Marrow for Both Responders and Non-responders at Baseline and After Three and Six Cycles
NCT00379912 (6) [back to overview]	Safety Profile of the Modified Dose/Schedule of Azacitidine and Erythropoietin or a Modified Dose of Azacitidine Alone
NCT00379912 (6) [back to overview]	Overall Response Rate After Six Cycles
NCT00386152 (4) [back to overview]	Number of Patients Receiving at Least 1 Packed Red Blood Cell (PRBC) Transfusion During Study
NCT00386152 (4) [back to overview]	Number of Patients (Hb >= 11 g/dL) During Study.
NCT00386152 (4) [back to overview]	Time to Achieve Hb >= 11 g/dL During Study
NCT00386152 (4) [back to overview]	Hemoglobin (Hb) Change From Baseline to Study Week 7
NCT00400686 (3) [back to overview]	Number of Patients With an at Least 1gm/dL Increase in Hgb
NCT00400686 (3) [back to overview]	Change From Baseline in Hemoglobin at Day 28
NCT00400686 (3) [back to overview]	Number of Patients With an at Least 2gm/dL Increase in Hgb
NCT00413894 (12) [back to overview]	Percentage of Participants With Hemoglobin Levels Within 10.0-13.0 g/dL by Dose Modification During Evaluation Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With HbLevels Within 10.0-13.0 g/dL by Dose Modification During Screening Phase
NCT00413894 (12) [back to overview]	Percentage of Participants Requiring Erythrocyte Transfusions
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 11.0-12.5 g/dL by Dose Modifications During Evaluation Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 11.0-12.5 g/dL by Dose Modification During Screening Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Fluctuations Within Screening Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Fluctuations Within Evaluation Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Changes Between Screening and Evaluation Phase With Respect To Hb Levels
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 10.0-13.0 g/dL During Evaluation Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 10.0-13.0 g/dL During Screening Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 11.0-12.5 g/dL During Screening Phase
NCT00413894 (12) [back to overview]	Percentage of Participants With Hb Levels Within 11.0-12.5 Grams Per Deciliter (g/dL) During Evaluation Phase
NCT00416624 (12) [back to overview]	Quality of Life as Measured by Brief Fatigue Inventory Overall All Follow-up Evaluations
NCT00416624 (12) [back to overview]	The Percentage of Participants With Dose Omitted Due to Hematologic Reason
NCT00416624 (12) [back to overview]	The Percentage of Participants Requiring Red Blood Cell (RBC) Transfusions
NCT00416624 (12) [back to overview]	Quality of Life as Measured by Functional Assessment of Cancer Therapy Scales for Anemia (FACT-AN) Over All Follow-up Evaluations
NCT00416624 (12) [back to overview]	Quality of Life as Measured by Linear Analogue Self Assessment Over All Follow-up Evaluation
NCT00416624 (12) [back to overview]	Quality of Life as Measured by Symptom Distress Scale (SDS) Over All Follow-up Evaluations
NCT00416624 (12) [back to overview]	Weekly Change in Hemoglobin Levels
NCT00416624 (12) [back to overview]	The Percentage of Participants Who Exhibit a Hematopoietic Response
NCT00416624 (12) [back to overview]	The Total RBC Transfusion Needed
NCT00416624 (12) [back to overview]	Time Required to Achieve Hemoglobin Levels >= 11.5 g/dL
NCT00416624 (12) [back to overview]	The Percentage of Participants Reported Grade 3 or 4 Adverse Events
NCT00416624 (12) [back to overview]	Mean Hemoglobin Change From Week 1 to Week 16
NCT00422513 (2) [back to overview]	The Number of Participants With Marked Laboratory Abnormalities Occurring in ≥5% of the Participants
NCT00422513 (2) [back to overview]	Number of Participants Assessed for AEs
NCT00425698 (1) [back to overview]	Kidney Graft Function by Estimated Glomerular Filtration Rate (eGFR)
NCT00440466 (9) [back to overview]	Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment
NCT00440466 (9) [back to overview]	Maximum Hemoglobin Concentration in Grams Per Deciliter (g/dL)
NCT00440466 (9) [back to overview]	Maximum Hemoglobin Rate of Rise in Grams Per Deciliter (g/dL/2 Weeks)
NCT00440466 (9) [back to overview]	Proportion of Weeks Per Patient With Hemoglobin Concentration Between 10.0 and 11.9 Grams Per Deciliter (g/dL)
NCT00440466 (9) [back to overview]	Participants Who Met or Exceeded 2.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
NCT00440466 (9) [back to overview]	Participants Who Met or Exceeded 1.5 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
NCT00440466 (9) [back to overview]	Participants Who Met or Exceeded 1.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
NCT00440466 (9) [back to overview]	Participants Who Exceeded a Hemoglobin Concentration of 11.9 Grams Per Deciliter (g/dL)
NCT00440466 (9) [back to overview]	Number of Participants Who Died
NCT00440557 (8) [back to overview]	Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22
NCT00440557 (8) [back to overview]	Maximum (Max) Hb Rate (g/dL/2 Weeks) of Rise During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Maximum Hb Concentration (g/dL) During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Participants Who Met or Exceeded Hb Rate of Rise >=1.0 g/dL/2 Weeks During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Participants Who Met or Exceeded Hb Rate of Rise >=1.5 g/dL/2 Weeks During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Particpants Who Met or Exceeded Hb Rate of Rise >=2.0 g/dL/2 Weeks During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Participants Who Exceeded a Hb Concentration of 11.9 g/dL During First 22 Weeks of Treatment
NCT00440557 (8) [back to overview]	Participants With an Increase of ≥1 g/dL in Hb Concentration From Baseline by Week 9
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Temperature
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Total Iron-binding Capacity
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Transferrin Saturation
NCT00442416 (15) [back to overview]	Number of Participants With Anti-erythropoietin Antibody in Human Serum
NCT00442416 (15) [back to overview]	Number of Participants With Anti-RO0503821 Antibody in Human Serum
NCT00442416 (15) [back to overview]	Number of Participants With Any AEs, Any Serious Adverse Events and Death
NCT00442416 (15) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00442416 (15) [back to overview]	Percentage of Participants With Safety-Related Hb Measures
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Weight
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Hb Concentration to Average Over the Evaluation Period
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Ferritin
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Iron
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Pulse Rate
NCT00442416 (15) [back to overview]	Mean Change From Baseline in Serum Transferrin
NCT00451698 (2) [back to overview]	Length of Hospitalization
NCT00451698 (2) [back to overview]	Biochemical Markers of Heart Damage
NCT00454246 (1) [back to overview]	Number of Participants Assessed for AEs and SAEs
NCT00462384 (5) [back to overview]	Time to Achievement of Response
NCT00462384 (5) [back to overview]	Time Spent in Hemoglobin Range of 11.0 to 13.0 g/dL During the EEP
NCT00462384 (5) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL Throughout the EEP
NCT00462384 (5) [back to overview]	Mean Change in Hemoglobin Concentration Between Baseline and the Efficacy Evaluation Period (EEP)
NCT00462384 (5) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin Concentration Within Hemoglobin Range 11.0 to 13.0 g/dL During the EEP
NCT00511901 (8) [back to overview]	FACIT Measurement System Fatigue Scale
NCT00511901 (8) [back to overview]	Grip Strength
NCT00511901 (8) [back to overview]	Motor-FIM Score
NCT00511901 (8) [back to overview]	POMS Depression-Dejection Scale
NCT00511901 (8) [back to overview]	Short Physical Performance Battery (SPPB) Score
NCT00511901 (8) [back to overview]	Activity Counts
NCT00511901 (8) [back to overview]	Mean Hemoglobin Concentration at 8 Weeks After Entry Into the Study
NCT00511901 (8) [back to overview]	Length of Stay in Subacute Rehabilitation Facility
NCT00513240 (4) [back to overview]	Relative Difference in Total Maturity Score (TMS) From Preoperative Brain MRI to 7 Day Postoperative MRI
NCT00513240 (4) [back to overview]	Scores on Bayley Scales of Infant Development III at Age 1 Years.
NCT00513240 (4) [back to overview]	EEG Seizure Burden in the First 72 Postoperative Hours. (Total Minutes of EEG Seizures).
NCT00513240 (4) [back to overview]	Pharmacokinetics of High Dose Erythropoetin: 7 Erythropoetin Levels in First 24 Hours After First Dose (Maximum EPO Plasma Concentration)
NCT00517413 (18) [back to overview]	Mean Creatinine, Iron, and Total Iron Binding Capacity Levels Over Time
NCT00517413 (18) [back to overview]	Mean Ferritin Levels Over Time
NCT00517413 (18) [back to overview]	Percentage of Participants Requiring Dose Adjustments of C.E.R.A During the DTP and EEP
NCT00517413 (18) [back to overview]	Mean C.E.R.A Dose To Maintain Hb Level Within the Range 10.5-12.5 g/dL Throughout the EEP
NCT00517413 (18) [back to overview]	Mean C-Reactive Protein Levels Over Time
NCT00517413 (18) [back to overview]	Mean White Blood Cells and Thrombocyte Levels Over Time
NCT00517413 (18) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT00517413 (18) [back to overview]	Mean Transferrin Saturation Levels Over Time
NCT00517413 (18) [back to overview]	Mean Albumin and Transferrin Levels Over Time
NCT00517413 (18) [back to overview]	Percentage of Participants Maintaining Their Mean Hb Concentration Within ±1.0 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter
NCT00517413 (18) [back to overview]	Percentage of Participants Maintaining Hb Concentration Within The Target Range 10.5 and 12.5 g/dL Throughout the EEP
NCT00517413 (18) [back to overview]	Mean Time Spent by the Participants in the Hb Target Range 10.5-12.5 g/dL During EEP
NCT00517413 (18) [back to overview]	Mean Change in the Hb Concentration Between the Stability Verification Period and the EEP
NCT00517413 (18) [back to overview]	Mean Phosphate and Potassium Levels Over Time
NCT00517413 (18) [back to overview]	Incidence of Red Blood Cell Transfusions During the C.E.R.A. Treatment Phase
NCT00517413 (18) [back to overview]	Mean Monthly Dose of C.E.R.A During the DTP and EEP
NCT00517413 (18) [back to overview]	Mean Hematocrit Levels Over Time
NCT00517413 (18) [back to overview]	Mean Haemoglobin Levels Over Time
NCT00517881 (7) [back to overview]	Percentage of Participants With Red Blood Cell Transfusion During the Study
NCT00517881 (7) [back to overview]	Mean Time Spent by Participants With Hemoglobin Concentration in the Target Range During the EEP
NCT00517881 (7) [back to overview]	Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Their Reference Hemoglobin and Within the Target Range
NCT00517881 (7) [back to overview]	Change in Hemoglobin Concentration Between Reference (SVP) and EEP
NCT00517881 (7) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within the Target Range During EEP
NCT00517881 (7) [back to overview]	Percentage of Participants Requiring Any Dose Adjustment
NCT00517881 (7) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00520468 (1) [back to overview]	Number of Participants With Response
NCT00535925 (2) [back to overview]	"Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"
NCT00535925 (2) [back to overview]	"Number of Participants Who Achieved of BP, HbA1c and Total, HDL and LDL Cholesterol Goals at the End of Intervention Phase"
NCT00545571 (10) [back to overview]	Mean Change in Time-Adjusted Hb From Baseline to EEP
NCT00545571 (10) [back to overview]	Mean Time Spent in the Target Range for Hb During the Long-Term Safety Period (LTSP)
NCT00545571 (10) [back to overview]	Mean Number of Months a Participant Required Dose Adjustment of Mircera/CERA During the DTP and LTSP
NCT00545571 (10) [back to overview]	Percentage of Participants Who Maintained Average Hb Within Target Range Throughout the EEP
NCT00545571 (10) [back to overview]	Mean Dose of Mircera/CERA During the DTP and LTSP
NCT00545571 (10) [back to overview]	Mean Excursions Above or Below Target Range for Hb During the LTSP
NCT00545571 (10) [back to overview]	Mean Time Spent Above or Below the Target Range for Hb During the LTSP
NCT00545571 (10) [back to overview]	Percentage of Hb Values Above or Below the Target Range During the LTSP
NCT00545571 (10) [back to overview]	Percentage of Participants Who Received Blood Transfusions During the DTP and LTSP
NCT00545571 (10) [back to overview]	Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb or Within Target Range During the Efficacy Evaluation Period (EEP)
NCT00546481 (8) [back to overview]	Mean Change From Baseline in Hemoglobin Concentration at Week 24
NCT00546481 (8) [back to overview]	Mean Change From Baseline in Vital Sign: Heart Rate Measurements up to Week 24
NCT00546481 (8) [back to overview]	Median Time in Which Hemoglobin Value Was Maintained Within Target Range of >/= 11g/dL up to Week 24
NCT00546481 (8) [back to overview]	Number of Participants Who Received Red Blood Cells Transfusions up to Week 49
NCT00546481 (8) [back to overview]	Number of Participants With Abnormal Changes in Electrocardiogram up to Week 24
NCT00546481 (8) [back to overview]	Percentage of Participants Who Achieved Hemoglobin Response up to Week 24
NCT00546481 (8) [back to overview]	Mean Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure up to Week 24
NCT00546481 (8) [back to overview]	Number of Participants With Any Adverse Events and Serious Adverse Events
NCT00550680 (6) [back to overview]	Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)
NCT00550680 (6) [back to overview]	Number of Participants Prematurely Withdrawn From the Study to Receive Blood Transfusion
NCT00550680 (6) [back to overview]	Mean Time Spent in the Target Range for Hb During the EEP
NCT00550680 (6) [back to overview]	Percentage of Participants Whose Hb Remained Within Target Range Throughout the EEP
NCT00550680 (6) [back to overview]	Mean Change in Time-Adjusted Hb From Baseline to EEP
NCT00550680 (6) [back to overview]	Percentage of Participants Who Required Any Dose Adjustment of Mircera/CERA During the Dose Titration Period (DTP) and EEP
NCT00551291 (3) [back to overview]	Mean Number of Blood Transfusions Per Visit
NCT00551291 (3) [back to overview]	Percentage of Participants With at Least One Adverse Event (AE)
NCT00551291 (3) [back to overview]	Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement
NCT00559637 (8) [back to overview]	Duration of Hemoglobin Values in the Range of 11-13 g/dL
NCT00559637 (8) [back to overview]	Total Number of Dose Adjustments
NCT00559637 (8) [back to overview]	Total Number of Red Blood Cell (RBC) Transfusions
NCT00559637 (8) [back to overview]	Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-13 g/dL
NCT00559637 (8) [back to overview]	Duration of Hemoglobin Values in the Range of 11-12 g/dL
NCT00559637 (8) [back to overview]	Percentage of Participants With Both Hemoglobin Values of the Evaluation Phase in the Range of 11-12 Grams Per Deciliter (g/dL)
NCT00559637 (8) [back to overview]	Change From Baseline in Hemoglobin Value to the Evaluation Phase
NCT00559637 (8) [back to overview]	Time to Increase of Hemoglobin Value to Over 11 g/dL
NCT00560404 (19) [back to overview]	Mean Values of Hematocrit at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Hemoglobin Concentration at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Leukocytes and Platelets Count at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Mean Corpuscular Volume at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Transferrin Saturation at Baseline and Week 36
NCT00560404 (19) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT00560404 (19) [back to overview]	Mean Values of Ferritin Concentration at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Change From Baseline in Hemoglobin Concentration Between Baseline and at the Efficacy Evaluation Period
NCT00560404 (19) [back to overview]	Mean Time Spent in Hemoglobin Range of 10.5 - 12.5 Gram/Decilitre During the Efficacy Evaluation Period
NCT00560404 (19) [back to overview]	Number of Participants Received Red Blood Cells Transfusions
NCT00560404 (19) [back to overview]	Number of Participants Who Required Dose Adjustments During the Dose Titration Period
NCT00560404 (19) [back to overview]	Number of Participants Who Required Dose Adjustments During the Efficacy Evaluation Period
NCT00560404 (19) [back to overview]	Number of Participants With Abnormal Changes in ECG From Baseline to Week 40
NCT00560404 (19) [back to overview]	Number of Participants With Abnormal Changes in Vital Signs From Baseline to Week 40
NCT00560404 (19) [back to overview]	Percentage of Participants Maintaining Individual Hemoglobin Concentration Within the Range of 10.5 - 12.5 Gram/Decilitre Throughout the Efficacy Evaluation Period
NCT00560404 (19) [back to overview]	Percentage of Participants Maintaining Their Mean Hemoglobin Concentration Within Plus or Minus 1 Gram/Deciliter of Their Reference Hemoglobin and Between the Target Range During Efficacy Evaluation Period
NCT00560404 (19) [back to overview]	Mean Values of Albumin and Transferrin Concentration at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Aspartate Transaminase and Alkaline Phosphatase at Baseline and Week 36
NCT00560404 (19) [back to overview]	Mean Values of Creatinine, Potassium, Phosphate, Parathyroid Hormone , Iron and Total Iron Binding Capacity Parameters at Baseline and Week 36
NCT00576303 (6) [back to overview]	Percentage of Participants Maintaining Average Hb Concentration Within Target Range of 10.5-12.5 g/dL Throughout the EEP
NCT00576303 (6) [back to overview]	Number of Participants With Red Blood Cell Transfusion
NCT00576303 (6) [back to overview]	Mean Number of Days Spent Within Hb Range of 10.5-12.5 g/dL During the EEP
NCT00576303 (6) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin Concentration Within +- 1 Gram/Deciliter of Their Reference Hb and Between 10.5 and 12.5 Gram/Deciliter During EEP
NCT00576303 (6) [back to overview]	Number of Participants Requiring Any Dose Adjustment During the DTP, EEP, and LTSP
NCT00576303 (6) [back to overview]	Mean Change in Hb Concentration From Baseline to the EEP
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter : Iron and Total Iron Binding Capacity
NCT00576628 (17) [back to overview]	Mean Time Spent in Target Hb Range of 11.0 -13.0 g/dL During the Efficacy Evaluation Period
NCT00576628 (17) [back to overview]	Number of Participants With Red Blood Cells Transfusions.
NCT00576628 (17) [back to overview]	Percentage of Participants Maintaining Average Hb Concentration Within the Target Range of 11.0-13.0 g/dL Throughout the EEP
NCT00576628 (17) [back to overview]	The Number of Participants Who Required Dose Adjustments During the Dose Titration Period
NCT00576628 (17) [back to overview]	The Number of Participants Who Required Dose Adjustments During the Efficacy Evaluation Period
NCT00576628 (17) [back to overview]	Time to Achievement of Response During the Efficacy Evaluation Period
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter : Hb Concentration
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter : Hematocrit
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter: Albumin and Transferrin Concentration
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter : Serum Creatinine
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter: C Reactive Protein
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameter: Ferritin Concentration
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameters: Potassium and Phosphate Concentration
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameters: Transferrin Saturation
NCT00576628 (17) [back to overview]	Mean Values of Laboratory Parameters: White Blood Cell and Thrombocyte Count
NCT00576628 (17) [back to overview]	Mean Change in Hb Concentration g/dL Between Baseline and the Efficacy Evaluation Period
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Long Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Short Term)
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Long Term)
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Short Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)
NCT00597584 (3) [back to overview]	Mean Change in Hemoglobin Between Baseline and the Evaluation Period
NCT00597584 (3) [back to overview]	Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)
NCT00597584 (3) [back to overview]	Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods
NCT00597753 (3) [back to overview]	Mean Change in Hemoglobin Between Baseline and the Evaluation Period
NCT00597753 (3) [back to overview]	Proportion of Participants Whose Mean Hemoglobin Level During the Evaluation Period is Within the Target Range of 10.0 - 12.0 Grams Per Deciliter (g/dL)
NCT00597753 (3) [back to overview]	Proportion of Participants Who Receive Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods
NCT00605293 (6) [back to overview]	Percentage of Participants Who Maintained Average Hemoglobin (Hb) Concentration Within Plus Minus (+/-) 1 Grams Per Deciliter (g/dL) of Their Reference Hb and Between 10 and 12 g/dL During the EEP
NCT00605293 (6) [back to overview]	Change in Hb Concentrations Between Baseline SVP and the EEP
NCT00605293 (6) [back to overview]	Percentage of Participants Who Required Dose Adjustments During the DTP and EEP
NCT00605293 (6) [back to overview]	Percentage of Participants Who Received Red Blood Cell (RBC) Transfusions During DTP and EEP
NCT00605293 (6) [back to overview]	Mean Time Spent in Hb Range 10-12 g/dL
NCT00605293 (6) [back to overview]	Percentage of Participants Who Maintained Hb Concentration Between 10 and 12 g/dL Throughout the EEP
NCT00626574 (1) [back to overview]	Incidence of Adverse Events After Administering Intravenous Doses of Procrit® Once Daily for Three Consecutive Days to Patients With Aneurysmal SAH Before and After Vascular Clipping
NCT00632125 (1) [back to overview]	Drug-related Adverse Events Consisting of Epoetin Alfa-induced Immunogenicity and Resulting Clinical Effects
NCT00642304 (6) [back to overview]	Percentage of Participants With Blood Transfusion
NCT00642304 (6) [back to overview]	Mean Time Spent in Hb Range of 10.5 to 12.5 g/dL During the EEP
NCT00642304 (6) [back to overview]	Mean Change in Hb Concentration Between SVP and the EEP
NCT00642304 (6) [back to overview]	Percentage of Participants With Dose Adjustment
NCT00642304 (6) [back to overview]	Percentage of Participants Maintaining Hb Concentration Within +/-1 Gram Per Deciliter (g/dL) of Their Reference Hb and Between 10.5 to 12.5 g/dL Throughout the Efficacy Evaluation Period (EEP)
NCT00642304 (6) [back to overview]	Percentage of Participants Maintaining Hb Concentration Within Hb Range 10.5 to 12.5 g/dL During the EEP
NCT00642668 (5) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin Concentration During Efficacy Evaluation Period (EEP) Within Target Range
NCT00642668 (5) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentrations Within Range of 10-12 Grams/Deciliter (g/dL) Throughout Efficacy Evaluation Period (EEP)
NCT00642668 (5) [back to overview]	Percentage of Participants With Adverse Events
NCT00642668 (5) [back to overview]	Change From Baseline in Hemoglobin Concentration to Efficacy Evaluation Period (EEP)
NCT00642668 (5) [back to overview]	Mean Time Spent in Hemoglobin Range of 10-12 g/dL During Efficacy Evaluation Period (EEP)
NCT00642850 (7) [back to overview]	Change in Hemoglobin Concentration Between Reference (SVP) and EEP
NCT00642850 (7) [back to overview]	Mean Time Spent by Participants With Hemoglobin Concentration in the Target Range During the EEP
NCT00642850 (7) [back to overview]	Number of Participants With Red Blood Cell Transfusion During the Study
NCT00642850 (7) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin Concentration Within +/-1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range
NCT00642850 (7) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within the Target Range During EEP
NCT00642850 (7) [back to overview]	Number of Participants With Anti-epoetin Antibody
NCT00642850 (7) [back to overview]	Percentage of Participants Requiring Any Dose Adjustment
NCT00654992 (2) [back to overview]	Change in Estimated Glomerular Filtration Rate (eGFR)
NCT00654992 (2) [back to overview]	Number of Participants Who Had AKI (Acute Kidney Injury)
NCT00656448 (2) [back to overview]	Number of Participants With Complete Remission
NCT00656448 (2) [back to overview]	Median Number of Participant Transfusions Required During 12 Weeks of Treatment
NCT00660023 (8) [back to overview]	Percentage of Participants Who Required Any Dose Adjustment of Mircera/CERA During the DTP and EEP
NCT00660023 (8) [back to overview]	Mean Change in Time-Adjusted Hb From Baseline to EEP
NCT00660023 (8) [back to overview]	Mean Dose of Mircera/CERA During the Dose Titration Period (DTP) and EEP
NCT00660023 (8) [back to overview]	Number of Participants Receiving Blood Transfusion During the DTP and EEP
NCT00660023 (8) [back to overview]	Percentage of Participants Whose Hb Remained Within Target Range Throughout the EEP
NCT00660023 (8) [back to overview]	Percentage of Participants Who Maintained Average Hb Within Plus/Minus (±) 1 g/dL of Reference Hb and Within Target Range During the Efficacy Evaluation Period (EEP)
NCT00660023 (8) [back to overview]	Mean Time Spent in the Target Range for Hb During the EEP
NCT00660023 (8) [back to overview]	Number of Blood Transfusions During the DTP and EEP
NCT00661388 (18) [back to overview]	Mean Time to Achievement of Response During the EEP
NCT00661388 (18) [back to overview]	The Percentage of Participants Whose Hb Concentrations Remained Within the Target Range of 10.0- 12.0 g/dLThroughout the EEP
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Albumin Concentration Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in C-Reactive Protein Concentration Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Creatinine Concentration Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Ferritin Concentration Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Hb Concentration Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Hematocrit Level Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Phosphate and Potassium Concentrations Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Total Iron Binding Capacity and Iron Concentrations Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in Transferrin Saturation Over Time
NCT00661388 (18) [back to overview]	Mean Change From Baseline in White Blood Cells and Platelets Concentrations Over Time
NCT00661388 (18) [back to overview]	Number of Participants Who Experienced Any Adverse Events or Serious Adverse Events
NCT00661388 (18) [back to overview]	Number of Participants Who Received Red Blood Cell Transfusions During the Study Period
NCT00661388 (18) [back to overview]	Percentage of Participants Requiring Dose Adjustments During Dose Titration Period and EEP
NCT00661388 (18) [back to overview]	Mean Change in Hb Concentration Between Baseline and the Efficacy Evaluation Period
NCT00661388 (18) [back to overview]	Mean Time Spent by Participants in the Target Range of 10.0- 12.0 g/dL During the EEP
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Leucocytes and Platelet at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Number of Participants Taking Concomitant Medications
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Transferrin and Albumin at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change in Hemoglobin Concentration Between the Stability Verification Period and the Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Mean C.E.R.A. Dose Required to Maintain Hemoglobin Level Within the Range 10.0-12.0 Gram/Deciliter Throughout the Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Iron, Total Iron Binding Capacity, and Creatinine at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Phosphate and Potassium at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Percentage of Participants Requiring Any Dose Adjustments in C.E.R.A. During the Dose Titration Period and Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Number of Participants Who Received Red Blood Cell Transfusions During the Dose Titration Period and Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Hemoglobin at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Hematocrit at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Ferritin at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Erythrocyte Mean Corpuscular Volume at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in C-Reactive Protein at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Percentage of Participants Who Maintained Their Mean Hemoglobin Concentration Within +/- 1.0 Gram/Deciliter of Their Reference Hemoglobin Concentration and Between 10.0 and 12.0 Gram/Deciliter During the Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within the Range of 10.0-12.0 Gram/Deciliter Throughout the Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Number of Participants With Reports of Anti-erythropoietin Antibodies
NCT00661505 (23) [back to overview]	Median Time Spent in the Hemoglobin Range 10.0-12.0 Gram/Deciliter During the Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Transferrin Saturation at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change From Baseline in Weight at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Change in From Baseline in Blood Pressure at Week 16 and Week 24
NCT00661505 (23) [back to overview]	Mean Monthly Dose of C.E.R.A. During the Dose Titration Period and Efficacy Evaluation Period
NCT00661505 (23) [back to overview]	Number of Participants With Any Adverse Events and Serious Adverse Events
NCT00666835 (2) [back to overview]	Mean Absolute Change in Hemoglobin Level From the Screening/Baseline Period to the Evaluation Period - ITT Population
NCT00666835 (2) [back to overview]	To Compare the Efficacy of HX575 Hexal AG and ERYPO® Janssen-Cilag.
NCT00680043 (3) [back to overview]	Proportion of Participants Achieving Hemoglobin Response During the Correction and Evaluation Periods
NCT00680043 (3) [back to overview]	Proportion of Participants Who Receive Red Blood Cell (RBC) or Whole Blood Transfusions During the Correction and Evaluation Periods
NCT00680043 (3) [back to overview]	Mean Change in Hemoglobin Between Baseline and the Evaluation Period
NCT00695396 (3) [back to overview]	RBC Transfusion From Day 29 Through the End of Study
NCT00695396 (3) [back to overview]	Red Blood Cell (RBC) Transfusion
NCT00695396 (3) [back to overview]	Transfusion Dependent
NCT00699348 (6) [back to overview]	Percentage of Participants Maintaining Mean Hemoglobin Concentration Within Plus or Minus (+/-) 1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range
NCT00699348 (6) [back to overview]	Percentage of Participants Requiring Any Dose Adjustment
NCT00699348 (6) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within the Target Range
NCT00699348 (6) [back to overview]	Change in Hemoglobin Concentration Between Reference SVP and EEP
NCT00699348 (6) [back to overview]	Median Time Spent by Participants With Hemoglobin Concentration in the Target Range During the EEP
NCT00699348 (6) [back to overview]	Number of Participants With Red Blood Cell Transfusion During the Study
NCT00701714 (3) [back to overview]	Weekly Epoetin Dose
NCT00701714 (3) [back to overview]	Immunogenicity
NCT00701714 (3) [back to overview]	Change in Hemoglobin Level
NCT00717366 (9) [back to overview]	Change in Average Reticulocyte Count Between the Baseline and Evaluation Period
NCT00717366 (9) [back to overview]	Number of Participants With an Average Hb Concentration During the Evaluation Period Above, Within or Below the Range of 10-12 g/dL
NCT00717366 (9) [back to overview]	Maximum Observed Serum Concentration (Cmax) of MIRCERA
NCT00717366 (9) [back to overview]	Change in Average Hb Concentration Between Baseline and Evaluation Period
NCT00717366 (9) [back to overview]	Time to Reach Cmax (Tmax) of MIRCERA
NCT00717366 (9) [back to overview]	Area Under the Serum Concentration-Time Curve From 0 to 672 Hours (AUC0-672h) of MIRCERA
NCT00717366 (9) [back to overview]	Number of Participants With an Average Hb Concentration During the Evaluation Period Within ±1 g/dL of Their Baseline Hb
NCT00717366 (9) [back to overview]	Number of Participants With Blood Transfusions
NCT00717366 (9) [back to overview]	Apparent Terminal Phase Half-Life (t1/2) of MIRCERA
NCT00737464 (18) [back to overview]	Mean Values of Serum Ferritin Over Time
NCT00737464 (18) [back to overview]	Mean Values of Serum Sodium and Serum Potassium Over Time
NCT00737464 (18) [back to overview]	Mean Values of Transferrin Over Time
NCT00737464 (18) [back to overview]	Mean Values of Transferrin Saturation Over Time
NCT00737464 (18) [back to overview]	Mean Values of White Blood Cells and Platelets Over Time
NCT00737464 (18) [back to overview]	Number of Participants With Abnormal Electrocardiogram
NCT00737464 (18) [back to overview]	Number of Participants With Treatment Emergent Adverse Events, Serious Adverse Events and Deaths
NCT00737464 (18) [back to overview]	Mean Values of Hypochromic Red Blood Cells Over Time
NCT00737464 (18) [back to overview]	Mean Values of Aspartate Aminotransferase, Alanine Transaminase and Serum Alkaline Phosphatase Over Time
NCT00737464 (18) [back to overview]	Mean Hemoglobin Concentration Between Stability Verification Period (Weeks -2 to -1) and Treatment Period (Weeks 8 to 12)
NCT00737464 (18) [back to overview]	Mean Change From Baseline in Heart Rate Over Time
NCT00737464 (18) [back to overview]	Mean Change From Baseline in Blood Pressure (Systolic Blood Pressure and Diastolic Blood Pressure) Over Time
NCT00737464 (18) [back to overview]	Percentage of Participants Maintaining Mean Hemoglobin Levels Within the Target Range During the Last 4 Weeks of the Treatment Period (Weeks 8 to 12)
NCT00737464 (18) [back to overview]	Mean Time Participants Spent Having Hemoglobin Range of 10.0 to 12.0 g/dL
NCT00737464 (18) [back to overview]	Mean Values of Iron Parameters (Serum Iron and Total Iron Binding Capacity) Over Time
NCT00737464 (18) [back to overview]	Mean Values of Serum Albumin and Serum Globulin Over Time
NCT00737464 (18) [back to overview]	Mean Values of Serum Creatinine, Blood Urea Nitrogen, Serum Phosphate and Serum Bilirubin Over Time
NCT00737464 (18) [back to overview]	Mean Corpuscular Volume Levels Over Time
NCT00737477 (13) [back to overview]	Percentage of Participants Requiring Blood Transfusions
NCT00737477 (13) [back to overview]	Percentage of Participants Who Maintained Average Hb Value Within Target Range During the EEP
NCT00737477 (13) [back to overview]	Change in Hb Value From Baseline to the EEP
NCT00737477 (13) [back to overview]	Absolute Change in Dose of Mircera/CERA by Study Week
NCT00737477 (13) [back to overview]	Number of Dose Adjustments of Mircera/CERA
NCT00737477 (13) [back to overview]	Percent Change in Dose of Mircera/CERA by Study Week
NCT00737477 (13) [back to overview]	Percentage of Participants Who Required Any Dose Adjustment of Mircera/CERA
NCT00737477 (13) [back to overview]	Time Spent in the Target Range for Hb During the EEP and the Overall Treatment Period
NCT00737477 (13) [back to overview]	Percentage of Participants With Down Excursions
NCT00737477 (13) [back to overview]	Percentage of Participants With Hb Value Within Plus/Minus (±) 1 g/dL of Reference Hb and Within the Target Range by Study Visit
NCT00737477 (13) [back to overview]	Percentage of Participants With Hb Values Within Target Range During the EEP
NCT00737477 (13) [back to overview]	Percentage of Participants With Up Excursions
NCT00737477 (13) [back to overview]	Percentage of Participants With Cycles or Excursions
NCT00737711 (28) [back to overview]	Mean Serum Albumin Over Time
NCT00737711 (28) [back to overview]	Mean Serum Alkaline Phosphatase Over Time
NCT00737711 (28) [back to overview]	Mean Serum Bilirubin Over Time
NCT00737711 (28) [back to overview]	Mean Serum Creatinine Over Time
NCT00737711 (28) [back to overview]	Mean Serum Ferritin Over Time
NCT00737711 (28) [back to overview]	Mean Serum Iron Over Time
NCT00737711 (28) [back to overview]	Mean Serum Phosphate Over Time
NCT00737711 (28) [back to overview]	Mean Serum Potassium Over Time
NCT00737711 (28) [back to overview]	Mean Serum Sodium Over Time
NCT00737711 (28) [back to overview]	Mean Total Iron-binding Capacity Over Time
NCT00737711 (28) [back to overview]	Mean Transferrin Over Time
NCT00737711 (28) [back to overview]	Mean Transferrin Saturation Over Time
NCT00737711 (28) [back to overview]	Mean Value of Mean Corpuscular Volume Over Time
NCT00737711 (28) [back to overview]	Mean White Blood Cell Count Over Time
NCT00737711 (28) [back to overview]	Number of Participants With Abnormal Electrocardiogram
NCT00737711 (28) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events and Deaths
NCT00737711 (28) [back to overview]	Number of Participants With Reports of Blood Transfusions
NCT00737711 (28) [back to overview]	Mean Serum Globulin Over Time
NCT00737711 (28) [back to overview]	Mean Change in Hemoglobin Concentration From Baseline to Week 16 of the Treatment Period
NCT00737711 (28) [back to overview]	Mean Time Required to Achieve Blood Hemoglobin Levels Within Target Range of 10.0-12.0 Gram/Deciliter
NCT00737711 (28) [back to overview]	Mean Time Spent in the Hemoglobin Range of 10.0-12.0 Gram/Deciliter From Week 12 to Week 16
NCT00737711 (28) [back to overview]	Number of Participants With Reports of Anti-Epoetin Antibodies
NCT00737711 (28) [back to overview]	Percentage of Participants With Average Hemoglobin Concentration Between 10.0-12.0 Gram/Deciliter From Week 12 to Week 16
NCT00737711 (28) [back to overview]	Mean Alanine Aminotransferase Over Time
NCT00737711 (28) [back to overview]	Mean Aspartate Transaminase Over Time
NCT00737711 (28) [back to overview]	Mean Blood Urea Nitrogen Over Time
NCT00737711 (28) [back to overview]	Mean Hypochromic Red Blood Cells Over Time
NCT00737711 (28) [back to overview]	Mean Platelet Count Over Time
NCT00737893 (22) [back to overview]	Patient Score on the Overall IIEF Questionnaire
NCT00737893 (22) [back to overview]	Hemoglobin Level at 2 Weeks After Surgery
NCT00737893 (22) [back to overview]	Erectile Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire Erectile Function Domain
NCT00737893 (22) [back to overview]	Erectile Function as Assessed by the IIEF Questionnaire Erectile Function Domain
NCT00737893 (22) [back to overview]	Erectile Function as Assessed by the IIEF Questionnaire Erectile Function Domain
NCT00737893 (22) [back to overview]	Erectile Function as Assessed by the IIEF Questionnaire Erectile Function Domain
NCT00737893 (22) [back to overview]	Patient Score on the Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain
NCT00737893 (22) [back to overview]	Patient Score on the Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain
NCT00737893 (22) [back to overview]	Number of Participants Requiring Transfusion During Hospitalization
NCT00737893 (22) [back to overview]	Patient Score on Health-related Quality of Life Questionnaires (SF-12 MCS)
NCT00737893 (22) [back to overview]	Patient Score on Health-related Quality of Life Questionnaires (SF-12 MCS)
NCT00737893 (22) [back to overview]	Patient Score on Health-related Quality of Life Questionnaires (SF-12 MCS)
NCT00737893 (22) [back to overview]	Patient Score on the Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain
NCT00737893 (22) [back to overview]	Patient Score on the Expanded Prostate Cancer Index Composite (EPIC) Sexual Domain
NCT00737893 (22) [back to overview]	Patient Score on the Overall IIEF Questionnaire
NCT00737893 (22) [back to overview]	Patient Score on the Overall IIEF Questionnaire
NCT00737893 (22) [back to overview]	Patient Score on the Overall IIEF Questionnaire
NCT00737893 (22) [back to overview]	Patient Score on the Quality of Erection Questionnaire (QEQ)
NCT00737893 (22) [back to overview]	Patient Score on the Quality of Erection Questionnaire (QEQ)
NCT00737893 (22) [back to overview]	Patient Score on Health-related Quality of Life Questionnaires (SF-12 MCS)
NCT00737893 (22) [back to overview]	Patient Score on the Quality of Erection Questionnaire (QEQ)
NCT00737893 (22) [back to overview]	Patient Score on the Quality of Erection Questionnaire (QEQ)
NCT00773513 (8) [back to overview]	Time to Non-Fatal and Fatal Stroke
NCT00773513 (8) [back to overview]	Time to Non-Fatal Cardiovascular Events (Myocardial Infarction or Stroke, Whichever Occurred First)
NCT00773513 (8) [back to overview]	Percentage of Participants With Anti-Erythropoietin Antibody-Mediated Pure Red Cell Aplasia (PRCA)
NCT00773513 (8) [back to overview]	Percentage of Participants With Gastrointestinal Bleeding
NCT00773513 (8) [back to overview]	Percentage of Participants With Thromboembolic Events
NCT00773513 (8) [back to overview]	Time to All-Cause Mortality
NCT00773513 (8) [back to overview]	Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and Date of Death or Non-Fatal Cardiovascular Events, Whichever Occurred First
NCT00773513 (8) [back to overview]	Time to Non-Fatal and Fatal Myocardial Infarction
NCT00773968 (6) [back to overview]	Percentage of Participants Maintaining Hb Concentrations Within the Range of 10.0 to 12.0 g/dL Throughout EEP
NCT00773968 (6) [back to overview]	Change in Hb Concentrations Between EEP and Stability Verification Period (SVP)
NCT00773968 (6) [back to overview]	Median Time Spent in the Hb Range of 10.0 to 12.0 g/dL During the EEP
NCT00773968 (6) [back to overview]	Percentage of Participants Maintaining Their Mean Hb Concentration Within Plus/Minus (±) 1 Grams Per Deciliter (g/dL) of the Reference Range and Between 10.0 and 12.0 g/dL During Efficacy Evaluation Period (EEP)
NCT00773968 (6) [back to overview]	Percentage of Participants Who Required Red Blood Cell Transfusions
NCT00773968 (6) [back to overview]	Percentage of Participants Requiring Any Dose Adjustment During Dose Titration Period (DTP) and EEP
NCT00843882 (9) [back to overview]	Duration of Major Erythroid Response (MER)
NCT00843882 (9) [back to overview]	Time to Major Erythroid Response (MER)
NCT00843882 (9) [back to overview]	Proportion of Patients With Cytogenetic Response
NCT00843882 (9) [back to overview]	Proportion of Patients With Bone Marrow Response
NCT00843882 (9) [back to overview]	Pretreatment Endogenous Erythropoietin Level
NCT00843882 (9) [back to overview]	Proportion of Patients With Minor Erythroid Response
NCT00843882 (9) [back to overview]	Proportion of Patients With Major Erythroid Response (MER) to Salvage Combination Therapy
NCT00843882 (9) [back to overview]	Proportion of Patients With Major Erythroid Response (MER) Among Those With Chromosome 5q31.1 Deletion
NCT00843882 (9) [back to overview]	Proportion of Patients With Major Erythroid Response (MER)
NCT00882713 (19) [back to overview]	Mean Change From Baseline in Pulse Rate Over Time
NCT00882713 (19) [back to overview]	Mean Change From Baseline in Weight Over Time
NCT00882713 (19) [back to overview]	Mean Creatinine, Iron, and Total Iron Binding Capacity Levels Over Time
NCT00882713 (19) [back to overview]	Mean Hematocrit Levels Over Time
NCT00882713 (19) [back to overview]	Mean Hemoglobin Levels Over Time
NCT00882713 (19) [back to overview]	Mean Phosphate and Potassium Levels Over Time
NCT00882713 (19) [back to overview]	Mean Transferrin Saturation Levels Over Time
NCT00882713 (19) [back to overview]	Mean White Blood Cells and Thrombocytes Over Time
NCT00882713 (19) [back to overview]	Number of Participants With Any Adverse Events or Serious Adverse Events
NCT00882713 (19) [back to overview]	Mean Change in Hemoglobin Concentration Between Reference (Stability Verification Period) and the Efficacy Evaluation Period
NCT00882713 (19) [back to overview]	Mean Ferritin Levels Over Time
NCT00882713 (19) [back to overview]	Mean Time Spent By Participants With Hemoglobin Range of 10.5-12.5 g/dL During the EEP
NCT00882713 (19) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within the Range of 10.5-12.5 g/dL Throughout the EEP
NCT00882713 (19) [back to overview]	Percentage of Participants Maintaining Mean Hemoglobin Concentration Within +/- 1 g/dL of Their Reference Hb and Between 10.5 and 12.5 g/dL During Efficacy Evaluation Period
NCT00882713 (19) [back to overview]	Incidences of Red Blood Cell Transfusions During the C.E.R.A. Treatment Phase
NCT00882713 (19) [back to overview]	Mean Albumin Levels Over Time
NCT00882713 (19) [back to overview]	Mean C-Reactive Protein Levels Over Time
NCT00882713 (19) [back to overview]	Mean Change From Baseline in Blood Pressure Over Time
NCT00882713 (19) [back to overview]	Percentage of Participants Requiring Any Dose Adjustment During DTP and EEP
NCT00910858 (10) [back to overview]	Monotherapy Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
NCT00910858 (10) [back to overview]	Monotherapy Phase: Area-under-the Concentration-time Curve (AUC0-5) for Lenalidomide
NCT00910858 (10) [back to overview]	Monotherapy Phase: Percent of Lenalidomide Excreted Over 5 Hours Post Day 14 Dose
NCT00910858 (10) [back to overview]	Percentage of Participants Overall With Erythroid Response by Baseline Erythropoietin Level
NCT00910858 (10) [back to overview]	Percentage of Participants With a Erythroid Response Across All Phases
NCT00910858 (10) [back to overview]	PK Phase: Maximum Plasma Concentration of Lenalidomide (Cmax)
NCT00910858 (10) [back to overview]	PK Phase: Percent of Administered Lenalidomide Excreted Over 24 Hours After a Single, Oral Dose
NCT00910858 (10) [back to overview]	PK Phase: Terminal Half-life (t1/2)
NCT00910858 (10) [back to overview]	Time to Grade 4 Neutropenia or Thrombocytopenia
NCT00910858 (10) [back to overview]	PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide
NCT00922116 (6) [back to overview]	Change in Hemoglobin Concentration Between SVP and the EEP
NCT00922116 (6) [back to overview]	Percentage of Participants Who Required Dose Adjustments During Dose Titration Period (DTP) and EEP
NCT00922116 (6) [back to overview]	Average Dose of Mircera Per Month
NCT00922116 (6) [back to overview]	Time Spent in Hemoglobin Range of 10.0 to 12.0 g/dL During DTP and EEP
NCT00922116 (6) [back to overview]	Percentage of Participants Maintaining Hemoglobin Concentration Within Hemoglobin Range 10.0 to 12.0 g/dL Throughout the EEP
NCT00922116 (6) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin Concentration Within the Target Range During the Efficacy Evaluable Period (EEP)
NCT00924781 (6) [back to overview]	Number of Participants With Composite Events of Transfusion-Related Adverse Experiences
NCT00924781 (6) [back to overview]	Number of Participants With Composite Events of Infusion Reactions
NCT00924781 (6) [back to overview]	Number of Participants With Composite Events of Death, Myocardial Infarction (MI), and Cerebrovascular Accident (CVA)
NCT00924781 (6) [back to overview]	Change From Baseline in Hg Level at Week 12
NCT00924781 (6) [back to overview]	Change From Baseline in Hemoglobin (Hg) Level at Week 4
NCT00924781 (6) [back to overview]	Number of Participants With Events of Death, MI, CVA, Peripheral Vascular Thromboses, Vascular Access Thrombosis, Congestive Heart Failure (CHF), Hypertension, Seizure, or Pure Red Cell Aplasia
NCT00938314 (12) [back to overview]	NIHSS Change From Baseline at Day 30
NCT00938314 (12) [back to overview]	Trails A Test Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	Trails B Test Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	Action Research Arm Test (ARAT) Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	Barthel Index at Day 90
NCT00938314 (12) [back to overview]	National Institutes of Health Stroke Scale (NIHSS) Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	NIHSS Response >=4 at Day 90
NCT00938314 (12) [back to overview]	Modified Rankin Scale (mRS) Response <=2 at Day 90
NCT00938314 (12) [back to overview]	Boston Naming Test (BNT) Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	Gait Velocity Test Change From Baseline at Day 90
NCT00938314 (12) [back to overview]	Geriatric Depression Scale at Day 90
NCT00938314 (12) [back to overview]	Line Cancellation Test Change From Baseline at Day 90
NCT01023035 (2) [back to overview]	Percentage of Participants Who Discontinued Treatment
NCT01023035 (2) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR)
NCT01034657 (9) [back to overview]	Mean Single Scoring Values of the IPSS - Randomized Phase
NCT01034657 (9) [back to overview]	Percentage of Participants With Objective Response During the Randomized Phase
NCT01034657 (9) [back to overview]	Mean Single Scoring Values of the IPSS - Core Phase
NCT01034657 (9) [back to overview]	Frequency Distribution of IPSS Score Status - Randomized Phase
NCT01034657 (9) [back to overview]	Frequency Distribution of IPSS Score Status - Core Phase
NCT01034657 (9) [back to overview]	Percentage of Participants With Objective Response During Core Phase
NCT01034657 (9) [back to overview]	Percentage of Participants With HI-E - Randomized Phase
NCT01034657 (9) [back to overview]	Percentage of Participants With Hematological Response of the Erythropoetic System (HI-E) - Core Phase
NCT01034657 (9) [back to overview]	Overall Survival (OS) - Overall Period
NCT01066000 (8) [back to overview]	Mean Time Spent by Participants in the Haemoglobin Range of 10 - 12 g/dL During the Efficacy Evaluation Period
NCT01066000 (8) [back to overview]	Mean Change in Haemoglobin Concentration From Screening Period and Efficacy Evaluation Period
NCT01066000 (8) [back to overview]	Mean Number of Months Per Participant Requiring Dose Adjustment During the Dose Titration and Evaluation Periods
NCT01066000 (8) [back to overview]	Proportion of Participants Maintaining Average Haemoglobin During the Efficacy Evaluation Period Within the Target Range (10-12 g/dl)
NCT01066000 (8) [back to overview]	Proportion of Participants Maintaining Haemoglobin Concentration Within the Haemoglobin Range 10-12g/dL Throughout the Efficacy Evaluation Period
NCT01066000 (8) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT01066000 (8) [back to overview]	Mean Monthly Dose of Methoxy Polyethylene Glycol-epoetin Beta During the Dose Titration and Evaluation Periods
NCT01066000 (8) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT01099202 (2) [back to overview]	Mean Number of RBC Units Transfused During Initial 5 Months of Treatment
NCT01099202 (2) [back to overview]	Number of PRBC Transfusions During Initial 5 Months of Treatment
NCT01102218 (1) [back to overview]	Change in Erythropoietin Dose
NCT01147666 (18) [back to overview]	Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for 19 Weeks
NCT01147666 (18) [back to overview]	Number of Participants Whose Hb Levels Were Maintained at Week 7 to Within ±1 g/dL of Their Mean 4-Week Screening Period Baseline Value for Participants Treated for At Least 6 Weeks
NCT01147666 (18) [back to overview]	Number of Participants With a Mean of Hb Within 10-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
NCT01147666 (18) [back to overview]	Number of Participants With a Mean of Hb Within 11-13 g/dL (Values Obtained at Weeks 17, 18, 19, and 20 for Participants Dosed for 19 Weeks)
NCT01147666 (18) [back to overview]	Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Hyporesponsive Participants Treated for at Least 6 Weeks
NCT01147666 (18) [back to overview]	Number of Participants Treated for 7-19 Weeks Whose Hb Levels at Weeks 8, 10, 12, 14, 17, 19, and 20 Were Greater Than Their Baseline Level
NCT01147666 (18) [back to overview]	Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for at Least 6-Weeks
NCT01147666 (18) [back to overview]	Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 6 Weeks Only
NCT01147666 (18) [back to overview]	Number of Participants Who Required Dose Adjustments During the Dosing Period for Participants Treated for 19 Weeks
NCT01147666 (18) [back to overview]	Change From Baseline in Hb at Week 7 for Participants Treated for at Least 6 Weeks
NCT01147666 (18) [back to overview]	Number of Participants Requiring Dose Reduction Secondary to Excessive Erythropoiesis During Dosing Period, Among Participants Treated for 19-Weeks
NCT01147666 (18) [back to overview]	Change From Baseline in Hb at Weeks 8, 10, 12, 14, 17, 19, and 20 for Participants Treated for 7-19 Weeks
NCT01147666 (18) [back to overview]	Number of Participants Treated for 6 Weeks Only Whose Hb Levels at Week 7 Were Greater Than Their Baseline Level
NCT01147666 (18) [back to overview]	Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for 19-Weeks
NCT01147666 (18) [back to overview]	Number of Participants With a Mean Hb Above 11 g/dL When the Mean Hb Values at Weeks 17, 18, 19, and 20 Were Averaged, Among Participants Treated for 19 Weeks
NCT01147666 (18) [back to overview]	Rate of Change in Hb Levels, Measured by Regression Slopes of the Hb Values During Treatment up to Week 6
NCT01147666 (18) [back to overview]	Number of Participants With Week 7 Hb ≥ Baseline Hb - 0.5 g/dL, Among Normoresponder Participants Treated for 6 Weeks Only
NCT01147666 (18) [back to overview]	Number of Participants Who Required Rescue Anemia Treatment Due to Hb Levels, Among Participants Treated for at Least 6 Weeks
NCT01156363 (5) [back to overview]	Mean Time Participants Spent Having Hb Concentration Within Target Range
NCT01156363 (5) [back to overview]	Percentage of Participants Requiring Dose Adjustments
NCT01156363 (5) [back to overview]	Mean Monthly Hb Values
NCT01156363 (5) [back to overview]	Change in Hb Concentration Between Reference and Treatment Period
NCT01156363 (5) [back to overview]	Percentage of Participants Maintaining Average Hemoglobin (Hb) Concentration Within the Target Range
NCT01168349 (32) [back to overview]	Relative Percent Change in Hb Concentration From Baseline Over the Study Period
NCT01168349 (32) [back to overview]	Percentage of Participants With Vitamins Prescription
NCT01168349 (32) [back to overview]	Percentage of Participants With Subcutaneous (SC) Route of Administration
NCT01168349 (32) [back to overview]	Percentage of Participants With Early Treatment Response: Day 21 to 42
NCT01168349 (32) [back to overview]	Karnofsky Performance Status (KPS): Baseline
NCT01168349 (32) [back to overview]	Percentage of Participants With At Least 1 Sick Leave
NCT01168349 (32) [back to overview]	Percentage of Participants With At Least 1 Red Blood Cell (RBC) Transfusion
NCT01168349 (32) [back to overview]	Mean Starting Dose of NeoRecormon® Injection
NCT01168349 (32) [back to overview]	Percentage of Participants With Professional Activity: Baseline
NCT01168349 (32) [back to overview]	Percentage of Participants With Pre-specified Dose and Frequency of Injections
NCT01168349 (32) [back to overview]	Percentage of Participants With Permanent Discontinuation From NeoRecormon® Treatment
NCT01168349 (32) [back to overview]	Mean Number of RBC Units
NCT01168349 (32) [back to overview]	Percentage of Participants With Adequate Iron Status
NCT01168349 (32) [back to overview]	Time to First RBC Transfusions
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 4 to 6
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 24 to 28
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Percentage of Participants With Current Employment at Week 12 to 16
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Percentage of Participants With Current Employment at Baseline
NCT01168349 (32) [back to overview]	Mean Number of RBC Transfusions
NCT01168349 (32) [back to overview]	Mean Number of Days of Sick Leave
NCT01168349 (32) [back to overview]	KPS: Week 4 to 6
NCT01168349 (32) [back to overview]	KPS: Week 24 to 28
NCT01168349 (32) [back to overview]	KPS: Week 12 to 16
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 4 to 6
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 24 to 28
NCT01168349 (32) [back to overview]	Self-Reported Questionnaire: Change From Baseline on the Impact of Health on Regular Activities at Week 12 to 16
NCT01168349 (32) [back to overview]	Percentage of Participants With Temporary Discontinuation From NeoRecormon® Treatment
NCT01168349 (32) [back to overview]	Percentage of Participants With Starting Dose Between 360 and 540 IU/kg/Weeks
NCT01168349 (32) [back to overview]	Percentage of Participants With NeoRecormon® SC Injections at a Weekly Dose of 30000 IU
NCT01168349 (32) [back to overview]	Percentage of Participants With Modifications of NeoRecormon® Regimen
NCT01168349 (32) [back to overview]	Percentage of Participants With Hb Concentration Within the Range of 10 to 12 g/dL
NCT01168349 (32) [back to overview]	Percentage of Participants With Early Treatment Response: Day 28 to 42
NCT01193660 (11) [back to overview]	Changes in Functional Performance in Daily Activities
NCT01193660 (11) [back to overview]	Changes in Functional Independence in Daily Activities
NCT01193660 (11) [back to overview]	Changes in Cognitive Neurodevelopmental Outcome
NCT01193660 (11) [back to overview]	Changes in Motor Performance
NCT01193660 (11) [back to overview]	Changes in Brain MRI
NCT01193660 (11) [back to overview]	Number of Participants With Serious Adverse Events as a Measure of Safety,Which Are Related to Umbilical Cord Blood, Erythropoietin, or Immunosuppressant
NCT01193660 (11) [back to overview]	Comparison of Changes in Brain Glucose Metabolism Using by Brain 18F-FDG PET: Increased and Decreased Areas of Brain Glucose Metabolism
NCT01193660 (11) [back to overview]	Changes in Standardized Gross Motor Function
NCT01193660 (11) [back to overview]	Changes in Muscle Strength
NCT01193660 (11) [back to overview]	Changes in Motor Neurodevelopmental Outcome
NCT01193660 (11) [back to overview]	Changes in Hand Function
NCT01194154 (7) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01194154 (7) [back to overview]	Change From Baseline in Urinary Albumin Creatinine Ratio (UACR) at Month 24
NCT01194154 (7) [back to overview]	Change From Baseline in Serum Creatinine Concentration at Month 24
NCT01194154 (7) [back to overview]	Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Month 24
NCT01194154 (7) [back to overview]	Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Modification of Diet in Renal Disease With 4 Variables (MDRD-4)
NCT01194154 (7) [back to overview]	Yearly Reduction Rate of Estimated Glomerular Filtration Rate (eGFR) Calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
NCT01194154 (7) [back to overview]	Change From Baseline in Serum Cystatin C Concentration at Month 24
NCT01235923 (2) [back to overview]	Baseline Retic Count
NCT01235923 (2) [back to overview]	Reticulocyte Count
NCT01342640 (3) [back to overview]	Change From Baseline in Mean Hb Concentration at Week 20
NCT01342640 (3) [back to overview]	Change From Baseline in Mean Hb Concentration at Week 28
NCT01342640 (3) [back to overview]	Change From Baseline in Mean Hb Concentration at Week 24
NCT01369732 (1) [back to overview]	Incidence of Acute Kidney Injury Based on RIFLE Criteria
NCT01378273 (4) [back to overview]	Number of Participants With a Serious Adverse Events (SAE)
NCT01378273 (4) [back to overview]	Number of Participants With Death or Severe Neurodevelopmental Impairment (NDI) at 22-26 Months Corrected Age
NCT01378273 (4) [back to overview]	Biomarkers
NCT01378273 (4) [back to overview]	Imaging
NCT01394991 (8) [back to overview]	Red Blood Cell Transfusions
NCT01394991 (8) [back to overview]	Mortality
NCT01394991 (8) [back to overview]	Number of Hemoglobin Responders
NCT01394991 (8) [back to overview]	Number of Participants With at Least 1 Clinically Relevant and Objectively Confirmed Thrombovascular Event From Randomization Through Week 16
NCT01394991 (8) [back to overview]	Number of Positively Adjudicated Thrombovascular Events
NCT01394991 (8) [back to overview]	Number of Suspected Thrombovascular Events
NCT01394991 (8) [back to overview]	Time to First Positively Adjudicated Thrombovascular Event
NCT01394991 (8) [back to overview]	Time to First Suspected Thrombovascular Event
NCT01473407 (24) [back to overview]	Mean Weekly Hemoglobin Level From Week 21 to Week 24
NCT01473407 (24) [back to overview]	Mean Weekly Hemoglobin Level Through 24 Weeks
NCT01473407 (24) [back to overview]	Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event
NCT01473407 (24) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
NCT01473407 (24) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Physical Examination
NCT01473407 (24) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT01473407 (24) [back to overview]	Percentage of Participants With Any Transient Change of Hemoglobin Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level
NCT01473407 (24) [back to overview]	Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
NCT01473407 (24) [back to overview]	Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range
NCT01473407 (24) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
NCT01473407 (24) [back to overview]	Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
NCT01473407 (24) [back to overview]	Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
NCT01473407 (24) [back to overview]	Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1 Gram Per Deciliter (g/dL)
NCT01473407 (24) [back to overview]	Number of Participants With Treatment Related Adverse Events (AEs)
NCT01473407 (24) [back to overview]	Percentage of Participants Who Received Blood Transfusions
NCT01473407 (24) [back to overview]	Percentage of Participants Who Required Permanent Dose Changes of Study Medication
NCT01473407 (24) [back to overview]	Percentage of Participants Who Required Temporary Dose Changes of Study Medication
NCT01473407 (24) [back to overview]	Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level
NCT01473407 (24) [back to overview]	Mean Weekly Dosage of Study Medication From Week 21 to Week 24
NCT01473407 (24) [back to overview]	Mean Weekly Dosage of Study Medication Through 24 Weeks
NCT01473407 (24) [back to overview]	Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range
NCT01473407 (24) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events by Severity
NCT01473407 (24) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01473407 (24) [back to overview]	Total Dose of Study Medication Administered
NCT01473420 (27) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Physical Examination
NCT01473420 (27) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
NCT01473420 (27) [back to overview]	Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event
NCT01473420 (27) [back to overview]	Mean Weekly Hemoglobin Level From Week 30 to Week 34: Maintenance Period
NCT01473420 (27) [back to overview]	Mean Weekly Hemoglobin Level From Week 19 to Week 34: Maintenance Period
NCT01473420 (27) [back to overview]	Mean Weekly Dosage of Study Medication From Week 30 to Week 34: Maintenance Period
NCT01473420 (27) [back to overview]	Mean Weekly Dosage of Study Medication From Week 19 to Week 34: Maintenance Period
NCT01473420 (27) [back to overview]	Number of Participants With Treatment Related Adverse Events (AEs)
NCT01473420 (27) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
NCT01473420 (27) [back to overview]	Percentage of Participants With General Tolerability
NCT01473420 (27) [back to overview]	Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Local Tolerability
NCT01473420 (27) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events by Severity
NCT01473420 (27) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01473420 (27) [back to overview]	Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level: Maintenance Period
NCT01473420 (27) [back to overview]	Total Dose of Study Medication Administered: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL): Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL): Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1.0 Gram Per Deciliter (g/dL): Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
NCT01473420 (27) [back to overview]	Percentage of Participants Who Required Temporary Dose Changes: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants Who Required Permanent Dose Changes: Maintenance Period
NCT01473420 (27) [back to overview]	Percentage of Participants Who Qualified as Optimally Titrated and Stable: Titration Period
NCT01473420 (27) [back to overview]	Percentage of Participants Who Received Blood Transfusions: Maintenance Period
NCT01473420 (27) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Vital Signs
NCT01478971 (5) [back to overview]	Percentage of Participants Undergoing Conversion to Peginesatide Injection
NCT01478971 (5) [back to overview]	Percentage of Participants Who Received a Whole Blood or Red Blood Cell Transfusion
NCT01478971 (5) [back to overview]	Peginesatide Dosing
NCT01478971 (5) [back to overview]	Percentage of Participants Who Received at Least One Intravenous Iron Dose
NCT01478971 (5) [back to overview]	Percentage of Participants With Hemoglobin Levels Greater Than 10 and Less Than or Equal to 11 g/dL
NCT01519947 (4) [back to overview]	Mean Dose Required to Achieve Target Hemoglobin of 11-12 g/dL
NCT01519947 (4) [back to overview]	Change in Hemoglobin Concentration
NCT01519947 (4) [back to overview]	Percentage of Participants With Adverse Events
NCT01519947 (4) [back to overview]	Percentage of Participants Achieving Target Hemoglobin Concentration 11-12 g/dL After 3 and 6 Months of Treatment
NCT01576341 (2) [back to overview]	Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)
NCT01576341 (2) [back to overview]	Anti-Erythropoietin (EPO) Antibodies
NCT01628107 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Hemoglobin Levels
NCT01628107 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)
NCT01628107 (22) [back to overview]	Number of Participants Who Received Concomitant Medication
NCT01628107 (22) [back to overview]	Mean Weekly Dosage of Epoetin Hospira : Over Week 1 to 48
NCT01628107 (22) [back to overview]	Mean Hemoglobin Levels: Over Week 1 to 48
NCT01628107 (22) [back to overview]	Mean Hematocrit Levels: Over Week 1 to 48
NCT01628107 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
NCT01628107 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
NCT01628107 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
NCT01628107 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Outside the Target Range
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12
NCT01628107 (22) [back to overview]	Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1
NCT01628107 (22) [back to overview]	Mean Hematocrit Levels for Interval of 12 Weeks
NCT01628107 (22) [back to overview]	Mean Hemoglobin Levels for Interval of 12 Weeks
NCT01628107 (22) [back to overview]	Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
NCT01628107 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48
NCT01628107 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Physical Examinations
NCT01628107 (22) [back to overview]	Percentage of Participants Who Received Blood Transfusions
NCT01628120 (22) [back to overview]	Percentage of Participants With Anti-Recombinant Human Erythropoietin (rhEPO) Antibodies
NCT01628120 (22) [back to overview]	Mean Weekly Dosage of Epoetin Hospira for Interval of 12 Weeks
NCT01628120 (22) [back to overview]	Mean Hemoglobin Levels: Over Week 1 to 48
NCT01628120 (22) [back to overview]	Mean Weekly Dosage of Epoetin Hospira: Over Week 1 to 48
NCT01628120 (22) [back to overview]	Number of Participants Who Received Concomitant Medication
NCT01628120 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in 12-Lead Electrocardiogram (ECG)
NCT01628120 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Hemoglobin (Hb) Levels
NCT01628120 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Laboratory Tests
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 12
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 1 to 48
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 13 to 24
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 25 to 36
NCT01628120 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
NCT01628120 (22) [back to overview]	Percentage of Participants Who Received Blood Transfusions
NCT01628120 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
NCT01628120 (22) [back to overview]	Number of Participants With Clinically Significant Change From Baseline in Physical Examinations
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Over Week 37 to 48
NCT01628120 (22) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (AEs): Week 1
NCT01628120 (22) [back to overview]	Percentage of Participants With Hemoglobin Level Outside Target Range
NCT01628120 (22) [back to overview]	Mean Hematocrit Levels for Interval of 12 Weeks
NCT01628120 (22) [back to overview]	Mean Hematocrit Levels: Over Week 1 to 48
NCT01628120 (22) [back to overview]	Mean Hemoglobin Levels for Interval of 12 Weeks
NCT01693029 (4) [back to overview]	Mean Weekly Dose During Evaluation Period (Week 21-28)
NCT01693029 (4) [back to overview]	Mean Absolute Change in Hemoglobin Levels Between the Screening/Baseline Period (Week -4 to Day 1) and the Evaluation Period (Week 21-28)
NCT01693029 (4) [back to overview]	Incidence of Antibody Formation Against Epoetin
NCT01693029 (4) [back to overview]	Change in Mean Hb Level Between Baseline (Week -4 to Day1) and Evaluation Period (Week 21-28)
NCT01736215 (9) [back to overview]	Reticulocyte Count
NCT01736215 (9) [back to overview]	Number of Participants With Serum Erythropoietin (EPO) Level (EPO Less Than or Equal to 45.2 or EPO Greater Than 45.3)
NCT01736215 (9) [back to overview]	Percentage of Participants With Response to Erythropoietin Treatment
NCT01736215 (9) [back to overview]	Number of Participants With C-Reactive Protein (CRP) Level Less Than or Equal to 10.3 or Greater Than 10.4
NCT01736215 (9) [back to overview]	Serum Hematocrit Level
NCT01736215 (9) [back to overview]	Transferring Iron Binding Capacity (TIBC)
NCT01736215 (9) [back to overview]	Serum Iron Level
NCT01736215 (9) [back to overview]	Serum Hemoglobin Level
NCT01736215 (9) [back to overview]	Serum Ferritin Level
NCT01737879 (2) [back to overview]	Peginesatide Dose by Visit
NCT01737879 (2) [back to overview]	Hemoglobin Concentration by Visit
NCT01783847 (2) [back to overview]	Number of Participants With Change/Improvement Visual Acuity From the Beseline
NCT01783847 (2) [back to overview]	Number of Participants With Relative Afferent Papillary Defect (RAPD) Grade +4
NCT01809314 (3) [back to overview]	Percentage of Participants Who Required Blood Transfusions During the Study
NCT01809314 (3) [back to overview]	Percentage of Participants by Change in Eastern Cooperative Oncology Group (ECOG) Performance Status From Baseline to EOT
NCT01809314 (3) [back to overview]	Change in Hemoglobin (Hb) Level From Baseline to End of Treatment (EOT)
NCT01868477 (15) [back to overview]	Summary of Erythroid Response Within 24 Weeks in Participants Randomized to EPO at Baseline and Not Switched to EPO+DFX After 12 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Platelets and Neutrophil Levels up to 24 Weeks
NCT01868477 (15) [back to overview]	Summary of Hematologic Improvement in Patients Randomized to EPO+DFX and EPO Alone, Within 24 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for Deferasirox + Erythropoietin Alpha Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin (Hb) From Baseline for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Serum Ferritin up to 24 Weeks for EPO+DFX at 12 Weeks Arm (Full Analysis Set)
NCT01868477 (15) [back to overview]	Summary of Erythroid Response in Participants Randomized to EPO Alone at Baseline and Switched to EPO+DFX After 12 Weeks of Treatment (Full Analysis Set)
NCT01868477 (15) [back to overview]	Absolute Change in Hemoglobin Values up to 24 Weeks
NCT01868477 (15) [back to overview]	Absolute Change From Baseline to Post-baseline Value for Hemoglobin(g/dL)(Full Analysis Set)
NCT01868477 (15) [back to overview]	Difference in Percentage of Patients Achieving Erythroid Response Within 12 Weeks, by Treatment Group (Full Analysis Set)
NCT01888003 (2) [back to overview]	Number of Subjects Requiring at Least One Blood Transfusion During Surgery.
NCT01888003 (2) [back to overview]	Number of Subjects With Blood Transfusions After Surgery and Prior to Discharge From Hospital
NCT01913340 (9) [back to overview]	Alberta Infant Motor Scale (AIMS)
NCT01913340 (9) [back to overview]	Growth Parameters: Head Circumference
NCT01913340 (9) [back to overview]	Warner Initial Developmental Evaluation (WIDEA) at 6 Months of Age
NCT01913340 (9) [back to overview]	Growth Parameters: Weight
NCT01913340 (9) [back to overview]	Moderate to Severe Neurodevelopmental Impairment
NCT01913340 (9) [back to overview]	Brain Injury, as Determined by Neonatal Brain MRI
NCT01913340 (9) [back to overview]	Markers of Organ Function
NCT01913340 (9) [back to overview]	Warner Initial Developmental Evaluation (WIDEA)
NCT01913340 (9) [back to overview]	Growth Parameters: Height
NCT01940484 (14) [back to overview]	Mean Methoxy Polyethylene Glycol-Epoetin Beta Dose During the Study
NCT01940484 (14) [back to overview]	Number of Participants With Dose Adjustments of Methoxy Polyethylene Glycol-Epoetin Beta
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 7 (Month 6)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 3 (Month 2)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 7 (Month 6)
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 4 (Month 3)
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 6 (Month 5)
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 5 (Month 4)
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 3 (Month 2)
NCT01940484 (14) [back to overview]	Number of Participants With Hemoglobin Values Within the Target Range of 11-12 g/dL at Visit 2 (Month 1)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 6 (Month 5)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 5 (Month 4)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 4 (Month 3)
NCT01940484 (14) [back to overview]	Mean Hemoglobin Value at Visit 2 (Month 1)
NCT02052310 (14) [back to overview]	Percentage of Participants With Exacerbation of Hypertension During Weeks 28 to 52
NCT02052310 (14) [back to overview]	Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (PPS Population)
NCT02052310 (14) [back to overview]	Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 36), Censoring for Rescue Therapy
NCT02052310 (14) [back to overview]	Median Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52
NCT02052310 (14) [back to overview]	Time to Achieve the First Hb Response up to Week 24 Censoring for Rescue Therapy
NCT02052310 (14) [back to overview]	Time to First Exacerbation of Hypertension During Weeks 28 to 52
NCT02052310 (14) [back to overview]	Mean Change From Baseline in Hb Levels Between Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)
NCT02052310 (14) [back to overview]	Time to First RBC Transfusion
NCT02052310 (14) [back to overview]	US (FDA Submission): Hb Responder Rate- Percentage of Participants Who Achieved a Hb Response at 2 Consecutive Visits at Least 5 Days Apart During First 24 Weeks of Treatment, Without Rescue Therapy Within 6 Weeks Prior to the Hb Response (ITT Population)
NCT02052310 (14) [back to overview]	Ex-US Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (PPS Population)
NCT02052310 (14) [back to overview]	US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Week 28 to Week 52), Regardless of Rescue Therapy (ITT Population)
NCT02052310 (14) [back to overview]	Percentage of Participants With Hb ≥10.0 g/dL Averaged Over Weeks 28 to 36 and 28 to 52, Regardless of Rescue Therapy
NCT02052310 (14) [back to overview]	Mean Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 8 to 12
NCT02052310 (14) [back to overview]	Mean Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 24
NCT02145026 (4) [back to overview]	Percentage of Participants With Platelet Response (in Participants With Pre-Treatment Platelets <100*10^9 Per Liter) at Week 12 as Assessed by IWG 2006 Response Criteria
NCT02145026 (4) [back to overview]	Proportion of Participants Achieving Erythroid Response at Week 12 as Assessed by International Working Group (IWG) 2006 Response Criteria
NCT02145026 (4) [back to overview]	Percentage of Participants With Adverse Events
NCT02145026 (4) [back to overview]	Percentage of Participants With Neutrophil Response (in Participants With Pre-Treatment Neutrophil <1.0*10^9 Per Liter) at Week 12 as Assessed by IWG 2006 Response Criteria
NCT02174731 (8) [back to overview]	Time-To-First Administration of RBC Transfusion as Rescue Therapy
NCT02174731 (8) [back to overview]	Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
NCT02174731 (8) [back to overview]	Mean Change in Hb From Baseline to the Participant's Mean Level Between Week 28 to Week 52 in Participants With Baseline High-Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
NCT02174731 (8) [back to overview]	Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
NCT02174731 (8) [back to overview]	Mean Monthly IV Iron Use From Week 36 to End of Study (EOS)
NCT02174731 (8) [back to overview]	Proportion of Total Time of Hb Within the Interval of >=10 g/dL From Week 28 to Week 52
NCT02174731 (8) [back to overview]	Proportion of Total Time of Hb Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
NCT02174731 (8) [back to overview]	Change in Hb From Baseline to the Mean Level During the Evaluation Period (Week 28 to Week 36) Without Having Received Rescue Therapy Within 6 Weeks Prior to and During the 8-Week Evaluation Period
NCT02238080 (9) [back to overview]	Serum IL-6 Level
NCT02238080 (9) [back to overview]	Serum Hemoglobin Level
NCT02238080 (9) [back to overview]	Correlation Coefficient (r) Between Serum IL-6 Level and Methoxy Polyethylene Glycol-Epoetin Beta Dose at Month 6
NCT02238080 (9) [back to overview]	Serum CRP Level
NCT02238080 (9) [back to overview]	Percentage of Participants With Change in Methoxy Polyethylene Glycol-Epoetin Beta Dose at Month 6
NCT02238080 (9) [back to overview]	Change From Baseline in Methoxy Polyethylene Glycol-Epoetin Beta Dose at Month 6
NCT02238080 (9) [back to overview]	Correlation Coefficient (r) Between Serum Interleukin-6 (IL-6) Level and Methoxy Polyethylene Glycol-Epoetin Beta Dose
NCT02238080 (9) [back to overview]	Correlation Coefficient (r) Between Serum CRP Level and Methoxy Polyethylene Glycol-Epoetin Beta Dose at Month 6
NCT02238080 (9) [back to overview]	Correlation Coefficient (r) Between Serum C-Reactive Protein (CRP) Level and Methoxy Polyethylene Glycol-Epoetin Beta Dose
NCT02253654 (8) [back to overview]	Hemoglobin Intra-subject Variability
NCT02253654 (8) [back to overview]	Number of RBC Units Transfused Overall and During Each Study Period
NCT02253654 (8) [back to overview]	Percentage of Participants With Hemoglobin Excursions at Each Visit
NCT02253654 (8) [back to overview]	Percentage of Participants With Transfusion Events Overall and During Each Study Period
NCT02253654 (8) [back to overview]	Weekly Epoetin Alfa Dose at Each Visit
NCT02253654 (8) [back to overview]	Hemoglobin Rate of Change at Each Visit
NCT02253654 (8) [back to overview]	Hemoglobin Concentration at Each Visit
NCT02253654 (8) [back to overview]	Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period
NCT02273726 (11) [back to overview]	Average Monthly IV Iron Use Per Patient-Exposure-Month (PEM) During Weeks 28 to 52
NCT02273726 (11) [back to overview]	Ex-U.S. Submission: Hb Responder Rate- Percentage of Participants With Mean Hb 10.0 to 12.0 g/dL Averaged Over Weeks 28 to 36, Censoring for Rescue Therapy
NCT02273726 (11) [back to overview]	Time to First Exacerbation of Hypertension During Weeks 28 to 52
NCT02273726 (11) [back to overview]	Time to First RBC Transfusion
NCT02273726 (11) [back to overview]	US (FDA Submission): Hb Responder Rate- Percentage of Participants With Mean Hb Level ≥10.0 g/dL Averaged Over Weeks 28 to 52, Regardless of Rescue Therapy
NCT02273726 (11) [back to overview]	Change From Baseline in Hb Levels Averaged Over Weeks 18 to 24 Regardless of Rescue Therapy in Participants Whose Baseline High Sensitivity C-Reactive Protein (Hs-CRP)> Upper Limit of Normal (ULN)
NCT02273726 (11) [back to overview]	Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol Averaged Over Weeks 12 to 28
NCT02273726 (11) [back to overview]	Change From Baseline in Mean Arterial Pressure (MAP) Averaged Over Weeks 20 to 28
NCT02273726 (11) [back to overview]	Change From Baseline in Short Form 36 (SF-36) Version 2 Physical Functioning Subscore and Vitality Subscore at Weeks 12 to 28
NCT02273726 (11) [back to overview]	Ex-U.S. Submission: Mean Hb Change From Baseline to the Average Weeks 28 to 36, Without Having Received Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period for Participants Enrolled Under the Original Protocol
NCT02273726 (11) [back to overview]	US (FDA) Submission: Mean Hb Change From Baseline to The Average Level During The Evaluation Period (Weeks 28 to 52), Regardless of Rescue Therapy
NCT02278341 (45) [back to overview]	Mean Monthly Intravenous (IV) Iron Per Participant During Weeks 37-52 and Weeks 53-104
NCT02278341 (45) [back to overview]	Number of Participants With CKD Who Achieved Antihypertensive Treatment Goal
NCT02278341 (45) [back to overview]	Number of Participants With Mean LDL Cholesterol < 100 mg/dL Over Weeks 12 to 28
NCT02278341 (45) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT02278341 (45) [back to overview]	Percentage of Hb Values ≥ 10 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy
NCT02278341 (45) [back to overview]	Percentage of Hb Values Within 10.0 to 12.0 g/dL in Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy
NCT02278341 (45) [back to overview]	Percentage of Participants With Improvements Measured by Patients' Global Impression of Change (PGIC)
NCT02278341 (45) [back to overview]	Time to First Hospitalization
NCT02278341 (45) [back to overview]	Time to First Occurrence of an Increase in Blood Pressure
NCT02278341 (45) [back to overview]	Time to First Occurrence of an Increase in Blood Pressure
NCT02278341 (45) [back to overview]	Time to First RBC Transfusion
NCT02278341 (45) [back to overview]	Time to First Use of IV Iron Supplementation
NCT02278341 (45) [back to overview]	Time to First Use of Rescue Therapy
NCT02278341 (45) [back to overview]	"Change From BL to the Average of Weeks 12 to 28 in Anemia Subscale (AnS) (Additional Concerns) of Functional Assessment of Cancer Therapy-Anemia (FACT-An) Score"
NCT02278341 (45) [back to overview]	Change From Baseline (BL) to the Average Hemoglobin (Hb) in Weeks 28-36 Without Rescue Therapy [EU (EMA)]
NCT02278341 (45) [back to overview]	Change From BL in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28
NCT02278341 (45) [back to overview]	Change From BL in Mean Arterial Pressure (MAP) to the Average MAP Value of Weeks 20 to 28
NCT02278341 (45) [back to overview]	Change From BL in Mean Arterial Pressure (MAP) to the Average of Weeks 20 to 28
NCT02278341 (45) [back to overview]	Change From BL in SF-36 Vitality (VT) Sub-score to the Average of Weeks 12 to 28
NCT02278341 (45) [back to overview]	Change From BL in Short Form-36 (SF-36) Health Survey Physical Functioning (PF) Sub-score to the Average of Weeks 12 to 28
NCT02278341 (45) [back to overview]	Change From BL to the Average Hb in Weeks 28 to 52 Regardless of Rescue Therapy [US (FDA)]
NCT02278341 (45) [back to overview]	Change From BL to the Average of Weeks 12 to 28 in Euroqol Questionnaire-5 Dimensions 5 Levels (EQ-5D 5L) Visual Analogue Scale (VAS) Score
NCT02278341 (45) [back to overview]	Change From BL to the Average of Weeks 12 to 28 in SF-36 Physical Component Score (PCS)
NCT02278341 (45) [back to overview]	Change From BL to the Average Value of Weeks 12 to 28 in Total FACT-An Score
NCT02278341 (45) [back to overview]	Mean Monthly Intravenous (IV) Iron Use
NCT02278341 (45) [back to overview]	Mean Monthly Number of RBC Packs Per Participant
NCT02278341 (45) [back to overview]	Mean Monthly Volume of RBC Transfusion Per Participant
NCT02278341 (45) [back to overview]	Number of Days of Hospitalization Per Year
NCT02278341 (45) [back to overview]	Number of Hospitalizations
NCT02278341 (45) [back to overview]	Percentage of Participants With a Hb Response During Weeks 28 and 36 Regardless of Use of Rescue Therapy
NCT02278341 (45) [back to overview]	Percentage of Participants With Hb Response During Weeks 28 to 36
NCT02278341 (45) [back to overview]	Percentage of Participants With Oral Iron Use Only
NCT02278341 (45) [back to overview]	Change From BL in Glycated Hemoglobin (HbA1c) Level to Weeks 12, 28, 36, 44, 52, 60, 84, 104 and EOS (up to Week 108)
NCT02278341 (45) [back to overview]	Change From BL in Hb to Each Postdosing Time Point
NCT02278341 (45) [back to overview]	Change From BL in Hb to the Average of Weeks 28 to 36, 44 to 52, and 96 to 104 Regardless of the Use of Rescue Therapy
NCT02278341 (45) [back to overview]	Change From BL in Serum Ferritin
NCT02278341 (45) [back to overview]	Change From BL in Serum Hepcidin
NCT02278341 (45) [back to overview]	Change From BL in Transferrin Saturation (TSAT)
NCT02278341 (45) [back to overview]	Change From BL to Each Post-dosing Study Visit in LDL-C/High-density Lipoprotein Cholesterol (HDL-C) Ratio
NCT02278341 (45) [back to overview]	Change From BL to Each Post-dosing Study Visit in Total Cholesterol
NCT02278341 (45) [back to overview]	Change From BL to Each Postdosing Study Visit in ApoB/ApoA1 Ratio
NCT02278341 (45) [back to overview]	Change From BL to Each Postdosing Study Visit in Apolipoproteins A1 (ApoA1)
NCT02278341 (45) [back to overview]	Change From BL to Each Postdosing Study Visit in Apolipoproteins B (ApoB)
NCT02278341 (45) [back to overview]	Change From BL to Each Postdosing Study Visit in Non-HDL Cholesterol
NCT02278341 (45) [back to overview]	Hb Level Averaged Over Weeks 28 to 36, 44 to 52, and 96 to 104 Without Use of Rescue Therapy
NCT02504294 (2) [back to overview]	Change From Baseline in Weekly Mean Study Medication Dose Over Final 8 Weeks of Study Treatment
NCT02504294 (2) [back to overview]	Percentage of Time When Participants Had Hemoglobin Levels Between 9 to 11 Gram Per Deciliter (g/dL)
NCT02538107 (12) [back to overview]	Hemoglobin Level Based on the Acute Bleeding Episode(s) During the Study
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 9 (Month 9)
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 11-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 11-12 Grams Per Deciliter (g/dL) From Visit 7 (Month 7) to Visit 9 (Month 9)
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 15 (Month 15)
NCT02538107 (12) [back to overview]	Hemoglobin Level Based on the Type of Kidney Transplantation Performed
NCT02538107 (12) [back to overview]	Hemoglobin Level Based on the Presence of Inflammatory Diseases
NCT02538107 (12) [back to overview]	Hemoglobin Level Based on the Glomerular Filtration Rate (GFR)
NCT02538107 (12) [back to overview]	Percentage of Participants With a Hemoglobin Value of 10-13 g/dL From Visit 7 (Month 7) to Visit 12 (Month 12)
NCT02538107 (12) [back to overview]	Hemoglobin Level Based on the Etiology of Chronic Kidney Disease
NCT02538107 (12) [back to overview]	Average Duration in Months Mircera Was Administered at Current Dose After the Previous Dose Adjustment
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 19-21
NCT02547454 (25) [back to overview]	Number of Dose Adaptations
NCT02547454 (25) [back to overview]	Median Dose of Methoxy Polyethylene Glycol-Epoetin Beta
NCT02547454 (25) [back to overview]	Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (100 to 130 g/L) at Baseline
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 7-9
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 4-6
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) After 21 Months up to 36 Months
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 4-6
NCT02547454 (25) [back to overview]	Average Dose of Methoxy Polyethylene Glycol-Epoetin Beta
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 16-18
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 13-15
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 10-12
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 1-3
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) After 21 Months up to 36 Months
NCT02547454 (25) [back to overview]	Percentage of Participants With Dose 0
NCT02547454 (25) [back to overview]	Median Time in Which Hb Value Was Maintained Within Target Range of 110-120 g/L
NCT02547454 (25) [back to overview]	Median Time in Which Hb Value Was Maintained Within Target Range of 100-130 g/L
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 19-21
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 16-18
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (100 to 130 g/L) at Months 7-9
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 13-15
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 10-12
NCT02547454 (25) [back to overview]	Percentage of Participants With Hb Value Within the Target Range (110 to 120 g/L) at Months 1-3
NCT02547454 (25) [back to overview]	Percentage of Participants With Hemoglobin (Hb) Value Within the Target Range (110 to 120 Grams Per Liter [g/L]) at Baseline
NCT02547454 (25) [back to overview]	Percentage of Participants With Iron Replacement
NCT02596945 (3) [back to overview]	Percentage of Participants With Hemoglobin Values in the Range of 11-12 Grams Per Deciliter (g/dL) During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)
NCT02596945 (3) [back to overview]	Percentage of Participants With Hemoglobin Values in the Range of 11-13 g/dL During the Evaluation Period of Visit 7 (Month 7) to Visit 9 (Month 9)
NCT02596945 (3) [back to overview]	Average Duration in Days Mircera Was Administered at a Stable Dose
NCT02761642 (8) [back to overview]	Percentage of Participants With Response to Treatment Based on Hemoglobin Levels
NCT02761642 (8) [back to overview]	Change From Baseline in Hemoglobin Levels After 12 Weeks of Study Treatment in Participants According to Chemotherapy at Baseline
NCT02761642 (8) [back to overview]	Change From Baseline in Hemoglobin Levels After 12 Weeks of Study Treatment in Participants According to the Hemoglobin Level at Baseline
NCT02761642 (8) [back to overview]	Change From Baseline in Hemoglobin Levels After 12 Weeks of Study Treatment in Participants According to the Time Spent on Chemotherapy at Baseline
NCT02761642 (8) [back to overview]	Overall Mean Change From Baseline in Hemoglobin Levels After 12 Weeks of Study Treatment
NCT02761642 (8) [back to overview]	Mean Time Needed to Increase Hemoglobin Level by At Least 1 g/dL
NCT02761642 (8) [back to overview]	Percentage of Participants With an Increase From Baseline in Hemoglobin Levels of At Least 1 g/dL After 4 Weeks
NCT02761642 (8) [back to overview]	Quality of Life Assessment Using Functional Assessment of Cancer Therapy-Anemia (FACT-An) Questionnaire Scores
NCT02767765 (6) [back to overview]	Percentage of Participants With Response to Treatment
NCT02767765 (6) [back to overview]	Percentage of Participants With No Response to Treatment After 4 Weeks of Study Treatment
NCT02767765 (6) [back to overview]	Percentage of Participants Who Required Transfusion
NCT02767765 (6) [back to overview]	Change From Baseline in Functional Assessment of Cancer Therapy-Anemia (FACT-An) Questionnaire Score at Week 4
NCT02767765 (6) [back to overview]	Time to Response
NCT02767765 (6) [back to overview]	Percentage of Participants With Response to Treatment After 2 Weeks of Study Treatment
NCT02811263 (9) [back to overview]	Number of Participants With Epilepsy
NCT02811263 (9) [back to overview]	Number of Participants With Death or Neurodevelopmental Impairment
NCT02811263 (9) [back to overview]	MR Evidence of Brain Injury - Brain Injury Score
NCT02811263 (9) [back to overview]	Bayley III Language Score
NCT02811263 (9) [back to overview]	Number of Participants With Behavioral Abnormalities Determined by the Externalizing Score of the Child Behavior Checklist
NCT02811263 (9) [back to overview]	Number of Participants Experiencing Cortical Visual Impairment, Per Parent/Caregiver Report, Compared Between the Epo and Placebo Groups.
NCT02811263 (9) [back to overview]	Number of Participants Experiencing Hearing Impairment Requiring Hearing Aids, Per Parent/Caregiver Report, Compared Between the Epo and Placebo Groups.
NCT02811263 (9) [back to overview]	Serial Circulating Biomarkers of Inflammation/Brain Injury
NCT02811263 (9) [back to overview]	Bayley III Cognitive Score
NCT02817555 (6) [back to overview]	Cost of Erythropoiesis Stimulating Agent
NCT02817555 (6) [back to overview]	Iron Cost
NCT02817555 (6) [back to overview]	Hemoglobin
NCT02817555 (6) [back to overview]	Iron Dose
NCT02817555 (6) [back to overview]	Transferrin Saturation (TSAT)
NCT02817555 (6) [back to overview]	Ferritin
NCT03007537 (2) [back to overview]	Number of Participants With Renal Replacement Therapy
NCT03007537 (2) [back to overview]	Number of Participants With Acute Kidney Injury
NCT03029247 (57) [back to overview]	AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57
NCT03029247 (57) [back to overview]	Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1
NCT03029247 (57) [back to overview]	Area Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
NCT03029247 (57) [back to overview]	Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT03029247 (57) [back to overview]	Absolute Values for Temperature
NCT03029247 (57) [back to overview]	Absolute Values for Pulse Rate
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameters: Hemoglobin and Erythrocyte Mean Corpusclar Hemoglobin Concentration ( Ery. MCHC)
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameters: Erythrocytes and Reticulocytes
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameter: Hematocrit
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameter: Erythrocyte Distribution Width
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Volume (MCV)
NCT03029247 (57) [back to overview]	Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Hemoglobin (MCH) and Reticulocyte Corpuscular Hemoglobin Content (CHr)
NCT03029247 (57) [back to overview]	Absolute Values for Electrocardiogram (ECG) Mean Heart Rate
NCT03029247 (57) [back to overview]	Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval Corrected for Heart Rate (QTc) and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB)
NCT03029247 (57) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indirect (Indrt) Bilirubin
NCT03029247 (57) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Calcium Corrected for Albumin (CCA), Glucose, Potassium, Phosphate and Sodium
NCT03029247 (57) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
NCT03029247 (57) [back to overview]	Absolute Values for Clinical Chemistry Parameters: Albumin and Protein
NCT03029247 (57) [back to overview]	Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)
NCT03029247 (57) [back to overview]	Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57
NCT03029247 (57) [back to overview]	Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57
NCT03029247 (57) [back to overview]	Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1
NCT03029247 (57) [back to overview]	AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57
NCT03029247 (57) [back to overview]	AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1
NCT03029247 (57) [back to overview]	Number of Participants Who Discontinued the Study Treatment
NCT03029247 (57) [back to overview]	Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
NCT03029247 (57) [back to overview]	Terminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
NCT03029247 (57) [back to overview]	Number of Participants With Any Serious Adverse Events (SAEs)
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2531398
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2506104
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2506102
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2487818
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2391220
NCT03029247 (57) [back to overview]	Plasma Concentrations of Daprodustat
NCT03029247 (57) [back to overview]	Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
NCT03029247 (57) [back to overview]	Change From Pre-dose in SBP, DBP and MAP at Day 1
NCT03029247 (57) [back to overview]	Change From Pre-dose in HR at Day 1
NCT03029247 (57) [back to overview]	Change From Baseline Values for Vital Signs: SBP and DBP
NCT03029247 (57) [back to overview]	Change From Baseline Values for Temperature
NCT03029247 (57) [back to overview]	Change From Baseline Values for Pulse Rate
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameters: Hemoglobin and Ery. MCHC
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameters: Erythrocytes and Reticulocytes
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameters: Ery. MCH and CHr
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameter: Hematocrit
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameter: Erythrocyte Distribution Width
NCT03029247 (57) [back to overview]	Change From Baseline Values for Hematology Parameter: Ery. MCV
NCT03029247 (57) [back to overview]	Change From Baseline Values for ECG Parameters: PR Interval, QRS Duration, QTc and QTcB
NCT03029247 (57) [back to overview]	Change From Baseline Values for ECG Mean Heart Rate
NCT03029247 (57) [back to overview]	Change From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indrt. Bilirubin
NCT03029247 (57) [back to overview]	Change From Baseline Values for Clinical Chemistry Parameters: CCA, Glucose, Potassium, Phosphate and Sodium
NCT03029247 (57) [back to overview]	Plasma Concentrations of Metabolite GSK2531401
NCT03029247 (57) [back to overview]	Change From Baseline Values for Clinical Chemistry Parameters: ALP, ALT and AST
NCT03029247 (57) [back to overview]	Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein
NCT03029247 (57) [back to overview]	Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1
NCT03029247 (57) [back to overview]	Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57
NCT03140722 (1) [back to overview]	Number of Participants With Treatment-emergent Adverse Events
NCT03400033 (13) [back to overview]	Change From Baseline in SBP, DBP and MAP at End of Treatment
NCT03400033 (13) [back to overview]	Change From Baseline at Weeks 8, 12, 28 and 52 in Patient Global Impression of Severity (PGI-S)
NCT03400033 (13) [back to overview]	Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)
NCT03400033 (13) [back to overview]	Percentage of Participants Permanently Stopping Study Treatment Due to Meeting Rescue Criteria
NCT03400033 (13) [back to overview]	Number of Participants With at Least One BP Exacerbation Event During the Study
NCT03400033 (13) [back to overview]	Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years
NCT03400033 (13) [back to overview]	Number of Hemoglobin Responders in the Hemoglobin Analysis Range (10 to 11.5 Grams/Deciliter) Over Evaluation Period (Week 28 to Week 52)
NCT03400033 (13) [back to overview]	Pre-dose Trough Concentration (Ctau) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)
NCT03400033 (13) [back to overview]	Maximum Observed Concentration (Cmax) of Daprodustat (GSK1278863) and Its Metabolites GSK2391220 (M2), GSK2487818 (M4), GSK2506102 (M5), GSK2506104 (M3), GSK2531398 (M6) and GSK2531401 (M13)
NCT03400033 (13) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Pressure (MAP) at Week 52
NCT03400033 (13) [back to overview]	Mean Change From Baseline in Hemoglobin Levels Over the Evaluation Period (Week 28 to Week 52)
NCT03400033 (13) [back to overview]	Mean Average Monthly On-treatment Intravenous (IV) Iron Dose Per Participant
NCT03400033 (13) [back to overview]	Change From Baseline in Hemoglobin Levels at Week 52
NCT03408639 (12) [back to overview]	The Proportion of Patients With Treatment Success
NCT03408639 (12) [back to overview]	The Proportion of Patients With Maintenance Success
NCT03408639 (12) [back to overview]	The Proportion of Patients With Any Permanent or Transient Dose Change
NCT03408639 (12) [back to overview]	The Proportion of Patients With Any Hb Measurement Outside the Target Range (10-12 g/dl)
NCT03408639 (12) [back to overview]	The Proportion of Patients With an Increase in Hb Concentration of > 1.0 g/dl for Four Consecutive Weeks
NCT03408639 (12) [back to overview]	The Proportion of Patients Needed Blood Transfusions
NCT03408639 (12) [back to overview]	The Percentage of Patients With Hematocrit Measurements More Than 30%
NCT03408639 (12) [back to overview]	The Percentage of Patients With Hb Measurements More Than 10.0 g/dl
NCT03408639 (12) [back to overview]	The Incidence of Hb Levels Above 13 g/dl
NCT03408639 (12) [back to overview]	The Incidence of Adverse Events
NCT03408639 (12) [back to overview]	Mean Weekly Epoetin Dosage Per kg Body Weight During the Last Four Weeks of Treatment
NCT03408639 (12) [back to overview]	Mean Hb Change Level During the Last Four Weeks of Treatment
NCT03799627 (41) [back to overview]	Mean Change From Baseline in Ferritin Concentration
NCT03799627 (41) [back to overview]	Mean Change From Baseline in Hepcidin Concentration
NCT03799627 (41) [back to overview]	Mean Change From Baseline in Iron Concentration
NCT03799627 (41) [back to overview]	Mean Change From Baseline in Reticulocyte Count
NCT03799627 (41) [back to overview]	Mean Change From Baseline in Total Iron Binding Capacity
NCT03799627 (41) [back to overview]	Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)
NCT03799627 (41) [back to overview]	Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group
NCT03799627 (41) [back to overview]	Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group
NCT03799627 (41) [back to overview]	Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Number of Participants With Hb Values Within the Target Range at the SEP
NCT03799627 (41) [back to overview]	Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing
NCT03799627 (41) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT03799627 (41) [back to overview]	Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group
NCT03799627 (41) [back to overview]	Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Number of Participants With Hb Values Within the Target Range at the PEP
NCT03799627 (41) [back to overview]	Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Number of Participants Classified as Hb Outliers
NCT03799627 (41) [back to overview]	Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose
NCT03799627 (41) [back to overview]	Mean Change in Hb Between Baseline and the SEP
NCT03799627 (41) [back to overview]	Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12
NCT03799627 (41) [back to overview]	Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation
NCT03799627 (41) [back to overview]	Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue
NCT03799627 (41) [back to overview]	Number of Participants Requiring Red Blood Cell (RBC) Transfusion
NCT03799627 (41) [back to overview]	Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP
NCT03799627 (41) [back to overview]	Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP
NCT03799627 (41) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
NCT03799627 (41) [back to overview]	Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
NCT03822884 (6) [back to overview]	Reticulocyte Response: AUC 0-120h
NCT03822884 (6) [back to overview]	Reticulocyte Response: Cmax
NCT03822884 (6) [back to overview]	AUC0-∞
NCT03822884 (6) [back to overview]	Tmax
NCT03822884 (6) [back to overview]	AUC0-t
NCT03822884 (6) [back to overview]	Cmax

Overall Survival

Time from randomization to death from any cause. Patients alive at the time of analysis were censored at the date of last contact. (NCT00003138)
Timeframe: Assessed every 3 months for 2 years, every 6 months for 3 subsequent years, and annually thereafter

Intervention	Months (Median)
Supportive Care	31
Erythropoietin	37

Intervention	Participants (Count of Participants)
	Disease Recurrence	No recurrence
Arm 1: CEF	141	560
Arm 2: EC/T	135	566
Arm 3: AC/T	191	511

Intervention	Participants (Count of Participants)
	Death	Alive
Arm 1: CEF	123	578
Arm 2: EC/T	107	594
Arm 3: AC/T	146	556

Intervention	Participants (Number)
	Phosphate -High; (n = 15, 15, 15, 15 , 16 , 15)	Phosphate -Low; (n = 15, 15, 15, 15 , 16 , 15)	Potassium -High; (n = 15, 15, 15, 15 , 16 , 15)	Potassium -Low; (n = 15, 15, 15, 15 , 16 , 15)	Platelets - High; (n = 15, 15, 15, 15 , 16 , 15)	Platelets - Low; (n = 15, 15, 15, 15 , 16 , 15)	WBC - High; (n = 15, 15, 15, 15 , 16 , 15)	WBC - Low; (n = 15, 15, 15, 15 , 16 , 15)	Basophils - High; (n = 15, 15, 14, 15 , 16 , 15)	Eosinophils - High; (n = 15, 15, 14, 15 , 16 , 15)	Lymphocytes - High; (n = 15, 15, 15, 15 , 16 , 15)	Lymphocytes - Low; (n = 15, 15, 15, 15 , 16 , 15)	Monocytes - High; (n = 15, 15, 15, 15 , 16 , 15)	Monocytes - Low; (n = 15, 15, 15, 15 , 16 , 15)	Neutrophils - Low; (n = 15, 15, 14, 15 , 16 , 15)	ALAT - High; (n = 15, 15, 15, 15 , 16 , 15)	ALP - High; (n = 15, 15, 15, 15 , 16 , 15)	ASAT - High; (n = 15, 15, 15, 15 , 16 , 15)	Total Bilirubin-High; (n = 15, 15, 15, 15, 16, 15)	Albumin - Low; (n = 15, 15, 15, 15 , 16 , 15)	Glucose Fasting -High; (n = 5, 6, 9, 6, 6 , 9)	Glucose Fasting -Low; (n = 5, 6, 9, 6, 6 , 9)
Cohort 1 (RO0503821 [0.25/150 1x/Week])	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0
Cohort 2 (RO0503821 [0.25/150 1x/2week])	1	1	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0
Cohort 3 (RO0503821 [0.4/150 1x/Week])	3	1	1	0	0	1	0	1	0	0	0	2	0	0	0	1	1	1	0	0	0	0
Cohort 4 (RO0503821 [0.4/150 1x/2week])	4	0	0	0	0	1	0	1	0	0	0	1	0	0	1	0	0	0	0	0	0	0
Cohort 5 (RO0503821 [0.6/150 1x/Week])	4	2	2	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
Cohort 6 (RO0503821 [0.6/150 1x/2week])	2	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	1	0	1	0	0	0

Intervention	Participants (Number)
	Any AEs	Any SAEs	Deaths
RO0503821 (1x/2Week)	37	20	2
RO0503821 (1x/Week)	42	20	3

Intervention	mm HG (Mean)
	DBP- before dialysis	DBP - After dialysis	SBP - before dialysis	SBP - After dialysis
Cohort 1 (RO0503821 [0.25/150 1x/Week])	-2	4	-1	6
Cohort 2 (RO0503821 [0.25/150 1x/2week])	-1	0	5	3
Cohort 3 (RO0503821 [0.4/150 1x/Week])	-10	-0	-15	-3
Cohort 4 (RO0503821 [0.4/150 1x/2week])	-8	-8	-15	-13
Cohort 5 (RO0503821 [0.6/150 1x/Week])	-6	-6	-11	-6
Cohort 6 (RO0503821 [0.6/150 1x/2week])	-10	-0	-15	-3

Intervention	g/dL (Median)
Cohort 1 (RO0503821 [0.25/150 1x/Week])	-0.29
Cohort 2 (RO0503821 [0.25/150 1x/2week])	-0.92
Cohort 3 (RO0503821 [0.4/150 1x/Week])	-0.04
Cohort 4 (RO0503821 [0.4/150 1x/2week])	-0.46
Cohort 5 (RO0503821 [0.6/150 1x/Week])	0.86
Cohort 6 (RO0503821 [0.6/150 1x/2week])	-0.07

Intervention	g/dL (Median)
Cohort 1 (RO0503821 [0.25/150 1x/Week])	-1.50
Cohort 2 (RO0503821 [0.25/150 1x/2week])	-3.01
Cohort 3 (RO0503821 [0.4/150 1x/Week])	-0.32
Cohort 4 (RO0503821 [0.4/150 1x/2week])	-1.62
Cohort 5 (RO0503821 [0.6/150 1x/Week])	2.73
Cohort 6 (RO0503821 [0.6/150 1x/2week])	-0.07

Intervention	participants (Number)
	Platelets - High, n = 16, 15, 19	Platelets - Low, n = 16, 15, 19	WBC - High, n = 16, 15, 19	Eosinophils - High, n = 15, 15, 19	Lymphocytes - Low, n = 15, 15, 19	Monocytes - High, n = 15, 15, 19	Neutrophils - High, n = 15, 15, 19	Neutrophils - Low, n = 15, 15, 19	ALT - High, n = 22, 21, 22	ALP - High, n = 22, 21, 22	AST - High, n = 22, 21, 22	Total bilirubin - High, n = 22, 21, 22	Albumin - Low, n = 22, 21, 22	Phosphate - High , n = 12, 13, 14	Phosphate - Low, n = 12, 13, 14	Potassium - High, n = 22, 21, 22	Potassium - Low, n = 22, 21, 22
RO0503821 (1x/2week)	1	0	0	1	2	0	3	2	1	0	1	0	0	6	1	2	0
RO0503821 (1x/3week)	0	3	1	2	1	1	3	0	1	2	2	1	2	1	1	2	0
RO0503821 (1x/Week)	0	0	0	0	2	0	0	0	1	1	2	0	2	7	2	3	1

Intervention	bpm (Mean)
RO0503821 (1x/Week)	65.6
RO0503821 (1x/2week)	68.4
RO0503821 (1x/3week)	75.4

Intervention	participants (Number)
	Participants with SAEs	Participants with AEs
RO0503821 (1x/2Week)	9	21
RO0503821 (1x/3week)	12	22
RO0503821 (1x/Week)	11	22

Intervention	g/dL (Median)
Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)	31.10
Cohort 2 (RO0503821,0.3 mcg/kg 1x/Week)	39.10
Cohort 3 (RO0503821,0.6 mcg/kg 1x/Week)	36.95
Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)	28.40
Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)	34.70
Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)	40.50
Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)	32.70
Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)	37.75
Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)	39

Intervention	Cells x10^3/UL (Median)
Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)	71.80
Cohort 2 (RO0503821,0.3 mcg/kg 1x/Week)	46.30
Cohort 3 (RO0503821,0.6 mcg/kg 1x/Week)	44.70
Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)	51.80
Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)	72.80
Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)	59.20
Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)	25.20
Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)	38.45
Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)	56.20

Intervention	gram/deciliter (g/dL) (Median)
Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)	0.48
Cohort 2 (RO0503821, 0.3 mcg/kg 1x/Week)	1.08
Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)	1.34
Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)	0.17
Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)	0.27
Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)	2.17
Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)	0.41
Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)	0.83
Cohort 9 (RO0503821, 1.8 mcg/kg 1x/3 Week)	1.28

Intervention	mmHg (Mean)
	DBP	SBP
Cohort 1 (RO0503821, 0.15 mcg/kg 1x/Week)	2	12
Cohort 2 (RO0503821,0.3 mcg/kg 1x/Week)	5	2
Cohort 3 (RO0503821, 0.6 mcg/kg 1x/Week)	6	5
Cohort 4 (RO0503821, 0.3 mcg/kg 1x/2 Week)	6	2
Cohort 5 (RO0503821, 0.6 mcg/kg 1x/2Week)	2	8
Cohort 6 (RO0503821, 1.2 mcg/kg 1x/2 Week)	-3	-11
Cohort 7 (RO0503821, 0.45 mcg/kg 1x/3 Week)	6	6
Cohort 8 (RO0503821, 0.9 mcg/kg 1x/3Week)	-2	3
Cohort 9 (RO0503821,1.8 mcg/kg 1x/3 Week)	4	-3

Intervention	participants (Number)
RO0503821 (1x/2 Weeks)	133
RO0503821 (1x/4 Weeks)	127
Epoetin (1-3x/Weeks)	138

Intervention	participants (Number)
	Number of participants with adverse events	Number of participants with serious adverse events	Number of deaths
Epoetin (1-3x/Weeks)	214	99	17
RO0503821 (1x/2 Weeks)	203	101	19
RO0503821 (1x/4 Weeks)	202	87	15

Intervention	millimeter of mercury (mmHg) (Mean)
	Change in SBP, BD at Wk 36 (n=189, 178,196)	Change in SBP, BD at Wk 52 (n=168, 166, 180)	Change in DBP, BD at Wk 36 (n=189, 178, 195)	Change in DBP, BD at Wk 52 (n=168, 166, 179)	Change in SBP, AD at Wk 36 (n=189, 177, 196)	Change in SBP, AD at Wk 52 (n=167, 168, 179)	Change in DBP, AD at Wk 36 (n=189, 177, 196)	Change in DBP, AD at Wk 52 (n=167, 168, 178)
Epoetin (1-3x/Weeks)	3	1	1	-1	-0	1	-2	-3
RO0503821 (1x/2 Weeks)	1	-0	0	1	3	2	-1	-1
RO0503821 (1x/4 Weeks)	-2	-3	-3	-3	-1	-0	-0	-0

Intervention	beats per minute (bpm) (Mean)
	Change from BL at Week 36 (n=188, 176, 193)	Change from BL at Week 52 (n=168, 166, 179)
Epoetin (1-3x/Weeks)	0	-1
RO0503821 (1x/2 Weeks)	1	1
RO0503821 (1x/4 Weeks)	2	1

Intervention	participants (Number)
	High Platelet (n=218, 216, 223)	Low Platelet (n=218, 216, 223)	High WBC (n=218, 217, 223)	Low WBC (n=218, 217, 223)	High RBC (n=124, 129, 89)	Low RBC (n=124, 129, 89)
Epoetin (1-3x/Weeks)	3	6	3	5	0	0
RO0503821 (1x/2 Weeks)	0	14	0	8	1	1
RO0503821 (1x/4 Weeks)	1	10	2	6	2	2

Intervention	gram per deciliter (g/dL) (Mean)
RO0503821 (1x/2 Weeks)	-0.10
RO0503821 (1x/4 Weeks)	0.01
Epoetin (1-3x/Week)	-0.10

Intervention	participants (Number)
	High ALT. (n=218, 216, 224)	High ALP (n=218, 216, 224)	Low Albumin (n=218, 216, 224)	High Phosphate (n=218, 216, 224)	Low Phosphate (n=218, 216, 224)	High Potassium (n=218, 216, 224)	Low Potassium (n=218, 216, 224)	High AST (n=218, 215, 224)	High Blood glucose in non-diabetic (n=114,131,110)	Low Blood Glucose in Non-Diabetic (n=114,131,110)
Epoetin (1-3x/Weeks)	5	16	18	94	17	36	3	4	1	0
RO0503821 (1x/2 Weeks)	4	15	14	106	21	33	10	6	0	0
RO0503821 (1x/4 Weeks)	2	14	13	95	21	35	3	3	3	1

Intervention	participants (Number)
	Any AE's	Any SAE's	Deaths
Epoetin Reference	167	85	12
RO0503821 (1x/2 Weeks)	171	70	13
RO0503821 (1x/4 Weeks)	177	73	18

Intervention	mm HG (Mean)
	DBP (Week 36, n=7,10,12 )	DBP (Week 52, n= 8, 9, 12)	SBP - (Week 36, n=7, 10, 12)	SBP - (Week 52, n=8, 9,12)
Epoetin Reference	2	2	7	12
RO0503821 (1x/2 Weeks)	2	1	3	4
RO0503821 (1x/4 Weeks)	-7	-8	-20	-20

Intervention	mmHG (Mean)
	DBP- before dialysis (Week 36, n=150,153, 157)	DBP- before dialysis (Week 52, n= 143, 136, 144)	DBP - After dialysis (Week 36, n=150, 150, 157)	DBP - After dialysis (Week 52, n= 141, 136, 142)	SBP - before dialysis(Week 36, n=150, 153, 158)	SBP - before dialysis(Week 52, n=143, 136,144)	SBP - After dialysis (Week 36, n=150, 152, 158)	SBP - After dialysis (Week 52, n=141, 136, 142)
Epoetin Reference	1	2	-1	2	-1	1	-2	2
RO0503821 (1x/2 Weeks)	0	-1	1	0	1	-1	-1	1
RO0503821 (1x/4 Weeks)	0	-1	-0	0	4	3	-0	-2

epoetin alfa

Description

Cross-References

Synonyms (4)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (1,745)

Market Indicators

Research Demand Index: 98.56

Study Types

Clinical Trials (506)

Trial Overview

Trial Outcomes

Overall Survival

Proportion of Patients Free of Transfusion at 4 Months

Quality of Life- Total Functional Assessment of Cancer Therapy - General (FACT-G) Score at 4 Months

Disease Free Survival

Overall Survival

Number of Participants With Marked Laboratory Abnormalities

Number of Participants With Any Adverse Events, Any Serious Adverse Events, And Deaths

Mean Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure Before and After Dialysis

Median Change From Baseline in Hemoglobin Levels to End of Initial Treatment Under Constant Dosing Regimen

Median Change From Baseline in Hematocrit Levels to End of Initial Treatment Under Constant Dosing Regimen

Mean Change in Pulse Rate

Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes Over Time

Heart Rate Over Time

Number of Participants With Any Serious Adverse Events and Any Adverse Events

Hematocrit Levels at End of Initial Treatment Under Constant Dosing Regimen

Reticulocyte Count at End of Initial Treatment Under Constant Dosing Regimen

The Change in Hemoglobin Over Time Between Baseline and End of Initial Treatment Based on Individual Regression Slopes

Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

Number of Participants Maintaining Average Hemoglobin Concentration During Evaluation Period Within +/- 1 Gram Per Deciliter (g/dl) of Average Baseline Hemoglobin Concentration.

The Incidence of Red Blood Cell (RBC) Transfusions During the Titration and Evaluation Periods

Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs) and Death

Mean Change in Blood Pressure From Baseline at Week 36 and Week 52

Mean Change in Pulse Rate (Sitting) From Baseline at Week 36 and Week 52

Number of Participants With Marked Laboratory Abnormalities in Platelet, White Blood Cell Counts (WBC) and Red Blood Cells (RBC)

Mean Change in Hemoglobin (Hb) Concentration From Baseline to Evaluation Period

Number of Participants With Marked Laboratory Abnormalities for Blood Chemistry and Electrolytes

Number of Participants With Any Adverse Events, Any Serious Adverse Events, and Deaths

Change From Baseline in Systolic and Diastolic Blood Pressure at Weeks 36 and 52 in Peritoneal Dialysis Participants

Change From Baseline in Systolic and Diastolic Blood Pressure - at Weeks 36 and 52 in Hemodialysis Participants

Mean Change in Hemoglobin Concentration From Baseline to Evaluation Periods

Number of Participants Maintaining Average Hb Concentration During the Evaluation Period Within +-1 g/dL of Their Average Baseline Hb Concentration

Number of Participants With Red Blood Cell Transfusions

Number of Participants With Marked Laboratory Abnormalities

Change From Baseline in Pulse Rate - Peritoneal Dialysis Participants

Change From Baseline in Pulse Rate at Weeks 36 and 52 in Hemodialysis Participants

Change From Baseline in Hemoglobin Concentration to the Last Month of Study Participation

Percentage of Patients Who Had at Least 1 Adverse Event

Return to Usual Activity (RTUA)

SF-36 PF Score

The Mean Change From Baseline to the Highest Reticulocyte Count up to Day 71

The Mean Change From Baseline to the Highest Ferritin up to Day 71

Mean Change From Baseline to the Highest Hemoglobin up to Day 71

The Mean Change From Baseline to the Highest Serum Transferrin Saturation (TSAT) up to Day 71

Change From Baseline to the Maximum Hemoglobin Level During Stage 2 (Week 9 Through Week 21).

Number of Adverse Events (AEs) Experienced as Measure of Safety and Tolerability.

Number of Subjects That Maintained Target Hemoglobin Level (11-12 g/dL) Maintenance Weekly for 12 Weeks

The Number of Patients Who Developed Peripheral Sensory Neuropathy (National Cancer Institute Common Toxicity Criteria (NCI CTC) Score >= 1) at Week 12.

The Number of Patients Who Developed Peripheral Sensory Neuropathy (National Cancer Institute Common Toxicity Criteria (NCI CTC) Score >= 2) at Week 12.

Change in Left Ventricular End-diastolic Volume

Glasgow Outcome Scale

Disability Rating Scale

Incidence of Adult Respiratory Distress Syndrome (ARDS)

Incidence of Infection

Mortality Rate

Number of Participants on Blood Pressure/Anti-Hypertensive Treatment According to Class Of Drugs

Number of Participants Experiencing Worsening of New York Heart Association (NYHA) Class (CL) of Chronic Heart Failure From Baseline (BL)

Mean Values of Echocardiography Parameters

Mean Values of Body Surface Area

Intervention	g/dL (Mean)
RO0503821 (1x/2 Weeks)	-0.00
RO0503821 (1x/4 Weeks)	-0.11
Epoetin Reference	-0.12

Intervention	participants (Number)
	Platelets, high; n=189,189, 188	Platelets, low; n=189,189, 188	RBC, high; n = 118, 112, 115	RBC, low; n = 118, 112, 115	WBC, high; n=189,189, 188	WBC, low; n=189,189, 188	ALAT, high; n=189,189, 188	ALP, high; n=189,189, 188	ASAT, high; n=185,189, 186	Albumin, low; n=182,186, 185	Phosphate, high; n=189,189, 188	Phosphate, low; n=189,189, 188	Potassium, high; n=189,189, 188	Potassium, low; n=189,189, 188	Glucose fasting, high; n=126,137, 124	Glucose fasting, low; n=126,137, 124
Epoetin Reference	1	1	1	73	5	4	6	11	2	17	82	18	38	1	2	0
RO0503821 (1x/2 Weeks)	0	8	0	48	1	3	6	5	4	16	84	14	32	1	1	0
RO0503821 (1x/4 Weeks)	1	11	2	48	2	4	11	8	5	20	78	17	38	4	2	0

Intervention	BpM (Mean)
	Pulse rate (Week 36, n=147,149, 156)	Pulse rate (Week 52, n= 140, 135, 142)
Epoetin Reference	6	2
RO0503821 (1x/2 Weeks)	1	-3
RO0503821 (1x/4 Weeks)	4	1

Intervention	BpM (Mean)
	Pulse rate (Week 36, n=147,149, 156 )	Pulse rate (Week 52, n= 140, 135, 142)
Epoetin Reference	-0	-0
RO0503821 (1x/2 Weeks)	-0	-0
RO0503821 (1x/4 Weeks)	1	1

Intervention	g/dL (Mean)
Methoxy Polyethylene Glycol-Epoetin Beta	-0.55
Comparator ESA	-0.38

Intervention	Percentage of participants (Number)
Methoxy Polyethylene Glycol-Epoetin Beta	94.3
Comparator ESA	93.3

Intervention	percentage of change (Mean)
Group A: Venofer and Erythropoietin EPO Fixed Dose	0.7226
Group B: Erythropoietin EPO Fixed Dose Only	0.4630

Intervention	ng/mL (Mean)
Group A: Venofer and Erythropoietin EPO Fixed Dose	545.05
Group B: Erythropoietin EPO Fixed Dose Only	70.523

Intervention	percentage of change (Mean)
Group A: Venofer and Erythropoietin EPO Fixed Dose	18.176
Group B: Erythropoietin EPO Fixed Dose Only	10.383

Intervention	g/dL (Mean)
Group A: Erythropoietin + Venofer (Responders)	2.6
Group B: Erythropoietin Only (Responders)	1.8
Group C: Erythropoietin + Venofer (Non-responders)	2.5
Group D: Erythropoietin Only (Non-responders)	1.3